Oesophageal and Gastric Cancer: optimising care and outcomes in changing clinical practice by Putten, M. (Margreet) van
Oesophageal and Gastric Cancer:
optimising care and outcomes in changing clinical practice
O
esophageal and G
astric Cancer: optim
ising care and outcom
es in changing clinical practice             M
argreet van Putten
Margreet van Putten 
Kaft Maag en slokdarm met kersenbloesem.indd   1 16-3-2018   12:23:52
UITNODIGING
Voor het bijwonen van de 
openbare verdediging van 
mijn proefschrift
Oesophageal and Gastric Cancer: 
optimising care and outcomes in 
changing clinical practice
op vrijdag 25 mei 2018 
om 11.30 uur in de Senaatszaal 
van Campus Woudestein, 
Burgemeester Oudlaan 50
te Rotterdam.
Aansluitend is er een 
receptie ter plaatse 
waar u van harte welkom bent.
Margreet van Putten
Kampsesteeg 8
5688 KJ Oirschot
Paranimfen
Amanda Bos
Sylvia van Putten
margreetpromoveert@gmail.com
Uitnodiging.indd   1 16-3-2018   12:25:45
Oesophageal and Gastric Cancer:
optimising care and outcomes in changing clinical practice 
Margreet van Putten
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   1 20-3-2018   22:24:27
Oesophageal and Gastric Cancer: optimising care and outcomes in changing clinical practice
© Margreet van Putten, the Netherlands, 2018
Omslag:
Op de voorkant van dit proefschrift staat een slokdarm en een maag afgebeeld omringd door 
kersenbloesems. Kersenbloesem wordt beschouwd als het begin van de lente, maar het is ook een metafoor 
voor het leven: mooi, maar vergankelijk. Kersenbloesem is vooral populair in Japan, één van de landen 
waar maagkanker veel voorkomt.
All rights reserved. No part of this thesis may be reproduced or transmitted in any form, by any means, 
without prior written permission of the author. The copyright of the articles that have been published or 
have been accepted for publication has been transferred to the respective journals. 
Financial support for printing of this thesis was kindly provided by:
Netherlands Comprehensive Cancer Organisation (IKNL), Catharina Hospital, Uitgeverij Jaap, Erbe Nederland 
BV, Servier Nederland Farma, Nutricia Advanced Medical Nutrition and ChipSoft BV.
Cover design and lay-out  Marlies van Hoof, www.madebymarlies.nl
Printed by    Ridderprint BV
ISBN    978-94-6299-938-1
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   2 20-3-2018   22:24:28
Oesophageal and Gastric Cancer:
optimising care and outcomes in changing clinical practice
Slokdarm- en maagkanker
Verbeteren van zorg en uitkomst in een veranderend zorglandschap
Proefschrift
ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam 
op gezag van de rector magnificus 
prof.dr. H.A.P. Pols 
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
vrijdag 25 mei 2018 om 11.30 uur
door 
Margreet van Putten
geboren te Deventer
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   3 20-3-2018   22:24:28
Promotiecommissie
Promotor   Prof.dr. V.E.P.P. Lemmens
Overige leden  Prof.dr. M.J. Bruno 
   Prof.dr. G.A.P. Hospers 
   Prof.dr. J.J.B. van Lanschot
Copromotoren  Dr. G.A.P. Nieuwenhuijzen
   Dr. R.H.A. Verhoeven
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   4 20-3-2018   22:24:29
Contents
Chapter 1 Introduction 7
Chapter 2 ‘Missed’ oesophageal adenocarcinoma and high-grade dysplasia 
in Barrett’s oesophagus patients: a large population-based study
19
Chapter 3 Hospital of diagnosis influences the probability of receiving 
curative treatment for oesophageal cancer
37
Chapter 4 Hospital of diagnosis and probability of having surgical 
treatment for resectable gastric cancer
57
Chapter 5 Improved survival after centralisation of gastric cancer surgery in 
the Netherlands
73
Chapter 6 Poor compliance with perioperative treatment in patients with 
resectable gastric cancer
91
Chapter 7 Association between timing of adjuvant chemotherapy 
and overall survival in patients undergoing perioperative 
chemotherapy and gastrectomy for cancer
113
Chapter 8 Impact of age and comorbidity on choice and outcome of two 
different treatment options for patients with potentially curable 
oesophageal cancer
133
Chapter 9 Definitive chemoradiation or surgery in elderly patients with 
potentially curable oesophageal cancer in the Netherlands: a 
nationwide population-based study on patterns of care and 
survival
151
Chapter 10 Effect of age on rates of palliative surgery and chemotherapy use 
in patients with locally advanced or metastatic gastric cancer
169
Chapter 11 Long-term survival improvement in oesophageal cancer in the 
Netherlands 
189
Chapter 12 Discussion and future perspectives 209
Summary 225
Nederlandse samenvatting (Dutch summary) 231
List of publications 243
Dankwoord (Acknowledgements) 249
Curriculum Vitae 255
PhD Portfolio 259
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   5 20-3-2018   22:24:29
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   6 20-3-2018   22:24:29
Chapter 1
Introduction
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   7 20-3-2018   22:24:35
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   8 20-3-2018   22:24:35
19Introduction |
Introduction
Cancer is a major burden of disease worldwide. Every year, over 10 million people are diagnosed 
with cancer around the world and more than half of them eventually die from it.1 As prevention 
and treatment of cardiovascular diseases improved, cancer became the number one killer 
in Europe and is on its way to become the number one killer in the United States and many 
other parts of the world.2-5 As cancer is primarily a disease of the elderly and population aging 
continues in many countries due to increasing life expectancy, cancer will evolve to be the major 
health problem around the globe.6
Epidemiology of oesophageal and gastric cancer
Oesophageal and gastric cancer are in the top-10 most common cancers worldwide as well as 
in the top-10 causes of cancer-related death.1 In the Netherlands, the incidence of oesophageal 
cancer is increasing while the incidence of gastric cancer is decreasing (Figure 1). Oesophageal 
cancer is currently the 8th most common cancer among males in the Netherlands. In 2016, 2800 
patients were diagnosed with oesophageal or cardia cancer and 1250 patients were diagnosed 
with non-cardia gastric cancer.7 Both remain devastating diseases with a 5-year overall survival 
rate of only 19%-25% in non-metastatic oesophageal cancer and 20-31% in non-metastatic 
gastric cancer.8,9 Among patients with metastatic disease, more than half of the patients die 
within 7 months after diagnosis.10,11 
Patients with oesophageal or gastric cancer are predominantly male and are of old age. At 
time of diagnosis, oesophageal cancer patients are on average 68, and gastric cancer patients 
73 years old (Figure 2).7 Due to the high age at diagnosis, a large proportion of the patients 
suffer from comorbidities. Two-third of the patients with oesophageal and gastric cancer has at 
least one comorbid condition.12,13 The most common concomitant diseases are cardiovascular 
diseases and hypertension followed by chronic obstructive pulmonary disease and diabetes.12
The majority of malignant oesophageal tumours can be subdivided in two histological 
groups, i.e. squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma is 
predominantly seen in the proximal oesophagus, while adenocarcinoma develops mainly in the 
distal part of the oesophagus. Globally, squamous cell carcinoma is the predominant histologic 
subtype with the highest burden in Asia and Africa, while in the Western world, including the 
Netherlands, oesophageal adenocarcinoma is more common.14 The incidence of oesophageal 
adenocarcinoma rapidly increased the last decennia in the Netherlands as well as in several 
other Western countries. As a result the incidence gap between oesophageal adenocarcinoma 
and oesophageal squamous cell carcinoma has widened (Figure 3).15-17 Tobacco use and alcohol 
consumption are the most important risk factors for squamous cell carcinoma.16 While the most 
important risk factors for oesophageal adenocarcinoma are obesity and gastro-oesophageal 
reflux disease.16 A long-standing gastro-oesophageal reflux disease is a primary risk factor for 
the development of Barrett’s oesophagus, which is linked to an even higher risk to develop 
oesophageal adenocarcinoma.16
A Barrett’s oesophagus is currently the only known precursor for oesophageal 
adenocarcinoma.16 In Barrett’s oesophagus the squamous mucosa of the oesophagus is 
replaced by columnar epithelium (intestinal metaplasia), and oesophageal endoscopy shows 
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a displacement cranially of salmon coloured mucosa into the oesophagus. Barrett’s epithelium 
can progress from non-dysplastic to low-grade dysplasia, to high-grade dysplasia and ultimately 
result in oesophageal adenocarcinoma.18 However, yearly only 0.4% of the Barrett’s oesophagus 
patients will progress to oesophageal adenocarcinoma.19-21 Endoscopic surveillance is currently 
recommended in long-segment Barrett’s oesophagus patients to reduce morbidity and 
mortality through early detection of dysplasia and cancer.22 A contributing problem for the 
optimal management of Barrett’s oesophagus surveillance is the occurrence of ‘interval’ and 
‘missed’ cancers. One study in this thesis focusses on the risk of ‘missed’ (pre)cancerous lesions 
at index endoscopy among patients with a Barrett’s oesophagus.
As shown in figure 1, the incidence of gastric cancer has been declining in Western countries, 
especially for non-cardia gastric cancer, probably due to the replacement of refrigerators instead 
of salt-preserved foods, a higher intake of fruit and vegetables and a lower prevalence of the 
Helicobacter pylori infection.8,23-26 Helicobacter pylori is reported to be a risk factor for gastric 
cancer.27 The prevalence of Helicobacter pylori has declined due to improved sanitation and 
eradication therapy. It causes the formation of precancerous lesions. By contrast, Helicobacter 
pylori infection is associated with a reduced risk of a Barrett’s oesophagus and oesophageal 
adenocarcinoma.28,29 The decreasing seropositivity for Helicobacter pylori might have 
contributed to the rising incidence of oesophageal adenocarcinoma.28,29                                                              



















	
	
		

		

		

		

		
	









	






Figure 1 Absolute incidence of oesophageal and gastric cancer in the Netherlands by year of diagnosis. 
Source: Netherlands Cancer Registry. The numbers for 2016 are based on estimations. 
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Figure 2 Age at diagnosis of patients with oesophageal and gastric cancer diagnosed in the Netherlands 
in 2014-2015 (n=5341 and n=2298, respectively). Source: Netherlands Cancer Registry.
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Figure 3 Incidence of oesophageal cancer in the Netherlands by year of diagnosis and morphology. Source: 
Netherlands Cancer Registry.
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Treatment of oesophageal and gastric cancer
Oesophageal and gastric cancer are challenging diseases to treat. About 40% of the patients 
with oesophageal and gastric cancer has systemic disease at time of diagnosis (Figure 4), 
leaving palliative chemo(radio)therapy, stents and best supportive care as the main choice 
of treatment . According to the Dutch clinical practice guideline for gastric cancer, a palliative 
gastrectomy to improve quality of life and/or survival may be considered for metastatic gastric 
cancer patients younger than 70 years with one item of incurability- either distant metastasis 
or tumour infiltrating surrounding organs.30 However, the effects of palliative gastrectomy on 
survival and quality of life remains unclear.31,32 
Furthermore, most patients who are eligible for curative treatment have locally advanced, 
lymph node positive disease which requires a combination of surgery and chemo(radio)therapy. 
Moreover, patients may be unfit for surgery because of fragility, severe comorbidity or a poor 
nutritional status. Definitive chemoradiotherapy is increasingly considered as a well-tolerated 
alternative for surgery in inoperable oesophageal cancer patients and especially in irresectable 
cervical oesophageal cancer.33 An endoscopic mucosal resection is the preferred treatment of 
early stage tumours without lymph node metastasis.34 
Even after radical surgery, many patients suffered from recurrence with consequently a poor 
prognosis.35,36 Therefore, several multimodality treatment approaches have been proposed and 
studied in the late 1990s and  2000s. As a result of these trials, preoperative chemoradiotherapy 
followed by surgery is currently the preferred treatment for locally advanced oesophageal 
cancer and perioperative chemotherapy is the preferred treatment for locally advanced gastric 
cancer in the Netherlands.37-39 Both treatment regimes have been shown to improve radicality, 
reduce local recurrence and increase survival. 
Over the last decade, more and more patients are treated by multimodality treatment 
approaches, including different combinations of endoscopic treatment, chemotherapy, 
Figure 4 Clinical tumour stage distribution for patients with oesophageal and gastric cancer in the 
Netherlands in the period 2014-2015. Source: Netherlands Cancer Registry.
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radiotherapy and surgery. However, the efficacy and tolerability of various treatment modalities 
varies from patient to patient in daily clinical practice. Therefore, it is highly desirable to move 
from a one-size-fits all approach to a more tailored treatment approach for the individual patient. 
Evaluating the results of treatment on outcome among subgroups of patients based on patients 
and tumour characteristics can identify patients who might benefit from a particular treatment 
approach. Moreover, it can avoid unnecessary mortality or morbidity in patients who have little 
or no benefit from that particular treatment. Several studies in this thesis focus on aspects of this 
multimodality approach in order to improve the quality of care for patients with oesophageal 
and gastric cancer, by investigating patterns of care and outcomes among specific patient 
groups. 
Centralisation of surgery and hospital of diagnosis
Surgery is the cornerstone of curative treatment for oesophageal and gastric cancer. However, 
both oesophagectomy and gastrectomy are high-risk surgical procedures associated with high 
postoperative morbidity and mortality rates. Due to the relatively low incidence, procedures 
used to be mainly performed in multiple low-volume hospitals.13,37,40 Over the last two decades, 
a large number of studies observed that increasing hospital volume is associated with lower 
postoperative mortality and higher survival rates in the Western world and Asia.41-45 Therefore, 
centralisation has been initiated in several European countries including the Netherlands. As 
of 2006, hospitals should perform a minimum of 10 oesophageal resections per year, and since 
2011 the minimal volume increased to 20 oesophageal resections per year in the Netherlands. 
Centralisation of gastric cancer surgery started somewhat later in the Netherlands. As of 2012 a 
yearly minimum of 10 gastric resections was implemented and since 2013 this minimal volume 
increased to 20 gastric resections per year. One study in this thesis investigates the impact of 
centralisation for gastric cancer surgery on patients outcomes. 
Although surgery for oesophageal and gastric cancer is nowadays centralised, the initial 
decision which treatment modality to perform, including the decision whether or not to refer 
patients for potential curative treatment, is made in all Dutch hospitals. Therefore, two studies in 
this thesis focus on the impact of the hospital diagnosis on the probability to undergo curative 
treatment for oesophageal and gastric cancer. Furthermore, the impact of variation in curative 
treatment among these hospitals of diagnosis on survival was investigated. 
Data source
Netherlands Cancer Registry
The research presented in this thesis was mainly based on the data from the Netherlands Cancer 
Registry. The registration of cancer in the Netherlands started in 1955 and comprised data of 
three hospitals located in Eindhoven. Data on all new cancer patients were collected directly 
from pathology reports and medical records. The area gradually expanded and from 1986 on 
it covers the entire province Noord-Brabant and the northern part of Limburg, an area of 2.4 
million inhabitants with 10 community hospitals and two radiotherapy institutions served by 
six regional pathology laboratories. 
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Since 1989 the entire Dutch population was covered by nine regional registries, together 
establishing the Netherlands Cancer registry, managed by nine regional Comprehensive 
Cancer Centres. In the period 2011-2014 the regional centres merged into the Netherlands 
Comprehensive Cancer Organisation (IKNL), which now maintains the Netherlands Cancer 
Registry. The uptake of data in this database is performed by specially trained data managers 
of IKNL. The Netherlands Cancer Registry is based on notification of all newly diagnosed 
malignancies in the Netherlands by the national automated pathological archive, PALGA. 
Additional sources are the national registry hospital discharge and radiotherapy institutions. 
Information is registered about diagnosis, tumour stage and treatment from the medical 
records. Information on vital status is obtained through an annual linkage with the Municipal 
Administrative Database, in which all deceased and emigrated persons in the Netherlands are 
registered. The municipal registries provide virtually complete coverage of all deceased citizens 
of the Netherlands.
Outline of this thesis
The studies presented in this thesis focus on important changes and challenges in diagnosis 
and treatment of oesophageal and gastric cancer.
The main objectives of the studies described in this thesis were:
1. To investigate patterns of care for patients with a Barrett’s oesophagus, with an emphasis 
on the quality of surveillance endoscopy. 
2. The examine the influence of the hospital of diagnosis on the probability to receive curative 
treatment and its impact on survival among patients with oesophageal and gastric cancer.
3. To investigate the effects of centralisation of surgery on survival among patients with gastric 
cancer. 
4. To study the patterns of care and its impact on survival for specific groups of patients with 
oesophageal and gastric cancer in a large population-based setting.
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Abstract
Background 
A systematic review suggests that 25% of oesophageal adenocarcinomas (OAC) are ‘missed’ at 
index endoscopy for Barrett’s oesophagus (BO); however this included few population-based 
studies and may be an overestimate.
Objective
The objective of this article is to quantify the ‘missed’ rates of high-grade dysplasia (HGD) and 
OAC at index BO endoscopy. 
Methods
Patients from the Northern Ireland BO register diagnosed between 1993-2010 (n=13 159) were 
linked to the Northern Ireland Cancer Registry to identify patients who developed OAC or HGD. 
Logistic regression analysis compared characteristics of ‘missed’ versus ‘incident’ HGD/OAC, 
defined as diagnoses within 3-12 months versus >1 year after incident BO, respectively. 
Results
A total of 267 patients were diagnosed with HGD/OAC ≥3 months after BO diagnosis, of which 
34 (12.7%) were potentially ‘missed’. The proportion of ‘missed’ HGD/OAC was 25% among BO 
patients with low-grade dysplasia (LGD) and 9% among non-dysplastic BO patients. Older age 
and BO-LGD carried a higher risk of ‘missed’ HGD/OAC. Non-dysplastic BO patients were more 
often diagnosed with a ‘missed’ OAC (rather than HGD; 89%), compared with BO-LGD patients 
(40%).
Conclusions
Approximately one in 10 HGD/OAC cases are ‘missed’ at incident BO diagnosis, which is 
significant but lower than previous reports. However ‘missed’ HGD/OAC cases represent only 
0.26% of all BO patients.
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Introduction
Barrett’s oesophagus (BO) is currently the only known precursor for oesophageal adenocarcinoma 
(OAC), which has a poor prognosis with five year survival rates between 15% and 20%.1  Although 
the incidence of BO and OAC are increasing in the Western world, only approximately 0.4% of 
BO patients will progress to OAC each year.2-5 This raises issues for how to manage the increasing 
number of patients with BO and how to identify high-risk patients, without overburdening 
services.
Endoscopic surveillance is recommended in BO patients to reduce morbidity and mortality 
through early detection of dysplasia and cancer.6, 7 The British Society of Gastroenterology (BSG) 
guidelines recommends repeated endoscopy at three- to five year intervals among BO patients 
with a Barrett’s length of under 3 cm,  and repeated endoscopy at two- to three year intervals is 
recommended for patients with longer Barrett’s segments or specialised intestinal metaplasia 
(SIM).6 Patients with low-grade dysplasia (LGD) should receive surveillance endoscopy at six 
monthly intervals. However, as of 2015, endoscopic ablation, preferably with radiofrequency 
ablation (RFA), has been recommended for high-grade dysplasia (HGD) or LGD diagnosed on 
two occasions in addition to repeat surveillance endoscopy at six months for patients with 
LGD.6 In spite of relatively intensive surveillance, the impact of these programs on preventing 
deaths from OAC is equivocal.8-10  A contributing problem for the optimal management of BO 
surveillance is the occurrence of ‘interval’ and ‘missed’ cancers.11, 12
‘Missed’ cancers can be defined as cancers that were already present at the index BO 
endoscopy, but were not detected, whereas it is hypothesised that truly incident cancers 
develop after the index BO endoscopy.13, 14 A recent systematic review found that amongst 
BO patients, 25% of patients who later developed OAC, were diagnosed within one year after 
index BO endoscopy, and could therefore be considered ‘missed’ cancers.14 However, this review 
included only a few population-based studies and included diagnoses within three months after 
the index BO endoscopy in their definition of a ‘missed’ cancer. Both of these considerations are 
likely to have resulted in an overestimate of the magnitude of ‘missed’ cancers. Therefore, this 
study aimed to quantify the ‘missed’ rates of HGD and OAC at index endoscopy among patients 
with a BO diagnosis utilising one of the largest population-based registers of BO worldwide. We 
further sought to identify risk factors which may contribute to these missed cases.
Methods
BO patients
The Northern Ireland Barrett’s register (NIBR) includes 13 294 patients with BO aged ≥ 16 
years diagnosed between 1993 and 2010 in Northern Ireland (NI) (population of 1.8 million). 
Descriptions of the NIBR have been previously reported.4 Strict criteria for BO were used, 
which was defined as columnar-lined epithelium of the oesophagus. Trained staff extracted 
information on BO length, the presence of SIM and visible BO at endoscopy, using standardised 
guidelines, from all pathology reports relating to oesophageal biopsies carried out in NI over 
this time period. The date of the earliest (index) biopsy showing BO was taken as the date of 
entry into the register. 
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Outcomes
The NIBR was matched to the Northern Ireland Cancer Registry (NICR),15 which was used to 
identify BO patients who progressed to oesophageal or gastric cardia adenocarcinoma (hereafter 
referred to as OAC) between January 1993 and 2013 in NI. Gastric cardia adenocarcinoma 
was also included as an outcome because it is likely that these tumours in BO patients are 
oesophageal in origin. This process has been described previously.3 Histologically unspecified 
cancers were reviewed by a gastrointestinal pathologist. Oesophageal squamous cell carcinomas 
were excluded. Deaths were identified through matching to the NI Registrar General’s Office. 
Matching of BO patients diagnosed after 2005 with the NICR was performed by using the unique 
Health and Social Care Number, which is available for over 90% of patients. The remaining 
patients and patients diagnosed before 2005 were matched using patients’ forename, surname 
and date of birth.  
BO patients who developed HGD were identified by examining all oesophageal pathology 
reports from NI for the period 1993-2013. Patients were considered to have HGD if diagnosed 
twice within one year or in two subsequent biopsies, even if the duration between them was 
more than one year, or if HGD was present in a single biopsy and the duration of available follow-
up after the development of HGD was less than one year. HGD which occurred in squamous 
epithelium was not included as an outcome. According to the Central Committee on Research 
involving Human Subjects (CCMO), this type of study does not require approval from an ethics 
committee.
Statistical analysis
The primary outcome was ‘missed’ OAC and HGD after a BO diagnosis. Patients with HGD/
OAC were divided in two categories: ‘missed’ and incident cases. In line with previous studies, 
‘missed’ HGD/OAC was defined as diagnoses within 3-12 months after the index BO biopsy. An 
outcome less than three months after index BO could be part of the diagnostic work-up instead 
of ‘missed’ and therefore these patients were excluded from the analysis (n=187).13, 16 Incident 
HGD/OAC was defined as being diagnosed at least one year after index BO biopsy.  Follow-up 
was defined from the first BO diagnosis until first HGD or OAC diagnosis and was available until 
31 December 2013. 
Data were analysed for the combined outcome of HGD and OAC, and for OAC only. 
Chi-squared tests and analysis of variance (ANOVA) were used to compare categorical and 
continuous variables, respectively, between patients diagnosed 3-12 months, one to three 
year and more than three year following BO diagnosis.  Univariable and multivariable logistic 
regression were used to examine factors associated with being diagnosed within 3-12 months 
after a BO diagnosis versus being diagnosed later than one year after BO diagnosis. 
Two analyses were performed among a selected group of BO patients. First, restriction was 
applied to the analysis to examine differences in the proportion of ‘missed’ HGD/OAC cases in 
the period 1993-2001 and 2002-2010. Patients who progressed more than three years after 
BO diagnosis were excluded from this particular analysis as the maximum time of follow-up 
was three years for patients diagnosed with BO in 2010. Second, restriction was applied to 
the analysis to investigate tumour stage according to time between BO diagnosis and HGD/
OAC diagnosis. As tumour stage was less accurately registered for BO patients who progressed 
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to OAC before 2002, only patients diagnosed with BO as of 2002 were included. A secondary 
analysis compared median survival time between all ‘missed’ and incident OAC patients for 
whom survival time was defined from OAC diagnosis until death or until 9 December 2016, 
whichever occurred earlier. Statistical analyses were conducted using Intercooled STATA V11.0.
Results
Proportion of ‘missed’ HGD/OAC cases 
During the study period, n=267 patients developed HGD/OAC after three months of follow-
up, of whom n=34 patients (12.7%) were diagnosed within 3-12 months after BO diagnosis 
(Table 1). The proportion of HGD/OAC classified as ‘missed’ was reduced in non-dysplastic BO 
(9%), whereas a higher proportion was observed in BO-LGD (25%). When restricting analysis 
to OAC progressors only, n=210 patients developed OAC after three months of follow-up, of 
whom n=26 patients (12%) were diagnosed within 3-12 months after BO diagnosis (Appendix 
1). The distribution of HGD/OAC diagnoses over time is shown in Figures 1 and 2. Figure 1 shows 
that approximately half of HGD/OAC progressors were diagnosed more than 5 years after their 
first BO biopsy. Furthermore, the proportion of non-dysplastic BO patients increases, and the 
proportion of LGD-BO patients decreases with increasing follow-up years after first BO biopsy 
among patients who progressed in HGD/OAC (Figure 2). 
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Figure 1  Distribution of time to HGD/OAC diagnosis among 267 detected cases of HGD/OAC.
BO: Barrett’s oesophagus; HGD: high-grade dysplasia; OAC: oesophageal adenocarcinoma
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Clinical factors associated with risk of ‘missed’ versus incident HGD/OAC
Patients with a ‘missed’ HGD/OAC were significantly older compared to patients diagnosed 
after three years with HGD/OAC (median age of 66.9 vs 60.1 years; Table 1).  Approximately a 
quarter of the patients who were 75 years or older and progressed to HGD/OAC progressed 
within 3-12 months after a BO diagnosis, whereas only 9% of progressors younger than 65 
years did so (P=0.008; Table 1). In multivariable analysis, patients aged ≥75 v. <65 years still 
had higher odds of a ‘missed’ compared with incident HGD/OAC (odds ratio (OR)= 2.78 95% 
confidence interval (CI) 1.02-7.61). Overall, sex, SIM, length of Barrett’s segment, visible segment 
seen at index endoscopy and socioeconomic status were not associated with risk of a ‘missed’ 
compared with incident HGD/OAC (Table 2). Similar findings were observed when restricted to 
OAC progressors only (data not shown).
Patients with LGD had 3.5-fold higher odds of being diagnosed within 3-12 months rather 
than incident HGD/OAC compared to non-dysplastic BO patients (OR=3.48 95%CI 1.56-7.76; 
Table 2).  LGD or non-dysplastic status also influenced the severity of HGD/OAC detected within 
‘missed’ cases. Among the BO-LGD patients, 40% developed HGD and 60% developed OAC. In 
contrast, within the non-dysplastic BO patients who developed a ‘missed’ HGD/OAC, only 11% 
had HGD detected and the majority (89%) had OAC detected (Figure 3).
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Figure 2 Dysplasia status at BO diagnosis by time to HGD/OAC diagnosis among 267 detected cases of 
HGD/OAC.
BO: Barrett’s oesophagus; HGD: high-grade dysplasia; OAC: oesophageal adenocarcinoma
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Table 1 Characteristics of patients with a Barrett’s oesophagus (BO) who progressed to HGD/ OAC after 
three months after a Barrett’s diagnosis (n=267)
Features at index BO endoscopy b HGD/OAC 
progressors 
≥ 3-12 months 
n=34 (13%)
HGD/OAC 
progressors 
within ≥ 1-3 year 
n=59 (22%)
HGD/OAC 
progressors 
≥ 3 years 
n=174 (65%)
n %c n %c n %c P value
Sex 0.601
Female 8 11.76 18 26.47 42 61.76
Male 26 13.07 41 20.60 132 66.33
Median age( IQR) 66.9 60.7-75.3 65.2 56.7-73.7 60.1 52.3-68.3 <0.001
Age group 0.008
<65 15 9.15 29 17.68 120 73.17
65-74 10 15.38 20 30.77 35 53.85
≥75 9 23.68 10 26.32 19 50.00
Socio-economic status a 0.146
Most deprived 16 15.53 16 15.53 71 68.93
Middle deprived 7 13.73 8 15.69 36 70.59
Least deprived 9 9.68 29 31.18 55 59.14
Unknown 2 10.00 6 30.00 12 60.00
Specialised intestinal metaplasia 0.412
Absent / unknown 9 14.75 14 22.95 38 62.30
Present 25 12.14 45 21.84 136 66.02
Visible segment seen at endoscopy 0.843
Unknown/no 22 13.02 39 23.08 108 63.91
Yes 12 12.24 20 20.41 66 67.17
Dysplasia <0.001
No dysplasia 19 9.13 40 19.23 149 71.63
Low-grade dysplasia 15 25.42 19 32.20 25 42.37
a Category ‘most deprived quintile’ and ‘quintile 2’ are merged into ‘most deprived’. Category ‘quintile 4’ and ‘Least deprived 
quintile’ were merged into ‘Least deprived’.
b Numbers for short, long and unknown Barrett’s segment are not presented due to small cell counts (<3) and to avoid 
disclosure of potentially identifiable information. 
c Percentages were calculated across the rows to emphasise the proportions of all missed or incident cancers over 
time, rather than calculating the percentages within the columns. 
HGD: high-grade dysplasia; OAC: oesophageal adenocarcinoma; IQR: interquartile range
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Figure 3 Progression in HGD/OAC according to dysplasia status among 34 ‘missed’ cases of HGD/OAC.
BO: Barrett’s oesophagus; HGD: high-grade dysplasia; OAC: oesophageal adenocarcinoma
 Proportion of missed HGD/OAC by period of BO diagnosis
We then sought to evaluate if proportions of ‘missed’ HGD/OAC diagnoses had changed over 
time. Similar proportions of HGD/OAC cases diagnosed within 3-12 months after their BO 
diagnosis were observed in the earlier 1993-2001 time period (36%) and the more recent 2002-
2013 period (38%) (Table 3). Results indicate a higher proportion of ‘missed’ cases compared 
to main results in Table 1 due to exclusion of patients diagnosed more than three years after a 
BO diagnosis. 
Tumour stage and survival among ‘missed’ versus incident OAC patients
Patients diagnosed with a ‘missed’ OAC were diagnosed with an earlier or unknown tumour 
stage compared with OAC patients diagnosed after 3 years (P=0·175). Among the patients with a 
‘missed’ OAC, 33% had a stage I tumour, whereas 27% and 18% of the patients diagnosed within 
one to three year and after three years, respectively, had a stage I tumour (Appendix 2). Better 
overall survival outcomes were also observed amongst ‘missed’ compared with incident OAC 
cases (median (interquartile range (IQR) 3.96 (0.90-9.46) and 1.94 (0.44-6.12) years, respectively). 
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Table 2 Univariable and multivariable logistic regression analysis to examine the likelihood of being 
diagnosed with HGD/ OAC after 3-12 months compared to ≥ 1 year after a Barrett’s oesophagus diagnosis 
(n=267).
Features at index BO endoscopy 3-12 months ≥ 1 year Univariable Multivariable b
n=34 n=233 OR 95%CI OR 95%CI
Sex
Female 8 60 ref ref
Male 26 173 1.13 0.48-2.62 1.31 0.51-3.33
Age group
<65 15 149 ref ref
65-74 10 55 1.81 0.77-4.26 1.90 0.77-4.67
≥75 9 29 3.08 1.23-7.71 2.78 1.02-7.61
Socio-economic status a
Most deprived 16 87 ref ref
Middle deprived 7 44 0.87 0.33-2.26 1.10 0.39-3.06
Least deprived 9 84 0.58 0.24-1.39 0.62 0.25-1.54
Unknown 2 18 0.60 0.13-2.86 0.75 0.15-3.79
Specialised intestinal metaplasia 
Absent / unknown 9 52 ref ref
Present 25 181 0.80 0.35-1.82 0.76 0.31-1.83
Visible segment seen at endoscopy
No / unknown 22 147 ref ref
Yes 12 86 0.93 0.44-1.98 0.97 0.42-2.27
Length of Barrett’ s segment c
Long ≥ 3 cm  NR NR 0.54 0.09-3.03 0.53 0.08-3.29
Short < 3 cm NR NR ref ref
Unknown 27 148 1.37 0.30-6.33 1.44 0.27-7.77
Dysplasia at index biopsy
No dysplasia 19 189 ref ref
Low-grade dysplasia 15 44 3.39 1.60-7.20 3.48 1.56-7.76
a Category ‘most deprived quintile’ and ‘quintile 2’ are merged into ‘most deprived’. Category ‘quintile 4’ and ‘Least 
deprived quintile’ were merged into ‘Least deprived’. b Adjusted for all variables listed in table 2. c Numbers for short 
and long Barrett’s segment are not presented due to small cell counts (<3) and to avoid disclosure of potentially 
identifiable information. HGD: high-grade dysplasia; OAC: oesophageal adenocarcinoma; NR= not reported; OR= 
adds ratio; CI: confidence interval
Table 3 Proportion of ‘missed’  HGD or OAC according to period of Barrett’s (BO) diagnosis among patients 
who progressed in HGD or OAC within 3-36 months after their Barrett’s diagnosis.a
Diagnosed 3-12 months after 
BO diagnosis
n=34
Diagnosed ≥1-3 year after   
BO diagnosis
n=59
P value b
Period of BO diagnosis 0.835
1993-2001 20 (36%) 36 (64%)
2002-2010 14 (38%) 23 (62%)
a Patients diagnosed more than three year after a BO diagnosis were excluded from the analysis as the maximum follow-
up is three year for BO patients diagnosed in 2010. b based on a chi-squared test. HGD: high-grade dysplasia; OAC: 
oesophageal adenocarcinoma
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Discussion
This is one of the largest population-based studies to date to investigate the magnitude of 
‘missed’ HGD or OAC in patients with BO. We defined a ‘missed’ case as being diagnosed with 
HGD/OAC within 3-12 months after index BO diagnosis. Results showed ‘missed’ rates of 13% 
and 9% among all BO patients and all non-dysplastic BO patients, respectively, who were 
subsequently diagnosed with HGD/OAC. The proportion of ‘missed’ cases remained stable 
during the study period.
The ‘missed’ rate reported in the present study is significant but lower than previously 
reported estimates. A systematic review of 24 studies reported a ‘missed’ rate of 25%.14 
Furthermore, three population-based studies, which were also included in the review, reported 
that 32-66% of the patients who progressed in OAC were diagnosed within one year after BO 
diagnosis.2, 3, 17 In contrast with our study, these studies defined ‘missed’ as being diagnosed with 
HGD/OAC within one year after BO diagnosis. However, HGD/OAC patients diagnosed less than 
three months after BO may be part of the diagnostic work-up.16 Chadwick et al also excluded 
patients diagnosed within three months after a BO diagnosis for the calculation of their ‘missed’ 
rate.13 They found that 7.8% of the patients with OAC underwent a previous endoscopy three to 
36 months preceding diagnosis of OAC, which is similar to the ‘missed’ rate of 9% detected in 
non-dysplastic BO patients in the present study.  Furthermore, Holmberg et al also noted a high 
incidence of OAC within the first 100 days after BO diagnosis.16 Still, it is worth noting that all 
of the above reported ‘missed’ rates after an oesophagogastroduodenoscopy are unfavourable 
compared with reported rates of missed colorectal cancers after a colonoscopy, which ranges 
from 0.5% to 6%.18, 19 
There could be two overarching explanations for the ‘missed’ cancers. First, the missed cancers 
may be truly missed, which means that the cancer or premalignant lesions were already present 
at index endoscopy but not detected. A previous study has found that errors by the endoscopist 
account for the majority (73%) of ‘missed’ oesophageal or gastric cancers at endoscopy and 
the remaining 27% were related to errors by pathologists.20 It is possible that HGD or OAC was 
not detected due to features that make them less likely to be seen by the endoscopist such as 
oesophagitis, oesophageal stricture and ulceration.20 Methods to increase detection of HGD/
OAC such as advanced endoscopic imaging techniques6, greater time examining BO segments21, 
greater number of targeted biopsies20 and dedicated time slots for examination22 may identify 
HGD or malignant lesions and decrease the burden of missed HGD/OAC through early detection 
of HGD/OAC which could increase cure and survival rates.7, 23 
Cases may be truly missed if the second endoscopy was not part of routine surveillance. 
Based on a previous case note review (unpublished) among 60% of the HGD/OAC progressors, 
more than half of the ‘missed’ cases were not entered into routine surveillance and surveillance 
was probably performed due to new symptoms. These cases may be truly ‘missed’ cases. 
Moreover, taking into account the time interval between BO and OAC, one can suggest that the 
OAC cases were already present at index endoscopy. Nevertheless, the missed cases represents 
only 0.26% of all BO patients diagnosed in NI over this timeframe, and so the ever-important 
question of identifying the very small proportion of high-risk patients ( ‘missed’ or incident HGD/
OAC) remains a considerable challenge.  
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Second, it is plausible that the missed cancers may be more aggressive cancers which have 
no visible evidence at index endoscopy but develop rapidly afterward. Therefore, biomarkers 
could assist in determining the risk of progression at BO diagnosis and guide the targeting 
of endoscopic surveillance.24 Previous studies indicate that there are two main pathways of 
progression among BO patients: 25, 26 a more indolent pathway which moves through to dysplasia 
to OAC, acquiring a variety of mutations and a more aggressive pathway dominated by genomic 
doubling with more frequent oncogenic amplification and less frequent inactivation of tumour 
suppressors.25 Results from the present study provide some support for these two pathways, 
as non-dysplastic BO patients were more often diagnosed with ‘missed’ OAC than ‘missed’ HGD 
compared to LGD patients. However, the present study has found that patients diagnosed within 
3-12 months after BO diagnosis had more often a stage I or stage II tumour and a longer median 
survival compared to patients diagnosed more than three year after BO diagnosis. Patients with 
a missed OAC had a better median survival probably because they had more often an earlier 
tumour stage which can effectively be treated with endoscopic techniques such as endoscopic 
resection and RFA.
A higher ‘missed’ rate of 25% among LGD-BO patients likely reflects appropriate clinical 
management and planned surveillance after BO diagnosis. Results of the present study support 
the effectiveness of BSG guidelines, which recommend more frequent surveillance endoscopy 
among LGD-BO patients, as these patients had a higher likelihood to have HGD/OAC diagnosed 
within 3-12 months, compared to non-dysplastic BO patients. This conclusion is supported by 
the proportion of ‘missed’ HGD cases among all ‘missed’ HGD/OAC cases being higher among 
patients with LGD-BO compared with non-dysplastic BO (60% vs 11%). Our study timelines pre-
date the recent changes to BSG guidelines6 to allow endoscopic ablation, preferably with RFA, 
for LGD patients, instead of repeated endoscopy after six months of being treated with proton 
pump inhibitors (PPIs).6, 27, 28  
We also explored if clinical or demographic features may differ between ‘missed’ or incident 
HGD/OAC cases. Having an older age was associated with a higher risk of a ‘missed’ HGD/OAC 
instead of an incident HGD/OAC. It is possible that simply the older you are the more likely you 
are to have cancer and therefore the more likely for it to be missed. However, higher rates of 
‘missed’ cases among elderly patients may simply reflect shorter life expectancies and therefore 
a reduced likelihood of developing HGD/OAC three years after first BO biopsy. In addition, a 
previous study from Visrodia et al found that the presence of a long-segment BO could  place 
patients at greater risk of ‘missed’ HGD or OAC.29 In contrast, the  length of Barrett’s segment 
was not associated with a higher risk of a ‘missed’ HGD or OAC in the present study. However, 
information on Barrett’s length was limited in our cohort. 
This study has important strengths, in particular the completeness of identification of 
outcomes, large size and population-based analysis within a region with limited migration.15 
However, this study also has some limitations. The exclusion of patients diagnosed within three 
months for the definition of ‘missed’ cases is somewhat arbitrary. However, a previous study also 
excluded these patients as a diagnosis within three months after BO diagnosis could be part 
of the diagnostic work-up.13 Furthermore, BO guidelines have been updated since conclusion 
of this study period. Within the updated BSG guidelines published in 2015, clinicians can now 
discharge patients from endoscopic surveillance who have a short Barrett’s segment and 
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repeated confirmation that SIM is not present.6 Therefore, future research may need to reassess 
these estimates to evaluate any impact on potential ‘missed’ diagnoses; however, the perceived 
low cancer risk in these patients is likely to have minimal influence. In addition, information 
about PPI use was not available. Finally, we acknowledge that the term ‘missed’ is somewhat 
controversial in the capacity of this, and similar, studies. We retained the term in this report 
primarily to ensure comparability with previous publications. However, we call on researchers 
to adopt a more appropriate term, such as underdiagnosed or short-term interval cancers, for 
future manuscripts.   
In conclusion, based upon a large population-based study, we observed  a ‘missed’ HGD/OAC 
rate of 13%, which is not negligible, but is substantially lower than rates suggested by a recent 
systematic review of this area.14 Increased awareness, adequate biopsy sampling and identifying 
biomarkers may reduce the number of BO patients with a ‘missed’ oesophageal malignant or 
premalignant lesion.  However, such efforts must be balanced in the context of ‘missed’ cases 
representing a small minority of the overall BO patient population.
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Appendix 1 Characteristics of patients with a Barrett’s oesophagus who progressed to OAC 3 months after 
a Barrett’s diagnosis (n=210)
Features at index BO endoscopy * Patients diagnosed 
≥ 3-12 months 
n=26 (12%)
Patients diagnosed 
≥ 1-3 year 
n=39 (19%)
Patients diagnosed
 ≥ 3 years 
n=145 (69%)
n % ** n % ** n % ** P value
Sex 0.424
Female 5 9.09 13 23.64 37 67.27
Male 21 13.55 26 16.77 108 69.68
Median age( IQR) 68.2 60.7-79.1 68.4 58.4-74.5 60.7 52.5-69.2 0.007
Age group 0.012
<65 11 13.11 16 13.11 95 77.87
65-74 7 12.96 15 27.78 32 59.26
≥75 8 23.53 8 23.53 18 52.94
Socio-economic status a 0.065
Most deprived 14 16.67 11 13.10 59 70.24
Middle deprived 6 14.29 4 9.52 32 76.19
Least deprived 5 7.04 21 29.58 45 63.38
Unknown 1 7.69 3 23.08 9 69.23
Specialised intestinal metaplasia 0.723
Absent/ unknown 6 12.24 11 22.45 32 65.31
Present 20 12.42 28 17.39 113 70.19
Visible segment seen at endoscopy 0.576
Unknown/no 17 12.50 28 20.59 91 66.91
Yes 9 12.16 11 14.86 54 72.97
Dysplasia 0.001
No dysplasia 17 10.24 24 14.46 125 75.30
Low-grade dysplasia 9 20.45 15 34.09 20 45.45
NR= not reported
a Category ‘most deprived quintile’ and ‘quintile 2’ are merged into ‘most deprived’. Category ‘quintile 4’ and ‘Least deprived 
quintile’ were merged into ‘Least deprived’. 
* Numbers for short, long and unknown Barrett’s segment are not presented due to small cell counts (<3) and to avoid 
disclosure of potentially identifiable information.
** Percentages were calculated across the rows as it rather suits the aim of this study than calculating the percentages 
within the columns.
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Appendix 2 Tumour stage and time until oesophageal adenocarcinoma (OAC) diagnosis for patients with 
a Barrett’s oesophagus diagnosed between 2002 and 2010 that progressed in OAC (n=76). 
Patients diagnosed with a BO before 2002 and progressed in OAC were excluded from the analysis as their tumour stage 
was less accurately reported.
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Abstract
Objective
The aim of this article was to study the influence of hospital of diagnosis on the probability 
of receiving curative treatment and its impact on survival among patients with oesophageal 
cancer. 
Background 
Although oesophageal cancer surgery is centralised in the Netherlands, the disease is often 
diagnosed in hospitals which do not perform this procedure.
Methods 
Patients with potentially curable oesophageal or gastro-oesophageal junction tumours 
diagnosed between 2005 and 2013 who were potentially curable (cT1-3,X, any N, M0,X) were 
selected from the Netherlands Cancer Registry. Multilevel logistic regression was performed to 
examine the probability to undergo curative treatment (resection with or without neoadjuvant 
treatment, definitive chemoradiotherapy or local tumour excision) according to hospital of 
diagnosis. Effects of variation in probability of undergoing curative treatment among these 
hospitals on survival were investigated by Cox regression.
Results 
All 13,017 patients with potentially curable oesophageal cancer, diagnosed in 91 hospitals, were 
included. The proportion of patients receiving curative treatment ranged from 37% to 83% and 
from 45% to 86% in the periods 2005-2009 and 2010-2013, respectively, depending on hospital 
of diagnosis. After adjustment for patient- and hospital-related characteristics these proportions 
ranged from 41% to 77% and from 50% to 82%, respectively (both P<0.001). Multivariable 
survival analyses showed that patients diagnosed in hospitals with a low probability of 
undergoing curative treatment had a worse overall survival (hazard ratio=1.13 95% confidence 
interval 1.06-1.20; hazard ratio=1.15; 95% confidence interval 1.07-1.24).
Conclusions 
The variation in probability of undergoing potentially curative treatment for oesophageal cancer 
between hospitals of diagnosis and its impact on survival indicates that treatment decision-
making in oesophageal cancer may be improved.
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Background
Oesophageal cancer is the eighth most common cancer and the sixth leading cause of cancer-
related mortality worldwide.1 The incidence of oesophageal cancer in the Western world has 
risen over the past four decades and is still rising but at a slower rate than previously observed.2,3 
Although survival rates have improved during the past decade, they still remain poor with a 
5-year relative survival ranging from 19%-25% for patients with M0 oesophageal cancer and a 
2-year relative survival of 9% for M1oesophageal cancer.4, 5
Oesophagectomy with neo-adjuvant chemoradiotherapy is the most commonly used 
curative treatment modality for patients with locally advanced oesophageal cancer.6, 7 Other 
curative treatment options include definitive chemoradiotherapy (dCRT) for non-metastasised 
patients with irrresectable tumours or patients who are too frail  to undergo surgery 8-10, 
whereas endoscopic mucosal resection (EMR) is indicated for early stage oesophageal cancer 
(T1a-lesions).11, 12 For oesophageal cancer patients with distant metastasis at diagnosis (40%), 
treatment with curative intent is no longer an option.12 Similarly, curative treatment should 
be withheld when patients are too frail, have severe comorbidities or a reduced performance 
status.13 
Previous nationwide studies have shown that the probability of undergoing curative 
treatment for gastric or pancreatic cancer is associated with hospital of diagnosis.14, 15 Referring 
physicians may have several reasons to consider the patient to be unsuitable for surgery and 
withhold possible curative options. Furthermore, a regional Dutch study showed that among 
potentially curable oesophageal cancer patients the percentage of patients undergoing surgical 
treatment varied between 33% and 67% according to hospital of diagnosis.16  These results were 
however based on data from eleven general hospitals in the South of the Netherlands, with only 
2 of them being centres for oesophageal cancer surgery. 
Both surgical treatment of oesophageal cancer and EMR for early cancer are nowadays 
centralised, but the initial decision which treatment modality to perform, including the decision 
whether or not to refer patients for a curative treatment option is made in all Dutch hospitals. 
Therefore, it is important to evaluate the impact of hospital of diagnosis on the referral pattern 
for curative treatment and ultimately survival. The aim of this study was to examine the influence 
of the hospital of diagnosis on the probability to undergo a curative treatment option for 
oesophageal cancer in the Netherlands. Furthermore, the association between the variation in 
curative treatment probability among hospitals of diagnosis and overall survival was assessed.
Methods
Netherlands Cancer Registry
Data were obtained from the Netherlands Cancer Registry (NCR). This registry serves the total 
Dutch population of 16.9 million inhabitants. The NCR is based on notification of all newly 
diagnosed malignancies in the Netherlands by the national automated pathological archive 
(PALGA). Additional sources are the national registry of hospital discharge, radiotherapy 
institutions and diagnosis therapy combinations (specific codes for reimbursement purposes). 
Specially trained data managers of the NCR routinely extracted information on diagnosis, 
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tumour stage and treatment from the medical records. Information on vital status was obtained 
through an annual linkage with the Municipal Administrative Database, in which all deceased 
and emigrated persons in the Netherlands are registered.
Topography and morphology were coded according to the International Classification of 
Diseases for Oncology (ICD-O-3),17 in which subsite distribution is divided as: proximal (C15.0, 
C15.3), mid (C15.4), distal (C15.5), overlapping or not otherwise specified (C15.8, C15.9) and 
gastro-oesophageal junction (GOJ) (C16.0). Tumour staging was performed according to the 
International Union Against Cancer (UICC) TNM classification that was valid at the time of 
diagnosis. Patients diagnosed between 2005 and 2009 were staged according to TNM-6 and 
patients diagnosed between 2010 and 2013 were staged according to TNM-7.18,19 Patients with 
GOJ cancer diagnosed between 2005 and 2009 were staged according to the TNM-6 classification 
for gastric and after 2010 according to the TNM-7 classification for oesophageal cancer. Clinical 
tumour stage was assessed for the inclusion of patients and used in the multilevel logistic 
regression analyses. For survival analyses, the pathologic reports of the resection specimen 
were assessed, or, if not available, clinical tumour stage was noted. 
Patients with a potentially curable oesophageal and GOJ cancer (cT1-3,X, any N, M0,X) were 
eligible for this study (Figure 1). Patients were considered to be potentially curable in this study if 
they had no clinically distant metastasis (cM0 and cM1a according to TNM-6 and cM0 according 
to TNM-7) and no tumour infiltrating into surrounding organs (no cT4 according to TNM-6 and 
no cT4A or cT4b according to TNM-7). For the analyses, patients with a cM1a tumour according 
to TNM-6 were categorised as having cN+ as most patients with a cM1a tumour had a distal 
tumour with coeliac lymph nodes which can be considered as having cN+ according to TNM-7. 
Furthermore, patients with unknown clinical distant metastases (cMX) were included. It should 
be noted that as of 2010 coding regulations to register a cM0 or cM1 status into the NCR were 
less strict than prior to 2010, and therefore as of 2010 relatively more patients were registered 
with a cM0 rather than a cMX into the NCR. To account for this, we decided to include all patients 
with cMX. 
Curative treatment
Curative treatment was defined as surgical resection, dCRT or a local tumour excision in potentially 
curable patients with cT1-3,X, any N, M0,X disease. A surgical resection could be combined with 
or without (neo)adjuvant therapy. dCRT was defined as undergoing chemotherapy combined 
with radiotherapy without a surgical resection. A local tumour excision was defined as having 
a local tumour excision or an EMR. 
Hospital of diagnosis 
As the focus of this study was the decision-making process, the hospital of diagnosis was 
investigated rather than the hospital of resection. Hospital of diagnosis was defined as the 
hospital of histological confirmation for patients with a histological confirmation of the tumour 
(98%). If patients only had a clinical diagnosis, the hospital of diagnosis was defined as the 
hospital of clinical diagnosis. Patients were excluded from the study if oesophageal cancer was 
diagnosed abroad.
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In the Netherlands, patients are diagnosed with oesophageal cancer in any of the 91 
hospitals, usually the one closest to the patient’s place of residence. If the hospital of diagnosis 
does not perform oesophageal cancer surgery or EMR, patients should be referred to an expert 
centre when these treatments are indicated. 
The experience of the hospital in performing oesophageal cancer surgery was divided in two 
categories: Those that performed at least 20 resections per year and those with a lower annual 
volume, according to the year of diagnosis. For example, if a patient was diagnosed in 2011 in 
a hospital that performed 20 or more resections in 2011, the patient was included in the group 
of hospitals with an annual resection volume of at least 20 procedures. 
Outcome measures
Curative treatment probability and overall survival were the primary outcomes investigated 
in this study. The curative treatment probability was defined as the proportion of patients 
diagnosed in a hospital who eventually underwent surgical resection, dCRT or local tumour 
excision, regardless of the hospital in which those treatments were undertaken. Survival time 
was defined as time from diagnosis to death or until February 1st 2016 for patients who were 
still alive.
Statistical analysis
Multilevel logistic regression analyses were used to analyse the hierarchically structured data as 
patients were nested within hospitals. These analyses provide more accurate estimates when 
dealing with hierarchically structured data than traditional logistic regression analyses since it 
accounts for dependency of patients within hospitals. 20,21 The outcome variable was curative 
treatment probability. Multilevel logistic regression models were performed for the periods 2005-
2009 and 2010-2013 as the entire study period included centralisation of oesophageal cancer 
surgery and two new treatment paradigms: the introduction of neoadjuvant chemoradiotherapy 
and the introduction of EMR. The multivariate multilevel regression models were generated, 
and patient-, tumour-, and hospital-related variables were added. The effect of a variable on 
the likelihood of curative treatment was expressed as an odds ratio (OR) with 95% confidence 
intervals (CIs).
Each patient’s adjusted likelihood of undergoing curative treatment was given by the 
following formula: P = eL ⁄(1+eL ) where L is the calculated value from the logistic regression 
for that particular patient. The mean adjusted curative treatment probability for each hospital 
of diagnosis was obtained by calculating the mean adjusted curative treatment probability 
of all patients diagnosed within a hospital adjusted for differences in patient- and tumour 
characteristics between hospitals. Differences between probabilities for hospitals were tested 
for statistical significance by means of analysis of variance (ANOVA) with Bonferroni correction. 
Information on comorbidity and socioeconomic status was not routinely collected by the NCR 
but only in a subcohort, that is, the Eindhoven Cancer Registry, which is also part of the NCR. 
Therefore, a similar analysis was performed in the group of patients within the Eindhoven Cancer 
Registry to examine the influence of comorbidity and socioeconomic status on the probabilities 
to undergo curative treatment depending on the hospital of diagnosis. 
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Multivariable Cox regression analyses were performed to investigate the impact of the 
variation in curative treatment probability among the hospitals of diagnosis on the overall 
survival of the patients, after adjustment for patient-, tumour- and hospital-related characteristics. 
The hospitals of diagnosis, including the patients, were clustered into three groups with a 
similar number of patients according to the adjusted probability to undergo curative treatment 
within a hospital. Two multivariable Cox regression analyses were performed to investigate 
the prognostic impact of the variation separately for the periods 2005-2009 and 2010-2013. 
Calculation of the curative treatment probabilities of the hospitals in the entire study period 
would not provide an accurate estimate and so hospitals, and thus patients, could be categorised 
erroneous. Results from survival analyses using Cox regression analyses were reported as hazard 
ratios (HRs) and 95% CI. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, 
North Caroline, USA) and reported P values of <0.050 were considered statistically significant.
Results
Patients
Between January 2005 and December 2013, 21 621 patients were diagnosed with oesophageal 
or GOJ cancer. Exclusion of patients (Figure 1) resulted ultimately in a study population of 13 
017 patients with potentially curable oesophageal or GOJ cancer (cT1-3,X, any N, M0,X). General 
characteristics of the patients are shown in table 1. The median age was 69 (interquartile range 
61-78) years and the majority (73%) of the patients were male. 
Figure 1 Study flowchart 
*The sum of the excluded patients per exclusion criteria is larger than the total number of excluded patients because 
some patients met two exclusion criteria. ** cM1B according to TNM-6 and cM1 according to TNM-7. Patients with a cM1A 
tumour were categorised as having a cN+ tumour. *** cT4 according to TNM-6 and cT4A and cT4B according to TNM-7.
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Curative treatment
The curative treatment rate was 57% (n=3950) in the period 2005-2009, of which 44% underwent 
surgery, 9% received dCRT and 4% underwent a local tumour excision. In the period 2011-2013, 
the curative treatment rate was higher; 68% (n=4162), of which 46% undergoing surgery, 16% 
received dCRT and 6% underwent a local tumour excision (Table 1). 
Patients were diagnosed with oesophageal cancer in 91 hospitals. Twenty of these hospitals 
performed at least 20 oesophageal cancer resections in 2013, whereas in 2005 only 2 hospitals 
had a volume of 20 or more resections. The hospitals that performed in 2013 at least 20 resections 
comprised both academic and teaching hospitals. Surgery was not performed in 33 hospitals 
in 2005, which increased to 66 hospitals in 2013. Furthermore, 42% of the patients (n=224) 
diagnosed in 2005 and who underwent a resection was referred to another hospital for surgery, 
whereas 67% of the patients (n=464) diagnosed in 2013 and who underwent a resection were 
referred to another hospital for surgery in 2013. 
Hospital of diagnosis and probability of curative treatment
The unadjusted percentage of patients who underwent a curative treatment differed significantly 
between hospitals of diagnosis in the period 2005-2009, varying from 37% to 83% (Figure 2a; P 
<0.001), and in the period 2010-2013 from 45% to 86% (Figure. 2b; P <0.001). In the most recent 
period, the proportion of patients who underwent surgery varied from 21% to 71%, while the 
percentage of patients receiving dCRT or local tumour resection varied from 0% to 38% and 
0% to 31%, respectively. 
Multivariate multilevel analysis confirmed the effect of hospital of diagnosis on the 
probability to undergo curative treatment. After adjustment for patient-, tumour- and hospital- 
related factors, curative treatment rates ranged from 41% to 77% in the period 2005-2009 and 
from 50% to 82% in the period 2010-2013 depending on the hospital of diagnosis (both P 
<0.001; Figure 3a and 3b). Subgroup analysis of patients within the Eindhoven Cancer Registry 
showed that, after adjustment for comorbidity and socioeconomic status, the mean probability 
to undergo curative treatment per hospital of diagnosis only changed by 0.1% to 1.5% compared 
with results from analyses without comorbidity and socioeconomic status. 
Additional analyses based on outcomes of the multilevel analyses showed that patients 
diagnosed in 9 hospitals had a significant higher probability to undergo curative treatment than 
the average probability of all hospitals in the period 2010-2013, whereas patients diagnosed in 
6 other hospitals had a significant lower probability than the average probability of all hospitals 
(Appendix 1). 
Results of the multivariate multilevel analysis showed that being diagnosed in a hospital 
that performed 20 or more resections per year was associated with a higher probability of 
undergoing curative treatment compared to being diagnosed in hospitals with less than 20 
resections in the earlier period (OR 1.54; 95%CI 1.19-1.98) (Table 2). However, in the recent 
period this association was no longer found. In figure 3a and 3b, hospitals which performed 20 
or more resections in 2009 and 2013 respectively, were highlighted. 
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Table 1 Characteristics and differences in curative treatment among patients with potentially curable 
oesophageal cancer (cT1-3,X,any N, M0,X), diagnosed between 2005 and 2013 in the Netherlands (N=13017)
Number of 
patients
%* Surgical 
treatment 
rate 
(%)**
dCRT 
rate
 
 (%)**
Local 
tumour-
excision
  (%)**
Curative 
treatment
rate 
 (%)**
P *** 
All patients 13017 100% 45% 12% 5% 62%
Gender <0.001
Male 9486 73% 48% 12% 5% 66%
Female 3531 27% 37% 12% 4% 53%
Age (years.) <0.001
< 60 2820 22% 66% 12% 5% 83%
60-74 5751 44% 56% 14% 5% 76%
≥ 75 4446 34% 17% 9% 5% 31%
Interval of diagnosis <0.001
2005-2009 6915 53% 44% 9% 4% 57%
2010-2013 6102 47% 46% 16% 6% 68%
Tumour location <0.001
Proximal 659 5% 9% 42% 2% 53%
Mid 1608 12% 34% 18% 4% 55%
Distal 7639 59% 48% 11% 6% 66%
GEJ 2550 20% 55% 5% 2% 62%
Overlapping, unknown 561 4% 28% 14% 5% 47%
Morphology <0.001
Squamous cell carcinoma 3185 24% 32% 23% 2% 57%
Adenocarcinoma 9211 71% 52% 8% 6% 66%
Other 621 5% 15% 13% 2% 31%
cT classification <0.001
T1 844 6% 37% 5% 36% 78%
T2 2378 18% 59% 14% <1% 73%
T3 5243 40% 61% 17% <1% 79%
TX 4552 35% 21% 7% 7% 35%
cN classification <0.001
N0 4492 35% 52% 11% 8% 71%
N+ 6165 47% 51% 17% <1% 68%
NX 2360 18% 15% 3% 13% 31%
cM classification <0.001
M0 11550 89% 49% 13% 5% 67%
MX 1467 11% 16% 5% 8% 28%
Number of oesophageal cancer 
resections in hospital of diagnosis <0.001
<20 10520 81% 45% 12% 4% 61%
≥20 2497 19% 45% 14% 11% 70%
dCRT= definitive chemoradiotherapy, GOJ= gastro-oesophageal junction, *column percentage **row percentage. *** 
chi2 test based on curative treatment rate. 
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Figure 2 Observed variation in the proportion of patients with potentially curable oesophageal cancer 
(cT1-3,X,any N, M0,X) who underwent a curative treatment (resection, definitive chemoradiotherapy or local 
tumour excision). a) period 2005-2009 (n=6915, P<0.01). b) period 2010-2013 (n=6102, P<0.01). 
Each bar represents one hospital.
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Figure 3 Case-mix adjusted variation in the proportion of patients with potentially curable oesophageal 
cancer (cT1-3,X,any N, M0,X) who underwent a curative treatment (resection, definitive chemoradiotherapy 
or local tumour excision) after adjustment for gender, age, cT classification, cN classification, tumour location, 
morphology, period of diagnosis and number of esophageal resections in the hospital of diagnosis. a) period 
2005-2009 (n=6915, P<0.01). b) period 2010-2013 (n=6102, P<0.01). 
Each bar represents one hospital and hospitals which performed 20 or more resections in 2009 and 2013 were highlighted 
in respectively figure 3a and 3b. 
*Patients who underwent a surgical resection or local tumour excision were combined as the multilevel logistic model 
provided inaccurate results as the number of patients who underwent a local tumour excision per hospital of diagnosis 
was too small.
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Table 2 Multivariate multilevel logistic regression analyses to examine predictors of curative treatment in 
patients diagnosed with potentially curable oesophageal cancer in the Netherlands.
Period 2005-2009
n=6915
Period 2010-2013
n=6102
Curative treatment Curative treatment
Yes No  OR* 95%CI Yes No OR* 95%CI
Gender
Male 3043 1965 1.00 3210 1268 1.00
Female 907 1000 0.87 0.75-0.99 952 672 0.80 0.68-0.94
Age (yrs.)
< 60 1250 324 1.00 1097 149 1.00
60- 74 2075 835 0.64 0.57-0.78 2303 538 0.62 0.50-0.76
≥ 75 625 1806 0.10 0.08-0.12 762 1253 0.10 0.08-0.13
cT classification
T1 301 109 1.05 0.77-1.42 356 78 1.43 1.04-1.97
T2 802 318 1.00 936 322 1.00
T3 1855 638 1.17 0.97-1.41 2266 484 1.57 1.30-1.89
TX 992 1900 0.28 0.23-0.33 604 1056 0.29 0.24-0.35
cN classification
N0 1583 710 1.00 1606 593 1.00
N+ 1934 1192 0.38 0.33-0.45 2253 786 0.64 0.55-0.76
NX 433 1063 0.31 0.26-0.37 303 561 0.38 0.30-0.47
Tumour location
Proximal 169 183 0.98 0.73-1.30 179 128 0.73 0.53-0.99
Mid 414 423 0.91 0.74-1.11 476 295 0.89 0.70-1.12
Distal 2389 1612 1.00 2638 1000 1.00
GEJ 870 565 1.47 1.25-1.73 716 399 0.67 0.56-0.80
Overlapping, unknown 108 182 0.62 0.45-0.85 153 118 0.65 0.47-0.89
Morphology
Squamous cell 882 788 0.67 0.56-0.79 944 571 0.57 0.47-0.70
Adenocarcinoma 2972 1897 1.00 3123 1219 1.00
Other 96 280 0.34 0.25-0.46 95 150 0.37 0.26-0.53
Number of oesophageal 
cancer resections in hospital 
of diagnosis 
<20 resections 3334 2671 1.0. 3031 1484 1.0
≥20 resections 616 294 1.54 1.19-1.98 1131 456 1.08 0.82-1.42
*Adjusted for all variables listed in table 2 and hospital of diagnosis by using multilevel analysis. GOJ= gastro-oesophageal 
junction.
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Table 3 Multivariable Cox proportional hazards analyses of overall survival for patients with potentially 
curable oesophageal cancer in the Netherlands for two separated periods of diagnosis.
Number 
of patients
Crude 
2-year OS
Univariable Multivariable 
HR 95%CI HR* 95%CI
2005-2009 (n=6915)
Curative treatment 
probability **
41%-53% 2261 32% 1.28 1.20-1.36 1.13 1.06-1.20
54%-59% 2128 33% 1.18 1.11-1.26 1.10 1.03-1.17
60%-77% 2526 42% 1.00 1.00
2010-2013 (n=6102)
Curative treatment 
probability **
50%-64% 2308 40% 1.26 1.18-1.36 1.15 1.07-1.24
65%-71% 1711 47% 1.13 1.04-1.22 1.05 0.96-1.14
72%-82% 2083 50% 1.00 1.00
OS= overall survival.
* Adjusted for gender, age, tumour stage, tumour location, morphology, tumour differentiation and number of 
oesophageal cancer resections in hospital of diagnosis.
** Patients were divided in three groups with a similar number of patients according to the adjusted probability to undergo 
curative treatment of the hospital in which they were diagnosed. 
Hospital of diagnosis and overall survival
Multivariable Cox regression analyses showed that patients diagnosed in hospitals with a 
lower probability of undergoing curative treatment had a worse overall survival than those 
diagnosed in hospitals with a higher probability. In the recent time period, patients diagnosed 
in hospitals with a probability to undergo curative treatment ranging from 72% to 82% had 
a significant favourable overall survival compared with patients diagnosed in hospitals with 
a lower probability ranging from 50% to 64% (HR=1.15 95%CI 1.07-1.24; Table 3). A similar 
association was also found in the earlier time period (HR=1.13 95%CI 1.06-1.20). Furthermore, 
the same multivariable Cox regression analyses demonstrated that patients diagnosed in high-
volume surgery hospitals had a favourable survival compared to patients diagnosed in low-
volume surgery hospitals (HR=0.90 95%CI 0.83-0.98). However, this association was not found 
in the recent time period (HR=0.99 95%CI 0.93-1.08).
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Discussion
In this population-based nationwide study the proportion of oesophageal cancer patients who 
underwent curative treatment (surgery, dCRT or local tumour excision) varied between 37% and 
83% in the period 2005-2009 and between 45% and 86% in the period 2010-2013. Multivariate 
multilevel regression analysis confirmed the effect of hospital of diagnosis on the likelihood 
to undergo curative treatment. Patients with oesophageal cancer who had been diagnosed in 
hospitals with a low probability to undergo curative treatment had a worse overall survival than 
those diagnosed in hospitals with a high probability.
Hospital variation and treatment probability
Our results show that the differences between hospitals in the proportion of patients that 
underwent dCRT were larger than the differences in the proportion of patients that underwent 
surgery. An explanation may be that dCRT has only recently been introduced. Therefore, 
increased awareness of the possibilities of chemoradiation combined with favourable results 
reported by previous studies might have played a role in the implementation of dCRT as a 
potential curative option.22,23 Furthermore, this variation might also be explained by the fact 
that the indications for dCRT are less well defined compared to the indications for surgery.
In previous studies it has been suggested that comorbidity and socioeconomic status play 
a role in the probability of undergoing curative treatment.13, 24 However, subgroup analysis of 
patients diagnosed in the Eindhoven Cancer Registry, in which comorbidity is registered, revealed 
only small changes in the probability of curative treatment after adjustment for comorbidity 
and socioeconomic status. These findings suggest that comorbidity and socioeconomic status 
only minimally contributed to the observed variation in curative treatment probability between 
the hospitals of diagnosis. 
Centralisation, specialisation, and multidisciplinary team meetings
In the Netherlands, oesophageal cancer surgery is currently performed in high volume hospitals. 
Since 2006, a yearly minimum of 10 oesophageal resections per hospital was enforced by the 
Dutch Health Care Inspectorate, which was increased to a yearly minimum of 20 oesophageal 
resections per hospital in 2011. Centralisation of surgical treatment for oesophageal cancer 
patients has shown to improve long-term outcome in the Netherlands.24-27 Results from the 
present study showed that the number of patient that are referred by the hospital of diagnosis for 
surgery increased during the study period, which is likely related to the centralisation of surgical 
treatment for oesophageal cancer patients. These changes due to centralisation emphasise the 
important role of the hospital of diagnosis on the likelihood to undergo a curative treatment.
The probability to undergo curative treatment may be influenced by various factors, such 
as type of hospital and its facilities, for example, the availability of radiotherapy, endoscopy, 
regional agreements, and treatment protocols that are used. In general, all hospitals in the 
Netherlands have at least an endoscopy unit and radiology department, including computed 
tomography (CT) scan for optimal staging. The probability of receiving curative treatment 
may also be affected by the available specialisation of the hospital and medical specialists. 
Two previous studies have reported that patients treated by medical specialists with higher 
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caseload were more likely to undergo surgery or other treatments compared to patients treated 
by medical specialists with a limited caseload.28,29 Higher-volume medical specialists also used 
a wider range of diagnostic investigations, which was not only explained by a better access to 
these facilities.28 Possibly, patients with potentially curable disease managed by low-volume 
medical specialists regarded incurable, could be regarded still curable by a more experienced 
physician because this physician may be more aware of the curative treatment possibilities.29 
The present study also shows that patients diagnosed in high-volume surgery hospitals had a 
greater likelihood of undergoing surgery and a better overall survival than those diagnosed in 
low-volume surgery hospitals. However, these associations were only found in the earlier period 
in which centralisation of surgery was initiated. 
All oesophageal cancer patients should be discussed in a multidisciplinary team (MDT) 
meeting for a consensus-based treatment decision in the Netherlands. Regional expert 
MDT meetings have been shown to alter initial treatment plans frequently in patients with 
oesophageal, gastric, colorectal and breast cancer.30-34 However, no information is available as 
to whether a medical specialist with experience in curative treatment of oesophageal cancer 
is always present in this MDT. Regional MDT meetings become even more important when 
treatment decisions are complex as in oesophageal cancer and it might be hypothesised that the 
presence of experienced specialists in these MDT meetings might explain differences between 
hospitals in the proportion of patients undergoing curative treatment. 
Survival 
The variation in the probability of curative treatment among hospitals of diagnosis was found 
to be associated with survival in both time periods. A similar study performed by the same 
lead author among patients with gastric cancer has also found that variation in the likelihood 
to undergo surgery was associated with survival.15 However, this study has only found an 
association in the more recent time period. An explanation for the differences in findings of 
these studies could be that centralisation of gastric cancer surgery has only been implemented 
since 2012, which is 6 years later than the implementation of centralisation of oesophageal 
cancer surgery. Centralisation of surgery could have led to a decrease in the number of medical 
specialists with experience in curative treatment options for oesophageal and gastric cancer 
patients in hospitals of diagnosis, which have no longer a program for these curative treatment 
options. This negative consequence of centralisation may have influenced the selection of 
patients who are eligible for curative treatment and subsequently the referral and survival of 
these patients among hospitals of diagnosis.
Strengths and limitations
This study has some limitations. First, some factors influencing treatment, such as performance 
status of the patient and information about MDT meetings decisions, were not registered and 
could therefore not be included in the analyses. Second, possible incompleteness of registration 
of local tumour excision in the earlier period could have led to more variation in curative 
treatment probability between hospitals in the earlier period compared with the recent period. 
Third, information about the intention of the chemoradiotherapy was not available. However, as 
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only potentially curable oesophageal cancer patients were included it was assumed that these 
patients underwent chemoradiotherapy with curative intention.  
Finally, patients with distant metastasis (cM1) and cT4 tumours were excluded from the 
study. However, the accuracy of the diagnostic and staging methods used is unknown. Because 
endoscopic ultrasonography is not always performed in patients with oesophageal cancer, 
clinical stage was unknown in a relatively high percentage of patients (Table 1). Nevertheless, 
the variation in cT, cN status and cM status between hospitals was much smaller than the 
interhospital variation in curative treatment probabilities and is therefore unlikely to have 
influenced the results substantially. Moreover, clinical decision-making in oesophageal cancer 
treatment is more often based on cN and cM rather than on cT status 35 and it is assumed that 
most of the patients with a cMX prior to 2010 had in fact a cM0 as the percentage of patients 
with a cM0 increased after 2010 when fewer diagnostic procedures were required to register a 
cM0 or cM1 according to the coding regulations of the NCR.
This study has also several strengths, such as its population-based design resulting in a 
large and representative study population. This nationwide study enabled the evaluation of the 
influence of the hospital of diagnosis on the probability to undergo curative treatment and its 
impact on survival among patients with oesophageal cancer.
Conclusions
This study revealed a large variation in the probability to undergo curative treatment for 
oesophageal cancer depending on the hospitals of diagnosis, which also affected the survival 
of these patients. Regional expert MDT meetings with involvement of experienced specialists 
in this field should be initiated for all patients with oesophageal cancer. The decisions made by 
these panels may improve the selection of patients with oesophageal cancer who are eligible 
for a curative treatment option leading to an overall improvement of survival on the long term.
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Appendix 1 Case-mix adjusted variation in the proportion of patients with potentially curable oesophageal 
cancer (cT1-3,X,any N, M0,X) who underwent a curative treatment (resection, definitive chemoradiotherapy 
or local tumour excision) in the period 2010-2013 on a log scale with an odds ratio for every hospital of 
diagnosis presented as a dot with 95% confidence interval. 
The 1-line represents the average probability of all hospitals. Patients diagnosed in hospitals with an odds ratio less 
than 1 had a lower likelihood to undergo curative treatment. Adjustment was made for gender, age, cT classification, cN 
classification, tumour location, morphology, period of diagnosis and number of esophageal resections in the hospital 
of diagnosis (n=6102).  
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Abstract
Background
Gastric cancer surgery is increasingly being centralised in the Netherlands, whereas the diagnosis 
is often made in hospitals where gastric cancer surgery is not performed. The aim of this study 
was to assess whether hospital of diagnosis affects the probability of undergoing surgery and 
its impact on overall survival.  
Methods
All patients with potentially curable gastric cancer according to stage (cT1/1b–4a, cN0–2, 
cM0) diagnosed between 2005 and 2013 were selected from the Netherlands Cancer Registry. 
Multilevel logistic regression was used to examine the probability of undergoing surgery 
according to hospital of diagnosis. The effect of variation in probability of undergoing surgery 
among hospitals of diagnosis on overall survival during the intervals 2005–2009 and 2010–2013 
was examined by using Cox regression analysis.
Results 
A total of 5620 patients with potentially curable gastric cancer, diagnosed in 91 hospitals, were 
included. The proportion of patients who underwent surgery ranged from 53.1 to 83.9 per 
cent  according to hospital of diagnosis (P < 0.001); after multivariable adjustment for patient 
and tumour characteristics it ranged from 57.0 to 78.2 per cent (P < 0.001). Multivariable Cox 
regression showed that patients diagnosed between 2010 and 2013 in hospitals with a low 
probability of patients undergoing curative treatment had worse overall survival (hazard ratio 
1.21; P < 0.001) 
Conclusion
The large variation in probability of receiving surgery for gastric cancer between hospitals of 
diagnosis and its impact on overall survival indicates that gastric cancer decision-making is 
suboptimal.
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Introduction
Gastric cancer is the fifth most common cancer and the third leading cause of cancer death 
worldwide.1 Although the incidence has decreased in recent  decades in the Netherlands, 
prognosis is still poor. The 5-year overall survival rate for patients with stage I–III disease is 31 
per cent and the median survival time for stage IV is only 6 months.2,3
Surgery is the only potential curative treatment for gastric cancer.4 Gastric surgery is 
associated with high morbidity and mortality rates, and performed mainly in low-volume 
hospitals.5,6 Therefore, centralisation by defining minimum volumes per centre has been initiated 
in the Netherlands. From 2012 onwards, hospitals should have performed a minimum of ten 
resections per year, increasing to a minimum of 20 resections annually from 2013. The probability 
of undergoing surgical treatment is influenced by several factors. Surgery with curative intent is 
generally not of benefit in patients with distant metastasis.2 Patients can otherwise be regarded 
as less suitable for gastric cancer surgery because of advanced age, severe comorbidity or 
decreased performance status. 
Previous studies7,8 have shown that the probability of receiving curative treatment for 
oesophageal and pancreatic cancer is associated with the hospital of diagnosis. Referring 
physicians may consider the patient too frail and unsuitable for surgery, and withhold possible 
curative options. In the study of patients with potentially curable oesophageal cancer8, the 
proportion who underwent oesophagectomy varied between 33 and 67 per cent according 
to hospital of diagnosis.  
It is of importance to evaluate the influence of hospital of diagnosis on referral for surgical 
treatment and, ultimately, survival, especially when surgical treatment for gastric cancer is 
being centralised within specialised centres. The aim of this study was, therefore, to examine the 
influence of hospital of diagnosis on the probability of undergoing surgery for gastric cancer in 
the Netherlands. The association between the variation in surgical treatment probability among 
hospitals of diagnosis and overall survival was also assessed.
Methods
Data were obtained from the Netherlands Cancer Registry (NCR). This registry serves the total 
Dutch population of 16.6 million inhabitants. The NCR is based on notification of all newly 
diagnosed malignancies in the Netherlands by the national automated pathological archive 
(PALGA). Additional sources are the national registry of hospital discharge and radiotherapy 
institutions. Information on diagnosis, staging and treatment is extracted routinely from the 
medical records by specially trained data managers of the cancer registry. 
Patients with a potentially curable non-cardia gastric cancer were eligible for this study. The 
gastro-oesophageal junction could be involved, but the bulk of the tumour had to be in the 
stomach. Patients were considered potentially curable if they had no clinical distant metastasis, 
no tumour infiltrating surrounding organs, and no non-regional or unresectable conglomeration 
of suspicious nodes.
Topography and morphology were coded according to the International Classification of 
Diseases for Oncology (ICD-O-3).9 Distribution of the location in the stomach is divided as follows: 
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   60 20-3-2018   22:25:04
461Variation in surgical treatment for gastric cancer by hospital of diagnosis |
proximal/middle (fundus, corpus, and lesser and greater curvature (C16.1, C16.2, C16.5, C16.6), 
pyloric and antrum (C16.3, C16.4), and overlapping or not otherwise specified (C16.8, C16.9). 
Tumours were staged according to the International Union Against Cancer (UICC) TNM 
classification that was valid at the time of diagnosis. Patients diagnosed between 2005 and 2009 
were staged using the sixth edition10, and those diagnosed between 2010 and 2013 according 
to the seventh edition.11 For this, the pathological stage of the resection specimen was used, or, 
if not available, clinical tumour stage was noted. Information on vital status was obtained from 
hospital records and by annual linkage with the Municipal Administrative Databases, which 
register all deceased and emigrated persons in the Netherlands.
Surgery 
Surgery for gastric cancer was classified according to the NCR as subtotal gastrectomy, total 
gastrectomy and multiple organ resection, which was defined as a gastrectomy and surgical 
removal of other organs. Laparoscopy as a staging method was not regarded as surgery. 
Hospital of diagnosis, hospital status, and volume
The hospital of diagnosis was defined as the hospital in which the histological diagnosis of 
gastric cancer was made. Patients were excluded from the study if the diagnosis was made in 
a hospital abroad. As the focus of this study was the decision-making process, the hospital of 
diagnosis was investigated rather than the hospital of resection. 
In the Netherlands, patients can be diagnosed in any of the 91 hospitals, usually the one 
closest to their place of residence. If the hospital of diagnosis does not perform gastrectomies, 
patients are referred when gastrectomy is indicated. Type of hospital of diagnosis was classified 
as university (academic) hospital, teaching non-university hospital or non-teaching hospital.
Hospital of diagnosis was divided into two categories according to the number of gastric 
cancer resections: those that performed at least 10 resections per year and those with a lower 
annual volume, according to the year of diagnosis. For example, if a patient was diagnosed in 
2008 in a hospital that carried out 10 or more resections in that year, the patient was included 
in the group of hospitals with an annual resection volume of at least 10.
Outcome measures
Surgical treatment probability and survival were the outcomes investigated in this study. 
The surgical treatment probability of a hospital of diagnosis was defined as the proportion of 
patients diagnosed in a certain hospital who eventually underwent surgery, regardless of the 
hospital in which the surgery was performed. Survival time was defined as time from diagnosis 
to death, or until 1 January 2015 for patients who were still alive. 
Statistical analysis
All analyses were conducted using SAS® version 9.4 (SAS Institute, Cary, North Carolina, USA). 
A multilevel logistic regression analysis was used to analyse the hierarchically structured data 
as patients were nested within hospitals. Multilevel regression analyses provide more accurate 
estimates when dealing with hierarchically structured data than traditional regression analyses 
as they accounts for dependency of patients within hospitals.12,13 The outcome variable was 
surgery (0, no; 1, yes). A multivariable multilevel logistic regression model was generated, and 
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patient- and tumour-related variables and type of hospital were added. The effect of a variable 
on the likelihood of surgical treatment was expressed as an odds ratio (OR) with 95 per cent c.i. 
Each patient’s adjusted chance of undergoing surgery was given by the following formula: 
P =  eL ⁄(1+eL), where L is the calculated value from the logistic regression for that particular 
patient. The mean adjusted surgical probability for each hospital of diagnosis was defined as 
the mean adjusted surgical probability of the patients diagnosed within that hospital. This 
resulted in a range of surgical probabilities adjusted for differences in patient characteristics 
between hospitals. The variation in surgical probabilities between hospitals of diagnosis was 
tested for statistical significance by means of ANOVA with Bonferroni correction. Information 
on comorbidity and socioeconomic status was not routinely collected by the NCR but solely by 
the Eindhoven Cancer Registry (ECR), which is representative of the NCR. Therefore, a similar 
analysis was performed in the subgroup of patients within the ECR to examine the influence of 
comorbidity and socioeconomic status on changes in surgical probabilities among hospitals 
of diagnosis.
Multivariable Cox regression analyses were undertaken to investigate the prognostic impact 
of the variation in surgical treatment probability among hospitals of diagnosis on overall 
survival, after adjustment for patient characteristics. The hospitals of diagnosis, and thereby 
the patients, were clustered within four groups with a comparable number of patients according 
to the adjusted surgical probabilities of the hospitals. Two multivariable Cox regression analyses 
were performed to investigate the prognostic impact of the variation separately in the intervals 
2005–2009 and 2010–2013. These two intervals were defined because from 2010 an increasing 
effect of centralisation of gastric cancer surgery in the data set might influence the surgical 
probabilities of hospitals of diagnosis. Furthermore, the interval 2005–2013 included a new 
treatment paradigm: the introduction of perioperative chemotherapy in the earlier time period. 
Therefore, calculation of the surgical probabilities of hospitals in the entire study interval (2005–
2013) would not provide an accurate estimate. Patients without histological confirmation were 
classified as having an adenocarcinoma in multivariable analyses, as approximately 99 per cent 
of the patients with histological confirmation of gastric cancer had an adenocarcinoma. Results 
from survival analyses using Cox regression analyses were reported as hazard ratios (HRs) with 
95 per cent c.i. P  < 0.050 was considered statistically significant.
Results
Between January 2005 and December 2013, 12 877 patients were diagnosed with non-cardia 
gastric cancer. Exclusion of patients for several reasons (Figure 1) resulted in a study population 
of 5620 patients with potentially curable gastric cancer (cT1/T1b–4a, cN0–2, cM0). 
General characteristics of the patients are shown in Table 1. The median age was 73 (i.q.r. 
64–73) years. The overall surgical resection rate was 69.1 per cent (3881 patients);  59.5 per cent 
of these patients underwent resection without neoadjuvant or adjuvant treatment, 16.3 per cent 
received only neoadjuvant chemotherapy, 20.9 per cent  received neoadjuvant chemotherapy 
as well as adjuvant chemotherapy or chemoradiotherapy and 3.3 per cent received adjuvant 
treatment alone. The most commonly performed operation was subtotal gastrectomy (64.3 per 
cent). Some 36.3 per cent of the patients were diagnosed in a non-teaching hospital and 69.7 
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per cent of these underwent surgery, either in the hospital of diagnosis or in a referral hospital 
(Table 1).
Surgical treatment
Surgical treatment rates were 74.0, 72.5 and 59 per cent for cT2, cT3 and cT4a tumours respectively 
(P < 0.001) (Table 1). Surgical treatment decreased with age. In addition, a small decline was 
noted in the use of surgery during the study; 73.4 per cent of the patients underwent surgical 
treatment in 2005–2009 compared with 64.6 per cent in 2010–2013 (P < 0.001).
Figure 1 Study flowchart 
*Some patients met two exclusion criteria.
** cT4 according to sixth edition of TNM classification and cT4b according to seventh edition.
*** Eligible for endoscopic mucosal resection instead of an operation. 
GIST, gastrointestinal stromal tumour
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Table 1 Characteristics of patients with potentially curable gastric cancer  (cT1/1b–4a, cN0–2, cM0), 
diagnosed between 2005 and 2013 in the Netherlands
No. of patients 
(n = 5620)
Surgical 
treatment 
rate (%) P†
Age (years) < 0.001
< 60 883 (15.7) 86.6
60–74 2119 (37.7) 81.2
≥ 75 2618 (46.6) 53.3
Sex < 0.001
M 3345 (59.5) 71.0
F 2275 (40.5) 66.2
Interval of diagnosis < 0.001
2005–2009 2853 (50.8) 73.4
2010–2013 2767 (49.2) 64.6
Morphology  < 0.001
Adenocarcinoma 5474 (97.4) 69.3
Other 56 (1.0) 50.0
No histological confirmation 90 (1.6) 0
Clinical tumour classification < 0.001
cT1/1b* 248 (4.4) 68.2
cT2 1038 (18.5) 74.0
cT3 619 (11.0) 72.5
cT4a 68 (1.2) 58.8
cTx/missing 3647 (64.9) 67.3
Clinical node classification < 0.001
cN0 2861 (50.9) 80.3
cN1 1065 (19.0) 71.6
cN2 258 (4.6) 61.6
cNx/unknown 1436 (25.6) 46.2
Type of hospital of diagnosis 0.694
Academic 370 (6.6) 68.1
Teaching 3212 (57.2) 68.7
Non-teaching 2038 (36.3) 69.7
No. of gastric cancer resections in hospital of diagnosis 
≥ 10 1890 (33.6) 73.7 < 0.001
< 10 3730 (66.4) 68.0
Values in parentheses are percentages. *T1 according to sixth edition of TNM classification (2005–2009) and cT4b 
according to seventh edition (2010–2013).  †chi2 test.
Patients were diagnosed with gastric cancer in 91 hospitals. Seven hospitals performed at 
least 20 gastric cancer resections in 2013, whereas no hospital reached a volume of 20 resections 
in 2005. Surgery was not performed in six hospitals in which the diagnosis of gastric cancer was 
made in 2005;  this increased to 47 hospitals in 2013. Furthermore, 6.0 per cent of the patients 
were referred to another hospital for surgery in 2005, whereas 57.6 per cent of the patients were 
referred from a hospital that did not perform gastrectomies in 2013.
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Hospital of diagnosis and probability of surgical treatment  
The proportion of patients who underwent surgical treatment differed significantly between 
hospitals of diagnosis, varying from 53.1 to 83.9 per cent (P < 0.001). Multivariable multilevel 
analysis confirmed the effect of hospital of diagnosis on the probability of undergoing surgery. 
After adjustment for patient-related factors and type of hospital, surgical treatment rates ranged 
from 57.0 to 78.2 per cent according to hospital of diagnosis (P < 0.001) (Figure 2a). Comparing 
2005–2009 with 2010–2013, the adjusted variation in surgical treatment probability between 
hospitals of diagnosis was comparable (54.3–84.8 per cent in 2005–2009 versus 47.8–78.4 per 
cent in 2010–2013) (Figure 2b,c). Subgroup analysis of patients within the ECR showed that, 
after adjustment for comorbidity and socioeconomic status, the mean probability of surgical 
treatment changed by 0.2 –2.3 per cent in the hospitals of diagnosis.
Table 2 Multivariable multilevel logistic regression analysis to examine predictors of surgery in patients 
diagnosed with potentially curable gastric cancer.
Odds ratio
Age (years)
< 60 1.00 (reference)
60–74 0.61 (0.48, 0.78)
≥ 75 0.16 (0.13, 0.21)
Sex
M 1.00 (reference)
F 0.83 (0.73, 0.95)
Interval of diagnosis
2005–2009 1.00 (reference)
2010–2013 0.47 (0.41, 0.55)
Clinical tumour classification
cT1/1b 0.60 (0.41-0.88)
cT2 0.92 (0.71-1.19)
cT3 1.00 (reference)
cT4a 0.59 (0.33-1.05)
cTx/missing 0.86 (0.68-1.07)
Clinical node classification
cN0 2.50 (1.85, 3.38)
cN1 1.16 (0.85, 1.60)
cN2 1.00 (reference)
cNx/unknown 0.45 (0.32, 0.61)
Type of hospital of diagnosis
Academic 1.00 (reference)
Teaching 1.19 (0.85, 1.67)
Non-teaching 1.34 (0.95, 1.90)
No. of gastric cancer resections in hospital of diagnosis 
≥10 1.55 (1.27, 1.89)
<10 1.00 (reference)
Values in parentheses are 95 per cent c.i. Analyses adjusted for morphology, tumour location and all variables listed in 
this table.
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Figure 2 Multilevel adjusted variation in the proportion of patients with potentially curable gastric 
carcinoma who received a gastrectomy in the interval a 2005–2013 (5620 patients), b 2005–2009 (2821 
patients) and c 2010–2013 (2739 patients). 
Adjustment was made for age, sex, cT classification, cN classification, tumour location, morphology, interval of diagnosis, 
type of hospital of diagnosis, and annual number of resections in hospital of diagnosis. Each bar represents one hospital. 
Three hospitals were excluded from b and c because each had ten or fewer diagnoses in that interval.
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Results of the multivariable multilevel analysis showed that, in addition to hospital of 
diagnosis, the following factors were associated with a lower probability of undergoing surgical 
treatment: older age, female sex, a cT1 tumour and clinically lymph node-positive disease. Being 
diagnosed in a hospital that performed ten or more resections per year was associated with 
a higher probability of having surgery (OR 1.55; P < 0.001) (Table 2). However, there was no 
association with type of hospital of diagnosis either in 2005–2009 or 2010–2013.  
Hospital of diagnosis and overall survival
Multivariable Cox regression analysis showed that patients diagnosed between 2010 and 2013 
in hospitals with a lower probability of undergoing surgical treatment (48–59 per cent) had 
worse overall survival than those diagnosed in hospitals with a higher probability (69–78 per 
cent) (adjusted HR 1.21; P < 0.001 (Table 3).  However, in 2005–2009 no such association was 
found (Table 4).
Table 3 Univariable and multivariable Cox proportional hazards analyses of overall survival for patients 
with potentially curable gastric cancer in the Netherlands, 2010–2013
Surgical treatment probability (%)*
No. of 
patients
(n = 2739)
Crude 2-year 
overall 
survival (%)
Hazard ratio
Univariable 
analysis
Multivariable 
analysis †
   48–59 473 37.5 1.45 (1.25, 1.68) 1.21 (1.04, 1.41)
   60–64 841 45.1 1.17 (1.03, 1.34) 1.04 (0.91, 1.19)
   65–68 722 44.6 1.20 (1.04, 1.37) 1.10 (0.95, 1.26)
   69–78 703 50.3 1.00 (reference) 1.00 (reference)
Values in parentheses are 95 per cent c.i. *Patients are included in one of the four groups according to the adjusted mean 
surgical treatment probability of the hospital where they were diagnosed in the interval 2010–2013. Twenty-eight patients 
were excluded from the analysis because they were diagnosed in a hospital that diagnosed ten or fewer patients in this 
interval. †Adjusted for age, sex, tumour stage, tumour location, morphology, tumour differentiation, type of hospital of 
diagnosis, and annual number of resections in hospital of diagnosis.
Table 4 Univariable and multivariable Cox proportional hazards analyses of overall survival for patients 
with potentially curable gastric cancer in the Netherlands, 2005–2009 
Surgical treatment probability (%)*
No. of 
patients
(n = 2821)
Crude 2-year 
overall 
survival (%)
Hazard ratio
Univariable 
analysis
Multivariable 
analysis†
   54–69 594 50.0 1.11 (0.98, 1.25) 1.00 (0.88, 1.13)
   70–72 604 48.2 1.15 (1.02, 1.30) 1.04 (0.91, 1.18)
   73–75 766 48.8 1.13 (1.01, 1.27) 1.03 (0.91, 1.16)
   76–85 857 52.0 1.00 (reference) 1.00 (reference)
Values in parentheses are 95 per cent c.i. *Patients are included in one of the four groups according to the adjusted mean 
surgical treatment probability of the hospital where they were diagnosed in the interval 2005–2009. Thirty-two patients 
were excluded from the analysis because they were diagnosed in a hospital that diagnosed ten or fewer patients in this 
interval.  †Adjusted for age, sex, tumour stage, tumour location, morphology, tumour differentiation, type of hospital of 
diagnosis, and annual number of resections in hospital of diagnosis.
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Discussion
In this population-based nationwide study the proportion of patients who underwent surgery 
varied between 53.1 and 83.9 per cent according to hospital of diagnosis. Multivariable multilevel 
logistic regression analysis confirmed the effect of hospital of diagnosis on the probability of 
undergoing surgical treatment. Patients with gastric cancer who had been diagnosed more 
recently in hospitals with a low probability of surgical treatment had worse overall survival than 
those diagnosed in hospitals with a high probability. 
Variation in the probability of surgical treatment between hospitals of diagnosis remained 
after adjustment for differences in patient characteristics and type of hospital of diagnosis. In a 
previous study14, it was suggested that comorbidity and socioeconomic status could also have 
influenced the probability of undergoing surgery.14 Subgroup analysis of data from the ECR in 
the present study revealed only slight changes in probability of surgery after adjustment for 
comorbidity and socioeconomic status, indicating a minimal contribution of these factors to 
the variation in probabilities between hospitals of diagnosis. The present study has confirmed 
the variation in treatment probability among patients with gastric cancer, as shown previously 
for numerous other types of cancer, including bladder, breast and colonic cancer.15–17
Factors associated with a lower probability of surgery were older age and female sex. In 
concordance with this, previous Dutch studies18,19  found that older age was associated with a 
lower probability of having surgery. There are no published reports on the relationship between 
sex and likelihood of gastric cancer surgery. However, four Dutch studies8,18–20 noted that sex 
did  not affect the probability of surgery for oesophageal cancer, whereas a North American 
study21 found a significantly lower probability of oesophagectomy among women. Furthermore, 
patients with cT1 tumour were less likely to undergo surgical treatment. This was probably a 
result of the introduction of endoscopic mucosal resection in recent years.
In the present study, patients diagnosed between 2005 and 2009 had a higher probability of 
having surgery than those diagnosed between 2010 and 2013. These findings may be explained 
by developments in more sensitive diagnostic modalities that have led to more accurate tumour 
staging.22 The decrease in resection rates could also be related to the introduction and extensive 
use of perioperative chemotherapy more recently, with some patients progressing to incurable 
disease during preoperative chemotherapy.
The type of hospital of diagnosis was not associated with the probability of surgery for gastric 
cancer in either time interval. This means that patients diagnosed in non-teaching hospitals do 
not have a lower chance of having surgery than those diagnosed in a teaching or academic 
hospital. Referral of patients diagnosed in non-teaching hospitals results in their likelihood of 
undergoing surgery being comparable to that of patients diagnosed in teaching and academic 
hospitals. However, there is still a large variation in probability of resection across hospitals 
of diagnosis that could probably be explained by factors other than institution type, such as 
patient frailty, patient preference, specialisation of the hospital and multidisciplinary team (MDT) 
meetings.23
In the Netherlands, gastric cancer surgery is increasingly being performed in higher-volume 
hospitals24, the minimum volume having been increased to 20 gastrectomies per year from 
2013. In Denmark, centralisation of gastric cancer has been associated with better surgical 
quality and a significant decline in mortality.25 Similarly, centralisation of surgical treatment for 
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oesophageal and pancreatic cancer in the Netherlands has also been associated with improved 
outcomes.24,26,27 Because centralisation of gastric cancer surgery has been introduced in the 
Netherlands more recently, the effect on mortality and survival could not be examined here. 
The probability of surgical treatment could be influenced by organisational structures 
within a hospital or department, radiotherapy and endoscopic facilities, established clinical 
pathways or regional agreements, and protocols between one or multiple hospitals. In general, 
all hospitals in the Netherlands have an endoscopy unit and CT available at least. The probability 
of having surgical treatment could also be affected by the grade of specialisation of the hospital 
and medical specialists. The present study has shown that patients diagnosed in high-volume 
hospitals had a greater likelihood of receiving surgery than those diagnosed in low-volume 
hospitals. Two previous studies22,28 reported that patients treated by medical specialists with 
higher  caseloads were more likely to undergo surgery and other treatments than patients 
treated by lower-volume medical specialists. Higher-volume specialists used a wider range of 
investigations, which could not be explained by better access to these facilities.22 
In the Netherlands, all patients with gastric cancer should be discussed in a MDT meeting 
for proper treatment decisions to be made. A MDT meeting could improve the adequacy and 
uniformity of treatment decisions, which may increase the probability of curative surgical 
treatment. Regional expert MDT meetings have shown to alter initial treatment plans frequently 
in patients with gastric, oesophageal, colorectal and breast cancer.29 However, it is unknown 
whether a surgeon with experience in gastrectomies is always present. Implementation of 
regional expert MDT meetings with involvement of experienced surgeons may increase the 
overall survival of patients with gastric cancer through better selection for curative treatment 
or optimal palliative treatment.
Centralisation could have led to a greater influence of hospitals of diagnosis in the recent 
time interval. Centralisation would have led to an overall decrease in the number of gastric 
cancer specialists in the hospitals of diagnosis with sufficient experience in clinical decision-
making, possibly resulting in fewer referrals to a specialised centre for curative treatment. 
However, in the earlier interval the introduction of perioperative chemotherapy, and thereby 
variation in quality of care, could have influenced survival more than hospital of diagnosis.
A  limitation of the present study was that some factors influencing treatment decisions, 
such as frailty of the patient and performance status, were not registered adequately and could 
not therefore be included in the analyses. Furthermore, patients with distant metastasis (M1) 
and T4b tumours were excluded. However, the accuracy of the clinical staging and diagnostic 
methods used are unknown. Because endoscopic ultrasonography is not always performed 
in patients with gastric cancer, clinical stage was unknown in a relatively high percentage of 
patients (Table 1). The variation in missing data on cT and cN status between hospitals was 
much smaller than the interhospital variation in resection probabilities and is unlikely to have 
influenced the results substantially. In addition, clinical decision-making in gastric cancer is 
more often based on cN and cM than cT status; the exact cT category is often unknown because 
endoscopic ultrasonography is not performed and so the cT status is estimated by CT. 
This study also has several strengths, such as its observational nature resulting in a 
representative population. This nationwide population-based study, including a large number 
of patients with potentially curable gastric cancer, has enabled evaluation of the probability of 
undergoing surgical treatment and its impact on survival.
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 Abstract
Background 
Centralisation of surgery has been shown to improve outcomes for oesophageal and pancreatic 
cancer and has been imposed for gastric cancer since 2012 in the Netherlands. This study 
evaluates the impact of centralising gastric cancer surgery on outcome for all patients with 
gastric cancer.
Methods
Patients diagnosed between 2009-2011 and 2013-2015 with non-cardia gastric adenocarcinoma 
were selected from the Netherlands Cancer Registry. Results were compared for the period 
before centralisation (2009-2011) and after centralisation (2013-2015). Cox regression analyses 
were used to assess differences in overall survival between periods. 
Results 
A total of 7204 patients were included. Resection rates slightly increased from 38.0% pre-
centralisation to 40.6% post-centralisation (P=0.026). Pre-centralisation, 50.1% of the surgically 
treated patients underwent a gastrectomy in hospitals that annually performed <10 procedures, 
whereas post-centralisation 9.2% of the patients underwent a gastrectomy in these low-
volume hospitals. Patients who underwent a gastrectomy in the second period were younger 
and underwent more often a total gastrectomy (29.3% pre-centralisation vs. 41.2% post-
centralisation). Postoperative 30- and 90-day mortality rates dropped from 6.5 to 4.1% and 
from 10.6 to 7.2%, respectively (P=0.004 and P=0.002). Two-year overall survival rates increased 
from 55.4 to 58.5% for patients who had gastrectomy (P=0.031) and from 27.1 to 29.6% for all 
patients (P=0.003). Improvements remained after adjustment for case-mix however, adjustment 
for hospital volume attenuated this association for surgically treated patients. 
Conclusions
Centralisation of gastric cancer surgery was related with a reduced postoperative mortality for 
surgically treated patients and an improved survival for gastric cancer patients, irrespective of 
treatment. 
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Introduction
Gastric cancer is the fifth most common cancer and the third leading cause of cancer death 
worldwide.1 Although the incidence has decreased over the last decades in the Netherlands, 
prognosis remains poor. The 5-year overall survival rate for patients with gastric cancer is 
approximately 25% in Western countries.2-4 Although survival remained dismal during the last 
two decades, only a minor improvement was observed in recent years in the Netherlands.3, 5 
Surgery is the cornerstone of curative treatment for gastric cancer, however due to the rather 
low incidence of gastric cancer in the Netherlands most hospitals in the Netherlands previously 
performed only a limited annual number of gastrectomies.6 Moreover, gastric cancer surgery is 
considered to be surgery with relative high morbidity and mortality rates.7-9 
Numerous studies have shown a strong and consistent inverse relationship between the 
hospital volume of high-risk surgical procedures and postoperative mortality.10-14 In order to 
improve survival and decrease morbidity for gastric cancer patients, centralisation has been 
initiated in the Netherlands. Since 2012, hospitals should perform a minimum of 10 gastrectomies 
per year, and since 2013 the minimal annual hospital volume of gastrectomies for cancer was 
increased to 20.
Results from previous studies investigating the effects of centralisation of gastric cancer 
surgery on patient outcome are ambiguous.12,14,15 On the one hand, studies from Denmark and 
the United Kingdom showed that patients who underwent a gastrectomy in the period after 
centralisation had a lower postoperative mortality and better overall survival compared to 
patients in the period before centralisation.12,14 Also other studies have shown that increased 
volumes were associated with a lower postoperative mortality and improved survival after 
gastric cancer surgery.11,13 On the other hand, a previous Dutch study including surgically treated 
patients in the Eastern part of the country, has found no improvement in overall survival for 
surgically treated patients after centralisation probably related to a small number of patients.15 
Furthermore, a study from Thompson et al found no relationship between hospital volume and 
long-term survival after gastric cancer surgery.16 
The abovementioned studies only included patients who underwent a gastrectomy. The 
improvement in survival after a gastrectomy found by several studies may be explained by 
patient selection rather than better care. Medical specialists may perform a more critical pre-
operative selection withholding the less fit patients from surgical treatment. As a result, overall 
survival may only be improved for the selected group of patients and may be worse for all 
patients.17 Tor avoid the possible confounding effect of selective patient referral, this study 
evaluates the impact of centralisation of gastric cancer surgery for all gastric cancer patients in 
a population-based setting.
Methods
Data source
Data were obtained from the population-based Netherlands Cancer Registry (NCR). This 
registry serves the total Dutch population of 16.9 million inhabitants. The NCR is based on 
notification of all newly diagnosed malignancies in the Netherlands by the national automated 
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pathological archive (PALGA). Additional sources are the national registry of hospital discharge 
and radiotherapy institutions. Specially trained data managers of the NCR routinely extract 
information on diagnosis, tumour stage, and treatment from the medical records. Information 
on vital status was obtained through an annual linkage with the Municipal Administration 
Database, in which all deceased and emigrated persons in the Netherlands are registered. This 
study was approved by the Privacy Review Board of the Netherlands Cancer Registry and does 
not require approval from an ethics committee in the Netherlands.
Patient selection criteria
The reporting of this study followed the Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) guidelines.18 For this study we selected patients diagnosed with non-
cardia gastric adenocarcinoma between 2009-2011 and 2013-2015 in the Netherlands from 
the NCR. This study compared overall survival for all patients between the period preceding 
centralisation (2009-2011) and the period after centralisation (2013-2015) and those treated 
surgically in the same intervals. We considered 2012 as a transition year, as the first initiatives to 
centralize gastric cancer surgery started in the first months of 2012 and the current minimum 
hospital volume of 20 resections per year was imposed as of 2013. Survival of all patients with 
gastric cancer, regardless of treatment, was evaluated to rule out the possible confounding 
effect of patient selection.
Tumour location and stage
Topography and morphology were coded according to the International Classification of 
Diseases for Oncology (ICD-O-3).19 Tumour staging was performed according to the International 
Union Against Cancer (UICC) TNM classification that was valid at the time of diagnosis. Patients 
diagnosed in 2009 were staged according to TNM-6 and patients diagnosed between 2010 
and 2015 were staged according to TNM-7.20,21 For analyses among all patients, regardless of 
treatment, the pathologic stage of the resection specimen was used, or, if not available, clinical 
tumour stage was noted. For analyses among patients who underwent a gastrectomy the 
pathological tumour stage was used. TNM-7 tumour staging was recoded according to TNM-6, 
which means that patients with a cT4A tumour according to TNM-7 were recoded as having a 
cT3 tumour according to TNM-6. Furthermore, patients with a cN1 or cN2 according to TNM-7 
were recoded as having a cN1 tumour according to TNM-6. 
Surgery
Surgery for gastric cancer was classified according to the NCR as subtotal gastrectomy, total 
gastrectomy or multi-organ resection, which was defined as a gastrectomy and surgical removal 
of other organs. The experience of hospitals performing gastrectomies was defined in categories. 
For example, if a patients underwent a gastrectomy  in 2015 in a hospital that performed 20 or 
more gastrectomies in 2015, the patient was included in the group of hospitals with an annual 
volume of at least 20 procedures. As gastrectomies could also be performed for tumours of the 
cardia, we included both cardia and non-cardia gastric cancer in our calculations for defining 
the annual number of gastrectomies per hospital. Data of cardia tumours were only used to 
define the annual number of gastrectomies per hospital and were not used for other purposes. 
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Statistical analysis 
Descriptive statistics were used to characterize the patients before and after centralisation of 
surgery. Differences in characteristics were analysed by means of chi-squared tests for nominal 
data and ANOVA for continuous data.
Kaplan-Meier curves were generated to examine overall survival before and after centralisation 
for all patients and for surgically treated patients. Survival curves were compared with the log-
rank test. Cox proportional hazard regression analyses were performed to investigate the effect 
of period on overall survival for all patients and surgically treated patients after adjustment 
for potential confounding factors. For survival analyses based on patients who underwent a 
gastrectomy survival time was defined as time from gastrectomy to death or until February 1st 
2017 for patients who were still alive. For survival analyses based on all patients, irrespective of 
treatment, survival time was defined as time from diagnosis to death or until February 1st 2017 
for patients who were still alive. Hazard ratios (HRs) were calculated with 95 percent confidence 
intervals. All analyses were conducted using SAS version 9.4 (Statistical Analysis System). All 
reported p values of <0.05 were considered statistically significant. 
Results
Between 2009-2011 and 2013-2015, 7204 patients were diagnosed with gastric cancer. 3777 
patients were diagnosed between 2009-2011 and 3427 patients between 2013-2015. No 
clinically relevant differences were observed for patients in the period before centralisation and 
after centralisation of surgery (Table 1).  Patients diagnosed in the period before centralisation 
had more often an unknown tumour stage compared to the period thereafter. The proportion 
of patients who underwent a gastrectomy slightly increased over time as 38.0 per cent of the 
patients underwent a gastrectomy in the period before centralisation and 40.6 per cent of the 
patients underwent a gastrectomy in the later period (P=0.026). 
In the first period, 50.1 per cent of the surgically treated patients underwent a gastrectomy 
in hospitals that performed less than 10 procedures each year, whereas in the second period 
only 9.2 per cent of the patients underwent a gastrectomy in these low-volume hospitals 
(Figure 1). After centralisation, 54.3 per cent of the patients underwent a gastrectomy in a high-
volume hospital (performing 20 or more procedures each year). The percentage of patients who 
underwent a gastrectomy in high-volume hospitals increased in the second period from 39.2 
per cent in 2013 to 61.0 per cent in 2015. Furthermore, the percentage of patients referred by 
the hospital of diagnosis to another hospital for preoperative chemotherapy slightly increased 
from 16.7 per cent in the period before centralisation to 24.7 per cent in the period thereafter. 
Compared with those who had a gastrectomy in the first period, patient who underwent 
a gastrectomy in the second period were younger, more often had a proximal tumour, a stage 
III tumour, and underwent more often pre- and/or postoperative chemotherapy (Table 2). The 
proportion of patients who underwent chemotherapy prior to surgery increased from 45.3 per 
cent pre-centralisation to 55.5 per cent post-centralisation. Furthermore, the proportion of 
patients who underwent a total gastrectomy increased from 29.3 percent pre-centralisation to 
41.2 percent post-centralisation. Patients who underwent a gastrectomy in the second period 
had a lower postoperative mortality. The postoperative 30- and 90-day mortality decreased 
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significantly from respectively 6.5 and 10.6 per cent before centralisation to 4.1 and 7.2 per 
cent in the period after centralisation. Furthermore, the proportion of patients with a radical 
resection increased from 76.8 per cent in the first period to 80.6 per cent in the second period 
and the proportion of patients with more than 15 resected lymph nodes retrieved increased as 
well, from 38.4 to 68.6 per cent during these time periods.  
Table 1 Characteristics of patients with non-cardia gastric cancer by period of diagnosis in the Netherlands, 
2009-2011 and 2013-2015 (n=7204).
2009-2011
n=3777
2013-2015
n=3427
n % n % P value
Gender 0.404
Male 2256 59.7 2080 60.7
Female 1521 40.4 1347 39.3
Age (yrs.) 0.149
< 60 646 17.1 619 18.1
60- 74 1440 38.1 1351 39.4
≥ 75 1691 44.8 1457 42.5
Tumour location 0.176
Proximal/ middle a 1101 29.2 1057 30.8
Antrum 1102 29.2 949 27.7
Pyloric 269 7.1 217 6.3
Overlapping, unknown 1305 34.6 1204 35.1
Pathological, or if not available clinical tumour stage <0.001
Complete response 49 1.3 79 2.3
I 496 13.1 431 12.6
II 549 14.5 509 14.9
III 595 15.8 617 18.0
IV 1576 41.7 1389 40.5
Unknown 513 13.6 402 11.7
Tumour grade 0.286
Moderate/ well differentiated 546 14.5 538 15.7
Poorly differentiated or anaplastic 1608 42.6 1459 42.6
Unknown 1623 43.0 1430 41.7
Treatment 0.001
Perioperative CT/CRT 375 9.9 447 13.0
Preoperative CT – surgery 310 8.2 303 8.8
Surgery alone 736 19.5 608 17.7
Chemotherapy alone 699 18.5 619 18.1
Other 350 9.3 304 8.9
None 1307 34.6 1146 33.4
a Proximal / middle = Fundus, corpus and greater and lesser curvature.
CT= chemotherapy, CRT=chemoradiotherapy
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Figure 1 Percentage of patients treated  with a gastrectomy for cancer per hospital volume category.
Table 2 continues on next page.
Table 2 Characteristics of patients with non-cardia gastric cancer who underwent a gastrectomy by period 
of surgery in the Netherlands, 2009-2011 and 2013-2015 (n=2819).
2009-2011
n=1418
2013-2015
n=1401
n % n % P value
Gender 0.220
Male 867 61.1 888 63.4
Female 551 38.9 513 36.6
Age (years) <0.001
< 60 290 20.5 304 21.7
60- 74 580 40.9 654 46.7
≥ 75 548 38.6 443 31.6
Tumour location 0.012
Proximal/ middle a 419 29.5 492 35.1
Antrum 506 35.7 468 33.4
Pyloric 147 10.4 119 8.5
Overlapping, unknown 346 24.4 322 23.0
Pathological tumour stage <0.001
Complete response 44 3.1 67 4.8
I 429 30.3 338 24.1
II 410 28.9 396 28.3
III 397 28.0 496 35.5
IV 137 9.7 96 6.9
Unknown 1 <1.0 8 <1.0
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Tumour grade 0.896
Moderate/ well differentiated 287 20.2 285 20.3
Poorly differentiated or anaplastic 713 50.3 693 49.5
Unknown 418 29.5 423 30.2
Preoperative chemotherapy <0.001
No 776 54.7 623 44.5
Yes 642 45.3 778 55.5
Postoperative treatment <0.001
No 1015 71.6 906 64.7
Yes 403 28.4 495 35.3
Type of gastrectomy <0.001
Total 415 29.3 577 41.2
Subtotal 962 67.8 792 56.5
Multi-organ /unknown 41 2.9 32 2.3
Hospital volume <0.001
1-9 711 50.1 129 9.2
10-19 523 36.9 511 36.5
≥ 20 184 13.0 761 54.3
Outcomes
Radicality 0.009
R0 1089 76.8 1129 80.6
R+ 274 19.3 210 15.0
Unknown 55 3.9 62 4.4
Number of investigated lymph nodes <0.001
< 15 868 61.2 425 30.3
≥ 15 544 38.4 961 68.6
Unknown 6 <1.0 15 1.1
Hospital stay in days (Median (IQR)) 10 8-15 9 7-13 <0.001b
Postoperative 30-day mortality 92 6.5 57 4.1 0.004
Postoperative 60-day mortality 124 8.7 81 5.8 0.003
Postoperative 90-day mortality 150 10.6 101 7.2 0.002
a Proximal / middle = Fundus, corpus and greater and lesser curvature. b ANOVA, unknown category excluded.
Kaplan Meier survival curves showed that patients who underwent a gastrectomy in the 
period after centralisation had a better 2-year overall survival compared to patients who 
underwent a gastrectomy in the period before centralisation (58.5 per cent and 55.4 per cent 
respectively, P=0.031; Figure 2). Multivariable Cox regression analysis confirmed that survival was 
better in the later period (HR=0.88 95%CI 0.79-0.98) after adjustment for age, gender, tumour 
location, tumour stage, neoadjuvant chemotherapy and type of gastrectomy (Table 3). However, 
additional adjustment for annual hospital volume attenuated this association (HR=0.91, 95%CI 
0.80-1.03) suggesting that increasing volume through centralisation contributed to the 
improved survival over time. Hospital volume itself was however not significant in the model, 
but results showed a hazard ratio smaller than 1 suggesting a better overall survival for patients 
who underwent surgery in a high- volume hospital.   
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The 2-year overall survival for non-surgically treated patients did not change significantly 
and was 7.8 per cent in the period before centralisation and 7.4 per cent in the period after 
centralisation. Median survival for non-surgically treated patients remained stable with 17 weeks 
in the period before centralisation and 18 weeks in the period after centralisation (P=0.463).
Figure 3 showed an improvement over time among all patients, irrespective of treatment, 
from a 2-year overall survival rate of 27.1 per cent in the period before centralisation to 29.6 per 
cent in the period after centralisation (P=0.003). Multivariable Cox regression analysis confirmed 
that survival was better in the period after centralisation even after adjustment for age, gender, 
tumour stage, tumour location and tumour grade (HR=0.95 95%CI 0.90-0.99; Table 4). 
Figure 2 Overall survival among patients who underwent gastrectomy for gastric cancer in the period 
2009-2011 and 2013-2015 (n=2819; P=0.031).
Survival time was defined as time from gastrectomy to death or until February 1st 2017 for patients who were 
still alive.
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Table 3  Univariable and multivariable Cox regression analyses of gastric cancer patients who underwent 
a gastrectomy in the period 2009-2011 and 2013-2015 (n=2819).
Univariable analysis Multivariable analysis Multivariable analysis**
HR (95%CI) HR (95%CI) HR (95%CI)
Period of resection
2009-2011 ref ref ref
2013-2015 0.89 (0.80-0.99) 0.88 (0.79-0.98) 0.91 (0.80-1.03)
Gender
Male ref ref ref
Female 0.96 (0.87-1.06) 0.98 (0.89-1.08) 0.98 (0.89-1.09)
Age (yrs.)
< 60 ref ref ref
60- 74 1.11 (0.97-1.27) 1.11 (0.96-1.28) 1.11 (0.96-1.27)
≥ 75 1.57 (1.36-1.80) 1.38 (1.18-1.61) 1.38 (1.18-1.62)
Tumour location
Proximal/ middle ref ref ref
Antrum 1.04 (0.92-1.18) 1.10 (0.96-1.26) 1.10 (0.96-1.26)
Pyloric 1.20 (0.99-1.43) 1.18 (0.98-1.43) 1.18 (0.97-1.42)
Overlapping, unknown 1.47 (1.29-1.67) 1.32 (1.16-1.50) 1.31 (1.15-1.50)
Pathological tumour stage
Complete response 0.31 (0.20-0.48) 0.36 (0.23-0.57) 0.36 (0.23-0.57)
I 0.48 (0.41-0.56) 0.47 (0.40-0.56) 0.47 (0.40-0.55)
II * ref ref ref
III 2.48 (2.19-2.81) 2.41 (2.13-2.72) 2.40 (2.12-2.71)
IV 4.55 (3.82-5.38) 4.49 (3.79-5.32) 4.47 (3.77-5.29)
Preoperative chemotherapy***
No ref ref ref
Yes 0.66 (0.60-0.73) 0.74 (0.66-0.84) 0.74 (0.66-0.84)
Type of gastrectomy
Total ref ref ref
Subtotal 0.75 (0.68-0.84) 0.77 (0.69-0.87) 0.77 (0.68-0.86)
Multi-organ /unknown 1.11 (0.82-1.51) 0.86 (0.63-1.17) 0.86 (0.63-1.17)
Hospital volume
1-9 ref ref
10-19 0.95 (0.84-1.07) 0.96 (0.85-1.08)
≥ 20 0.89 (0.79-1.01) 0.92 (0.79-1.06)
Survival time was defined as time from gastrectomy to death or until February 1st 2017 for patients who were still alive.
* including 9 patients with an unknown pathological tumour stage
** Additionally adjusted for hospital volume
*** No adjustment was made for receiving postoperative chemotherapy as adjustment for postoperative chemotherapy 
would result in immortal time bias for patients who underwent postoperative chemotherapy
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Figure 3 Overall survival among all patients with gastric cancer in the period 2009-2011 and 2013-2015 
(n=7204; P=0.003).
Survival time was defined as time from diagnosis to death or until February 1st 2017 for patients who were still alive.
Discussion
This population-based study on the effect of centralisation of surgery for gastric cancer 
demonstrated an improvement of surgical quality (i.e. lymph node retrieval and radical resection 
rate), a reduction of postoperative mortality and an improvement in overall survival for all 
patients in the period after centralisation. Although other mechanisms may play a role, the fact 
that survival improved for both surgically treated patients and for all patients irrespective of 
treatment, but not among patients who did not undergo a gastrectomy, suggests that advances 
in (peri-)operative treatment and factors closely related to surgical treatment have made an 
important contribution to these improvements. Moreover, the variable ‘period’ was correlated 
with hospital volume for patients who underwent surgery. 
Although centralisation of oesophageal and pancreatic cancer surgery has been shown to be 
beneficial in terms of overall survival, the benefits of centralising gastric cancer surgery seemed 
ambiguous according to previous studies.11,16,22 Some studies found a reduced postoperative 
mortality and better overall survival for patients who underwent a gastrectomy in the period 
after centralisation, while others found no improvement in overall survival after centralisation, 
probably related to the small number of patients included.12,14,15 These previous studies included 
only patients who underwent surgical treatment. To the best of our knowledge, the effect of 
centralisation of surgery for surgically as well as non-surgically treated patients with gastric 
cancer was not shown previously. Therefore, this study investigated the effect of centralisation 
of surgery for all patients with gastric cancer irrespective of treatment to rule out the possible 
confounding effect of selective referral. Results showed an improvement in overall survival for 
all gastric cancer patients which is in concordance with results from previous studies which 
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investigated the impact of centralisation of surgery for all oesophageal and pancreatic cancer 
patients.10,23 
An explanation for improved survival after centralisation could be ‘practice makes perfect’. 
This suggests that more experience gained in hospitals that treat a greater number of patients 
could lead to improvements in the management of patients across the whole treatment 
pathway.17 For example, specialisation of a surgeon should increase their experience including a 
better or more radical resection with extensive lymph node dissection in a higher proportion.24,25 
It is conceivable that the greater exposure of other medical specialists and nurses to patients 
after gastric cancer surgery increases their ability to timely recognize and treat complications 
at an earlier stage and by doing so decrease the failure to rescue rate and subsequently 
postoperative mortality.26,27 Moreover, better patient selection by appropriate preoperative 
staging using endoscopic ultrasound and PET performed by experienced radiation oncologists 
and gastroenterologists is likely to play a significant role in improving survival.28,29 
Table 4  Multivariable Cox regression analysis of all gastric cancer patients diagnosed in the period 2009-
2011 and 2013-2015 (n=7204)
Univariable analysis Multivariable analysis
HR (95%CI) HR (95%CI)
Period of diagnosis
2009-2011 ref ref
2013-2015 0.92 (0.87-0.97) 0.95 (0.90-0.99)
Gender
Male ref ref
Female 1.05 (0.99-1.11) 1.03 (0.97-1.08)
Age (yrs.)
< 60 ref ref
60- 74 1.14 (1.06-1.24) 1.27 (1.17-1.37)
≥ 75 1.65 (1.53-1.78) 2.04 (1.89-2.21)
Tumour location
Proximal/ middle ref ref
Antrum 0.97 (0.90-1.04) 1.05 (0.97-1.12)
Pyloric 0.97 (0.87-1.09) 1.02 (0.91-1.15)
Overlapping, unknown 1.54 (1.45-1.64) 1.26 (1.18-1.34)
Pathological, or if not available clinical tumour stage
I * 0.65 (0.58-0.74) 0.65 (0.57-0.74)
II ref ref
III 2.12 (1.91-2.35) 2.09 (1.89-2.32)
IV 5.76 (5.25-6.32) 5.73 (5.22-6.30)
Unknown 4.98 (4.47-5.55) 4.05 (3.62-4.52)
Tumour grade
Moderate/ well differentiated ref ref
Poorly differentiated or anaplastic 1.48 (1.36-1.60) 1.28 (1.18-1.40)
Unknown 1.57 (1.45-1.70) 1.25 (1.15-1.36)
Survival time was defined as time from diagnosis to death or until February 1st 2017 for patients who were still alive.
*Including patients with a complete response as only a few patients of all patients with gastric cancer have a complete 
response.
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‘Practice makes perfect’ may also be reflected by another trend found by the present 
study. Results demonstrated a 11.9 per cent increase in the number of total gastrectomies 
and a decrease of 11.3 per cent in the number of subtotal gastrectomies after centralisation. 
Interestingly, even though a total gastrectomy, which is associated with more postoperative 
complications, is more commonly performed, postoperative mortality and survival still improved 
for surgically treated patients in the present study.30,31 Furthermore, surgically treated patients 
had more often a stage III tumour in the period after centralisation compared to the period 
before which may be explained by stage migration due a more extensive lymph node dissection. 
The improvement in survival after centralisation of gastric cancer surgery may also be 
supported by developments other than those affecting surgical volume. The increased use 
of perioperative chemotherapy since 2006 may have improved overall survival for patients 
who underwent a gastrectomy.7 Medical oncologists may be more aware of the possibilities 
of perioperative chemotherapy when treating more patients with gastric cancer. In addition, 
postoperative complications are the main reason for not starting with chemotherapy after 
a gastrectomy.7 The use of postoperative chemotherapy probably increased due to less 
complications after a gastrectomy. Even though we adjusted for preoperative chemotherapy 
in the multivariable analysis, survival was still better after centralisation for surgically treated 
patients. However, no adjustment was made for receiving postoperative chemotherapy as 
adjustment for postoperative chemotherapy would result in immortal time bias for patients 
who underwent postoperative chemotherapy. A landmark approach, assessing survival after 
four months after a gastrectomy, would have decreased the immortal time bias, however it 
excludes the patients who died within four months after a gastrectomy and obscures the effect 
of a reduced postoperative mortality on overall survival. 
A reduction in postoperative mortality and improved overall survival for surgical patients 
with gastric cancer is sometimes challenged due to selection of patients that already have a 
higher chance on superior outcomes.17 This phenomena can be accompanied by a decreased 
resection rate. In the present study however, the resection rate increased. On the other hand, 
patients were slightly younger in the period after centralisation. Nevertheless, overall survival 
improved for all patients in the period after centralisation. So, selective referral of patients may 
slightly have influenced the improved results found for surgically treated patients, but can 
certainly not be the only cause for improvement in survival.
During the study period the use of laparoscopic gastrectomy increased. It is suggested 
that laparoscopic gastrectomy causes less perioperative blood loss, fewer post-operative 
complications, shorter hospital stay, but have equal surgical oncological results (i.e. radicality 
and lymph nodes harvest) and post-operative mortality.32,33 Furthermore, a previous Dutch 
study from Brenkman et al, also based on the NCR, found a comparable 1-year overall survival 
for patients who underwent an open versus laparoscopic gastrectomy in the period 2010-
2014.34 Therefore, improved survival for surgically treated patients after centralisation cannot 
be explained by the increased use of laparoscopic gastrectomy.
This study has some limitations. First, the impact of centralisation on other important 
outcomes was not examined, such as postoperative complications, health care cost or quality 
of life. Second, it was not possible to adjust for performance status and comorbidity as this 
information was lacking nationwide. A major strength of the present study is its population 
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based nature, which enables us to capture all patients with gastric cancer in the Netherlands 
and compare the outcomes for the entire group of patients before and after the period of 
centralisation.
In conclusion, the present study found an improved overall survival for all patients in the 
period after centralisation of gastric cancer surgery. The impact on survival is likely to be both 
due to individual surgical experience and collective team expertise. 
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Abstract
Background 
In several European countries it is recommended to treat gastric cancer patients with 
perioperative chemotherapy if they are eligible for surgery. However, little is known about its 
use in daily clinical practice. This study examines the use of perioperative treatment and its 
impact on survival in the Netherlands. 
Methods
Patients diagnosed with potentially resectable gastric cancer (cT1N+/cT2-T3,X any cN, cM0,X) 
between 2006 and 2014 were selected from the Netherlands Cancer Registry (n=5824). 
Treatment trends were examined. Propensity score matching was used to create a subsample 
to reduce selection bias. Cox regression analysis was used to assess differences in overall survival.
Results
The percentage of patients treated with perioperative treatment increased from 3% in 2006 
to 26% in 2014 and the use of only surgery decreased from 60% to 26%. 35% of all patients 
did not undergo surgery. Of the patients who underwent preoperative chemotherapy and 
surgery, 43% did not commence postoperative treatment. Cox regression analysis showed 
a better overall survival for patients who underwent perioperative treatment compared to 
patients who underwent preoperative treatment only (HR=0.80 95%CI 0.70-0.93; propensity 
matched sample: HR=0.84 95%CI 0.71-0.99), whereas survival was comparable for patients 
who underwent preoperative chemotherapy versus surgery alone (HR=0.89 95%CI 0.77-1.02, 
propensity matched sample: HR=0.85 95%CI 0.72-1.01). 
Conclusion
This population-based study highlights that a significant proportion of the patients did not 
receive perioperative treatment. More research is necessary to elucidate the importance of the 
individual components of perioperative treatment. 
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Introduction
Gastric cancer is one of the leading cancers in incidence and mortality throughout the world. 
Survival rates are dismal with a 5-year relative survival of 18-33% in Europe.1 Therefore, during 
the past decade several randomised trials have been conducted to improve survival of patients 
with gastric cancer. These studies showed a benefit of multimodality treatment in patients with 
resectable gastric cancer.2-4 However, an international consensus on the best multimodality 
treatment has not been reached. In Northern America perioperative chemotherapy or 
postoperative chemoradiotherapy is the preferred treatment for patients with resectable gastric 
cancer whereas in Japan postoperative chemotherapy is the preferred treatment. 2,5,6 
In several European countries perioperative chemotherapy is recommended based on the 
results of the UK MAGIC trial.7 Results of the this trial demonstrated that patients with resectable 
gastric or lower oesophageal adenocarcinoma randomised for perioperative chemotherapy 
had a 13% improved overall survival compared to surgery alone (35% vs. 23%).2 According 
to the results of this trial perioperative chemotherapy consisting of epirubicine, cisplatin and 
5-FU (ECF) or a similar regime is the recommended treatment as of May 2009 in the Dutch 
guidelines for patients with resectable gastric cancer unless patients are too frail or have severe 
comorbidities.2,3,8 
Although perioperative chemotherapy is recommended for resectable gastric cancer in 
several European countries, the actual use seems limited in patients with gastric cancer as 
only 66% of the gastric cancer patients included in the MAGIC trial allocated to perioperative 
chemotherapy were able to start postoperative treatment.2,9,10 However, to our knowledge, 
no data are available on the utilisation and impact of perioperative treatment on survival in 
daily clinical practice. Therefore, the aim of this nationwide observational study was to analyse 
trends in administration of perioperative treatment and its impact on survival among potentially 
resectable gastric cancer patients in the Netherlands. 
Methods
Netherlands Cancer Registry
Data were obtained from the Netherlands Cancer Registry (NCR). This registry serves the total 
Dutch population of 16.9 million inhabitants. The NCR is based on notification of all newly 
diagnosed malignancies by the national automated pathological archive (PALGA). Additional 
sources are the national registry of hospital discharge and radiotherapy institutions. Specifically 
trained data managers of the NCR extract information on diagnosis, staging and treatment 
from the medical records. Information on vital status was obtained through an annual linkage 
with the Municipal Administrative Database, in which all deceased and emigrated persons in 
the Netherlands are registered. This study was approved by the Privacy Review Board of the 
Netherlands Cancer Registry and does not require approval from an ethics committee in the 
Netherlands.
Patients with a potentially resectable non-cardia gastric adenocarcinoma diagnosed in the 
period 2006-2014 eligible for perioperative treatment (cT1 cN+ / cT2-3,X, any cN, cM0,X (TNM-
6)) were included in the study. The gastro-oesophageal junction could be involved, but the 
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bulk of the tumour had to be in the stomach. The study period 2006-2014 was chosen as the 
results of the MAGIC trial were published in 2006 which favoured perioperative chemotherapy 
for resectable gastric cancer patients instead of surgery alone2. Topography and morphology 
were coded according to the International Classification of Diseases for Oncology (ICD-O-3).11
Tumour staging was performed according to the International Union Against Cancer  TNM 
classification that was valid at the time of diagnosis.12, 13 TNM-7 tumour staging was recoded 
according to TNM-6. Patients were considered potentially resectable if they had no distant 
metastasis (cM1) and no infiltration into surrounding organs (cT4 according to TNM-6). 
Patients with a cT1N0 tumour were also excluded as they were not eligible for perioperative 
chemotherapy according to the Dutch guidelines (A STROBE diagram of the study population is 
presented in figure 1). Patients with unknown clinical distant metastasis (cMX) were considered 
as having a cM0 and were therefore included in the study. Prior to 2010 coding regulations to 
register a cM0 or cM1 status into the NCR were strict and patients who were treated as cM0 
were sometimes registered as cMX (due to certain coding regulations). As of 2010 the coding 
regulations were less strict which resulted in almost no cMX patients since 2010 and an increase 
in cM0 patients (with virtually no increase in cM1 patients). Therefore, to avoid bias due to 
changing regulations, all patients with cMX were included.
Treatment definitions
Perioperative treatment was defined as preoperative chemotherapy followed by a surgical 
resection and postoperative chemotherapy or chemoradiotherapy. As information on the 
number of received cycles was not available in the NCR for the study period, preoperative and 
postoperative chemotherapy were defined as receiving at least one dose of chemotherapy pre- 
and/or postoperative. Surgical resection was defined as a subtotal or total gastrectomy. Surgery 
alone was defined as receiving surgery without preoperative or postoperative treatment. Patients 
who did not undergo surgery were allocated to the groups ‘preoperative chemotherapy without 
surgery’ or ‘neither chemotherapy nor surgery’, whichever was appropriate. As the intention 
of chemotherapy (preoperative or palliative) was not registered in the NCR, we assumed that 
patients who were potentially resectable and received chemotherapy without surgery, had 
started with preoperative chemotherapy with curative intent and were therefore allocated to 
the group ‘preoperative chemotherapy without surgery’.
Subgroup analysis were performed to estimate the number of cycles received for patients 
diagnosed between 2010 and 2014 based on the number of days between start of chemotherapy 
and end of chemotherapy. This period was chosen as the date of end of chemotherapy was not 
routinely registered prior to 2010. Treatment duration of 1-20 days was defined as 1 cycle, 21-41 
days as 2 cycles, and 42-70 days as 3 cycles, whereas all other treatment durations were defined 
as unknown. 
Statistical analysis
Descriptive statistics were used to characterise the patients according to type of treatment i.e. 
perioperative treatment, preoperative chemotherapy with surgery, surgery alone, preoperative 
chemotherapy without surgery and neither chemotherapy nor surgery. Differences in 
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characteristics between treatment groups were analysed by means of chi-squared tests for 
nominal data and ANOVA for continuous data.
Kaplan-Meier curves were generated to examine overall survival according to type of 
treatment for all potentially resectable patients and were compared with the log-rank test. For 
this analysis, survival time was defined from diagnosis until death or until February 1st 2017. 
Survival curves were also generated for patients who underwent surgery with or without pre- 
and/or postoperative treatment using the Kaplan-Meier method. For this and all other survival 
analyses survival time was defined as time from four months after surgery to death or until 
February 1st  2017 for patients who were still alive. This landmark at four months postoperative 
addressed immortal time bias of patients receiving postoperative treatment, which starts 6 to 8 
weeks after surgery and takes approximately 9 weeks to complete the three cycles.
Differences in overall survival were compared between patients who underwent perioperative 
treatment and patients who underwent only preoperative chemotherapy (comparison 1) as 
well as between patients who underwent only preoperative chemotherapy versus patients 
who underwent surgery alone using multivariable Cox regression analyses (comparison 2). 
Furthermore, propensity score matching was performed to minimise confounding due to 
nonrandomised assignment of treatment. Selection of covariates for matching unrelated 
to survival was avoided, even though they were associated with the treatment received, as 
this may increase bias.14, 15 For comparison 1 a logistic regression was used to determine the 
probability of perioperative treatment, i.e. the propensity score, based on gender, age, period 
of diagnosis, tumour location, pT classification, pN classification, tumour grade, type of surgery, 
margin involvement and duration of postoperative hospital stay. For comparison 2 a logistic 
regression was used to determine the probability of only preoperative chemotherapy, i.e. the 
propensity score, based on gender, age, period of diagnosis, tumour location, cT classification, 
cN classification and tumour grade. On the basis of propensity scores patients were then 1:1 
matched within tight bound of the propensity scores; predicted probabilities could vary by 
no more than 0.01 (1%) on a scale of 0 to 1. Subsequently, Cox regression analyses were also 
performed for the propensity matched sample to investigate the prognostic impact of  the 
treatment received. Reported p values of <0.05 were considered statistically significant. Analyses 
were conducted using SAS version 9.4 (Statistical Analysis System).
Results
Patients
Between January 2006 and December 2014, 12 117 patients were diagnosed with non-cardia 
gastric adenocarcinoma. Based on our inclusion and exclusion criteria a study population of 
5824 patients was identified (Figure 1). Patient characteristics were summarised in table 1. 
Perioperative treatment was administered in 962 patients (17%) and preoperative 
chemotherapy without postoperative treatment was administered in 724 patients (12%). Surgery 
alone was performed in 2114 patients (36%). Patients who underwent perioperative treatment 
were more often younger than patients who underwent only preoperative chemotherapy 
followed by surgery or surgery alone (Table 1). 
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Figure 1 STROBE diagram of the study population.
* The sum of the excluded patients per exclusion criteria is larger than the total number of excluded patients because 
some patients met two exclusion criteria.
** cT4 according to TNM-6 and cT4B according to TNM-7. Patients with a cT4A tumour according to TNM-7 were recoded 
as having a cT3 tumour according to TNM-6. 
***Perioperative treatment was defined as preoperative chemotherapy followed by a surgical resection and postoperative 
chemotherapy or chemoradiotherapy
CT= chemotherapy.
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Trends in treatment
Administration of perioperative treatment increased over time (Figure 2). In 2006 3% of the 
patients underwent perioperative treatment and in 2014 26% underwent perioperative 
treatment. The number of patients who started with preoperative chemotherapy followed by 
surgery regardless of receiving postoperative treatment, increased from 6% in 2006 to 42% in 
2014. Of the patients who underwent preoperative chemotherapy and surgery, 43% did not 
commence postoperative treatment in 2014.
In line with these findings, the percentage of patients who underwent surgery alone 
decreased from 60% in 2006 to 26% in 2014. The percentage of patients who started with 
preoperative chemotherapy and did not undergo surgery remained stable over the study period 
varying from respectively 4% to 7%. Similarly, the percentage of patients who received neither 
chemotherapy nor surgery also remained stable over time varying from 28% to 32%. 
Subgroup analysis among patients who underwent preoperative chemotherapy with or 
without postoperative treatment in the period 2010-2014 showed that 89% of the patients who 
underwent perioperative treatment received 3 cycles of chemotherapy preoperatively, whereas 
patients who underwent preoperative treatment without postoperative treatment received less 
often 3 cycles of chemotherapy preoperatively (58%, Appendix 1).
Survival
Kaplan Meier survival curves of all potentially resectable patients showed that overall survival 
was worst for patients who received preoperative chemotherapy without surgery and for 
patients who received neither chemotherapy nor surgery with an almost equal 1-year overall 
survival rate of 22% and 21%, respectively (Figure 3).
Among patients who underwent surgery and survived the first four months after surgery, 
univariable overall survival was most favourable for patients who underwent perioperative 
treatment with a 5-year overall survival rate of 48% (P<0.01). Patients who underwent only 
preoperative chemotherapy had an 5-year overall survival comparable to patients who 
underwent surgery alone, respectively 43% and 39% (P=0.22; Figure 4). 
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Figure 2 Trends in multimodality treatment among patients with potentially resectable non-cardia gastric 
adenocarcinoma (cT1N+/cT2-T3,X, any cN, cM0,X) diagnosed in the period 2006-2014 (n=5824).
CT= chemotherapy.
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Figure 3 Overall survival among patients with potentially resectable non-cardia gastric adenocarcinoma 
(cT1N+/cT2-3,X, any cN, cM0,X) diagnosed in the period 2006-2014 (n=5824). 
Survival time was defined as time from diagnosis to death or 1nd of February 2017 for patients who were still alive. CT= 
chemotherapy.
Figure 4 Overall survival among patients with potentially resectable non-cardia gastric adenocarcinoma 
(cT1N+/cT2-T3,X, any cN, cM0,X) who underwent surgery with or without pre- and/or postoperative 
treatment and were diagnosed in the period 2006-2014 (n=3389; P <0.01). 
*Survival time was defined as time from four months after surgery to death or 1nd of February 2017 for patients who 
were still alive. Patients who died within 4 months after surgery were excluded from the analysis. 
CT= chemotherapy.
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Multivariable Cox regression analysis also showed a favourable survival for patients who 
underwent perioperative treatment compared to patients who underwent only preoperative 
chemotherapy (HR=0.80 95%CI 0.70-0.93; Table 2a). A similar association was investigated 
among the propensity score matched sample. Characteristics of the matched patients were 
comparable and shown in appendix 2. After adjustment for confounders, the Cox regression 
analysis among the propensity score matched sample showed that perioperative treatment was 
associated with a better overall survival (HR=0.84 95%CI 0.71-0.99; Table 2a). 
Multivariable Cox regression analysis demonstrated no significant difference in overall 
survival for patients who underwent only preoperative chemotherapy and for patients 
who underwent surgery alone (HR=0.89 95%CI 0.77-1.02; Table 2b). Survival analysis for the 
propensity score matched sample also showed no significant difference in survival (HR=0.85 
95%CI 0.72-1.01 (Table 2b). Characteristics of the matched patients were comparable and shown 
in appendix 3.
Table 2a Multivariable Cox proportional hazards analyses of overall survival for potentially resectable non-
cardia gastric adenocarcinoma patients who underwent preoperative chemotherapy followed by surgery 
with or without postoperative treatment for all patients and for the propensity score matched sample.
All patients
n=1598
Propensity score matched sample**
n=1062
Crude 2-year 
OS
Multivariable analysis * Crude 2-year 
OS
Multivariable analysis*
% HR 95% CI % HR 95% CI
Treatment
Perioperative treatment 67 0.80 0.70-0.93 67 0.84 0.71-0.99
Preoperative 
chemotherapy - surgery 60 ref 61 ref
OS=overall survival. Patients who died within 4 months after surgery were excluded from the analysis.
*Adjusted for gender, age ,period of diagnosis, tumour location, pT classification, pN classification, tumour grade, type 
of surgery, margin involvement and duration of postoperative hospital stay.
**Characteristics of the propensity score matched sample were demonstrated in appendix 2.
Table 2b Multivariable Cox proportional hazards analyses of overall survival for potentially resectable non-
cardia gastric adenocarcinoma patients who underwent preoperative chemotherapy followed by surgery 
without postoperative treatment and for patients who underwent surgery alone; for all patients and for 
the propensity score matched sample.
All patients
n=2429
Propensity score matched sample**
n=967
Crude 2-year 
OS
Multivariable analysis * Crude 2-year 
OS
Multivariable analysis *
% HR 95% CI % HR 95% CI
Treatment
Preoperative 
chemotherapy - surgery 60 0.89 0.77-1.02 61 0.85 0.72-1.01
Surgery alone 59 ref 58 ref
OS=overall survival. Patients who died within 4 months after surgery were excluded from the analysis.
*Adjusted for gender, age ,period of diagnosis, tumour location, cT classification, cN classification and tumour grade. 
**Characteristics of the propensity score matched sample were demonstrated in appendix 3.
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Discussion
This population-based study of potentially resectable gastric cancer patients has demonstrated 
an increase in the administration of perioperative treatment of 3% to 26% in the course of 
time which may have led to a survival benefit compared to treatment with only preoperative 
chemotherapy followed by surgery. However, in 2014 still 74% of the patients was not treated 
with perioperative treatment. In addition, postoperative treatment was not administered to 
43% of the patients who started with preoperative chemotherapy followed by surgery in 2014. 
There are hypotheses that might explain the low percentage of resectable gastric cancer 
patients receiving perioperative treatment (26%), despite the publication of the MAGIC trial and 
the French FNCLCC/FFCD trial both demonstrating a significant survival benefit of perioperative 
treatment compared to surgery alone.2, 4 Many patients with gastric cancer have an older age, 
comorbidities and suffer from malnutrition and weight loss which could preclude them from 
starting with the perioperative treatment regimen.16  After preoperative chemotherapy there 
could be several reasons for not undergoing surgery such as  disease progression, toxicity from 
chemotherapy, patient request and death.2, 17 Moreover, gastric cancer surgery is associated with 
substantial morbidity and postoperative complications which could interfere with receiving 
postoperative treatment. 2,18-20 As only a minority of the patients is actually capable of receiving 
the full regimen, one could argue about the appropriateness of perioperative chemotherapy 
as a reference regime for patients with resectable gastric cancer.
In this observational study, many patients (43%) did not start postoperative treatment 
after preoperative chemotherapy followed by surgery. This percentage was somewhat higher 
compared to the results of the MAGIC trial 2 and CRITICS trial 21 but similar to the FLOT4-AIO 
trial 22, in which respectively 35%, 38% and 40%, of the patients did not start with postoperative 
treatment. However, the patients included in the trials were highly selected for trial eligibility 
and may therefore differ from the general gastric cancer patient population who probably have 
a worse performance status and are less ideal candidates for perioperative treatment. Another 
retrospective study found that 35% of the patients did not start with postoperative treatment 
after preoperative chemotherapy followed by surgery. 23
Our survival results, based on real world data, support the survival benefits reported by the 
MAGIC trial and the French FNCLCC/FFCD trial.2,4 Both trials reported an increase in 5-year overall 
survival of respectively 13% and 14% in the perioperative chemotherapy group compared 
to the surgery only group which is rather similar to the 10% increase found in the present 
study.2,4 Multivariable Cox regression analyses, among all patients and the propensity score 
matched sample, indicated a favourable survival after perioperative treatment compared to 
only preoperative chemotherapy. 
Even tough, propensity score matching was performed to minimise confounding due to 
nonrandomised assignment of treatment, groups may not be completely comparable and 
confounding due to nonrandomised assignment may still exists. For example, the differences 
in number of preoperative cycles received strongly suggests that patients who underwent 
only preoperative chemotherapy were less fit than patients who underwent perioperative 
treatment. This may, at least partially, explain why survival was comparable for patients 
who received only preoperative chemotherapy and patients who underwent surgery alone. 
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Furthermore, propensity score matching may amplify the risk of residual bias by unmeasured 
confounders as matching is only performed for measured confounders forcing balance of these 
confounders.24 In addition, there could still be bias due to incomplete matching as 58% of 
the patients who received perioperative treatment, 77% of the patients who underwent only 
preoperative treatment and 26% of the patients who underwent surgery alone were excluded 
from the propensity score matched samples. Full matching instead of 1 to 1 matching seems 
a more appropriate method when performing survival analysis, however after full matching 
imbalance remained in characteristics between the treatment groups.25 Although propensity 
score matching has uses and limitations, the authors decided to present the results of both the 
unmatched and propensity score matched analyses to facilitate the ongoing debate about the 
added value of propensity score matching to estimate causal effects.
Compliance to perioperative treatment in patients with resectable gastric cancer is poor, even 
in selected trial patients. Only 36% to 47% of all trial patients completed the entire treatment 
protocol.2,4,22,26 As a substantial number of patients do not receive postoperative treatment, 
preoperative approaches may be particularly attractive.27 Therefore, the CRITICS II trial which 
is a future Dutch multi-centre randomised phase II study that aims to assess the feasibility and 
safety of three preoperative treatment approaches (chemotherapy vs chemoradiotherapy vs 
chemotherapy plus chemoradiotherapy) will include no additional postoperative treatment. 
This study has some limitations. First, information was not available about performance status, 
comorbidities and postoperative complications. However, age and duration of postoperative 
hospital stay may be proxies for comorbidities and postoperative complications, respectively. 
Second, because endoscopic ultrasonography is not always performed in patients with gastric 
cancer, clinical stage was unknown in a relatively high percentage of patients (64% cTX stage 
and 28% cNX stage; Table 1). Missing data for cT and cN might have led to an underestimation of 
the proportion of patients who underwent perioperative chemotherapy as inclusion of patients 
is based on clinical stage. However, the underestimation may only be to a small extent as most 
patients who were not eligible for perioperative chemotherapy were excluded from the study 
based on cM stage (67%) which is less often missing compared to cT and cN stage (Figure 1). 
Moreover, the missing values for cT and cN stage provide valuable information on care in daily 
clinical practice. Third, the number of cycles of preoperative or postoperative chemotherapy 
received was unknown for the total study period and was therefore not included in the analysis. 
Finally, if patients were treated with preoperative intent but failed to undergo surgery, these 
patients were assigned to preoperative chemotherapy without surgery, and as a consequence 
the patients treated with preoperative intent followed by surgery may represent a selection of 
the fittest patients. 
To conclude, this study, based on real world data, highlights that a significant proportion of 
the patients did not receive perioperative treatment. More research is necessary to elucidate 
the importance of the individual components of perioperative treatment.
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Appendix 1 Number of cycles received preoperatively for patients who underwent preoperative 
chemotherapy followed by surgery with or without postoperative treatment in the period 2010-2014.
Perioperative treatment 
n=570**
Preoperative CT and surgery
n=350**
n % n %
Preoperative number of cycles *
1 13 2% 52 15%
2 50 9% 94 27%
3 507 89% 204 58%
*The number of cycles was based on the number of days between start and end date of chemotherapy. 
**The number of cycles was unknown for 223 patients (20%) in the period 2010-2014.
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Appendix 3 Characteristics of potentially resectable non-cardia gastric adenocarcinoma patients who 
underwent preoperative chemotherapy followed by surgery without postoperative treatment and for 
patients who underwent surgery alone; for all patients (n=2838) and the propensity score matched sample 
(n=1108).
All patients Propensity score matched sample
Preoperative 
CT- surgery
Surgery alone Preoperative 
CT- surgery
Surgery alone
n % n % P value n % n % P value
Total 724 100% 2114 100% 554 100% 554 100%
Gender 0.93 0.67
Male 437 60% 1272 60% 334 60% 341 62%
Female 287 40% 842 40% 220 40% 213 38%
Age in years 
(median, IQR)
67 60-72 76 69-81 <0.01 69 63-73 70 61-77 0.44
Period of diagnosis <0.01 0.67
2006-2008 167 23% 993 47% 157 28% 146 26%
2009-2011 268 37% 608 29% 195 35% 193 35%
2012-2014 289 40% 513 24% 202 36% 215 39%
Tumour location <0.01 0.54
Proximal/ middle 266 37% 562 27% 184 33% 175 32%
Antrum 232 32% 815 39% 191 34% 185 33%
Pyloric 46 6% 236 11% 40 7% 53 10%
Overlapping, 
unknown
180 25% 501 24% 139 25% 141 25%
cT classification <0.01 0.22
cT1 4 <1% 19 <1% 4 <1% 3 <1%
cT2 316 44% 525 25% 214 39% 222 40%
cT3 33 5% 93 4% 22 4% 36 6%
cTX 371 51% 1477 70% 314 57% 293 53%
cN classification <0.01 0.91
cN0 395 55% 1274 60% 319 58% 320 58%
cN+ 218 30% 414 20% 142 26% 146 26%
cNX 111 15% 426 20% 93 17% 88 16%
Tumour grade <0.01 0.96
Moderate/ well 
differentiated
83 11% 599 28% 77 14% 74 13%
Poorly 
differentiated or 
anaplastic
366 51% 1165 55% 301 54% 304 55%
Unknown 275 38% 350 17% 176 32% 176 32%
CT=chemotherapy
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Abstract
Background
For patients who qualify for perioperative chemotherapy and gastrectomy, the optimal timing 
of adjuvant chemotherapy (aCTx) seems equivocal. The aim of this study was to assess the 
association between timing of aCTx and overall survival (OS) in patients receiving perioperative 
chemotherapy for gastric cancer. 
Methods
Data from patients undergoing perioperative chemotherapy and gastrectomy for gastric 
adenocarcinoma with curative intent (2010-2014) were extracted from the nationwide 
population-based Netherlands Cancer Registry. Timing of aCTx was analysed as a linear 
and categorical variable (<6 weeks, 6-8 weeks, and >8 weeks). Multivariable regression was 
performed to identify risk factors for a late start of aCTx (≥6 weeks), and to assess the association 
between timing of aCTx and OS.
Results
Among 1066 patients who underwent neoadjuvant chemotherapy and gastrectomy, 463 (43%) 
patients started aCTx. aCTx was administered within 6 weeks in 208 (45%) patients, within 6-8 
weeks in 155 (33%) patients, and after 8 weeks in 100 (22%) patients. A total of 419 (91%) and 
351 (76%) patients finished all cycles of neoadjuvant and aCTx, respectively. A late start of aCTx 
was associated with a longer hospital stay (+1 hospital day: OR=1.15, 95%CI 1.08-1.23, P<0.001). 
Timing of aCTx was not associated with OS (6-8 weeks vs. <6 weeks, HR=1.14, 95%CI 0.79-1.65, 
P=0.471; >8 weeks vs. <6 weeks, HR=1.04, 95%CI 0.79-1.65, P=0.872). 
Conclusion
This nationwide study demonstrates that timing of aCTx is not associated with OS. The results 
suggest that the early postoperative period may be safely used for recovery and optimising 
patients for the start of aCTx.
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Introduction
In most European countries, the preferred treatment for patients with potentially curable 
gastric cancer is gastrectomy with perioperative chemotherapy.1-3 Unfortunately, only 23% 
to 42% of the patients complete the total multimodality treatment regimen of gastrectomy 
and perioperative chemotherapy according to results from randomised controlled trials.1,3 
Discontinuation of treatment is mostly observed after gastrectomy; patients do not start with 
the adjuvant chemotherapy component of perioperative chemotherapy  (aCTx), frequently due 
to gastrectomy related complications.1,4 
For patients who are candidates for aCTx, optimal timing of aCTx seems equivocal. Initially, 
patients need time to recover from surgery, which can take up to several months depending on 
the postoperative course.5 On the other hand, an early start of aCTx seems rational to achieve 
an optimal oncological result. For other cancer types, such as colon and breast cancer, studies 
indeed demonstrated that an early start of aCTx is associated with a better survival.6-8 
Current studies on the association between timing of aCTx and survival for gastric cancer 
specifically are inconclusive.9-11 However, these studies included patients receiving aCTx only, 
whereas perioperative chemotherapy is standard of care in most European countries. Moreover, 
(inter)national guidelines are lacking.1 Therefore, the primary aim of this study was to assess 
the association between timing of aCTx and overall survival (OS) in a population of patients 
receiving perioperative chemotherapy and gastrectomy for cancer. Second, we aimed to identify 
risk factors for a late start of aCTx.
Methods
Study design
This study was conducted with data from the Netherlands Cancer Registry (NCR), which includes 
all newly diagnosed cancers in the Netherlands. The NCR is based on notification of all newly 
diagnosed malignancies by the national automated pathological archive (PALGA). Additional 
sources are the national registry of hospital discharge and radiotherapy institutions. Specifically 
trained data managers of the NCR extract information on diagnosis, staging and treatment from 
the medical records. This study was approved by the Privacy Review Board of the NCR.
Patient population 
Patients who underwent neoadjuvant chemotherapy and gastrectomy for non-cardia gastric 
adenocarcinoma with curative intent based on clinical staging (cT1-4a-x, any cN, cM0-x) between 
2010 and 2014 were selected from the NCR. Patients were not included if they had distant 
metastases (pM1) or infiltration into surrounding organs (pT4b), as these patients could most 
likely no longer receive aCTx with curative intent. Moreover, patients with cT1N0 tumours were 
not included, as guidelines do not recommend neoadjuvant chemotherapy for these patients. 
The study period was chosen as data on timing of aCTx before 2010 was not routinely registered. 
Patients who did not undergo aCTx, who underwent (neo)adjuvant (chemo)radiotherapy, or 
who had incomplete data on timing of aCTx or OS were excluded (Appendix 2). Furthermore, 
patients who started more than 12 weeks after surgery were excluded from the statistical 
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   116 20-3-2018   22:25:33
7117Timing of adjuvant chemotherapy in gastric cancer patients |
analysis to ensure that treatment had an adjuvant and not a palliative intention and since the 
MAGIC trial performed aCTx within 12 weeks after surgery.1 
Tumour staging and treatment
According to the nationwide guidelines for patients with gastric cancer, tumour staging 
consists of gastroscopy and computed tomography in all patients.12 Tumour staging was 
based on the American Joint Committee on Cancer TNM staging system (7th edition).13 
The guideline recommends perioperative chemotherapy (including epirubicin, cisplatin or 
oxalipatin, and capecitibine or fluorouracil)1,14 and a (sub)total gastrectomy along with a D2 
lymphadenectomy.15,16 Topography and morphology were coded according to the International 
Classification of Diseases for Oncology (ICD-O-3).17
Definitions
Perioperative treatment was defined as neoadjuvant chemotherapy followed by a surgical 
resection and aCTx. As information on the number of received cycles was not available in the 
NCR, the number of days between start of chemotherapy and end of chemotherapy was used to 
determine by proxy the number of cycles received, based on the MAGIC regimen.1 A treatment 
duration of 1-20 days was defined as 1 cycle, 21-41 days as 2 cycles, and 42-70 days as 3 cycles. All 
other treatment durations were defined as unknown. Timing of aCTx was defined as the interval 
between surgery and the start of aCTx. Patients were a priori divided into 3 groups according 
to the timing of aCTx (<6 weeks, 6-8 weeks, and >8 weeks). These groups were chosen based 
on consensus among the co-authors about clinically relevant groups and by evaluation of the 
dataset (to make the groups more or less equal in numbers). 
Statistical analysis
Differences between groups were compared by using the chi-square or Fisher’s exact test for 
categorical variables, and the one-way ANOVA or Kruskal-Wallis for continuous variables. Missing 
values for duration of hospital stay (7%), and duration of neoadjuvant treatment (14%) were 
considered at random and imputed by the median value. Missing categorical variables – most 
concerning tumour differentiation – were included in the analyses by creation of a dummy 
variable. Multivariable logistic regression was performed to identify risk factors associated with 
a late start (≥6 weeks) of aCTx. Kaplan-Meier curves were generated to examine OS according 
to timing of aCTx and were compared with the log-rank test. The association between timing 
of aCTx and OS was assessed using uni- and multivariable Cox regression analysis, providing 
hazard ratios (HRs) with 95% confidence intervals (CIs). To adjust for possible confounders, all 
baseline variables were entered in multivariable analysis. OS was defined as time from 5 months 
after surgery to death or until February 1st 2017 for patients who were still alive. This landmark 
at 5 months after surgery was chosen to address immortal time bias of patients receiving aCTx 
during the total period of the start (maximum of 12 weeks after surgery) and completion of all 
cycles of aCTx (9 weeks). The proportional hazard assumption was evaluated by constructing 
log minus log survival plots, and the assumption was met. Sensitivity analyses were performed 
to evaluate the association between timing of aCTx and OS for both early (pTNM-stage 0-I) and 
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advanced tumours (pTNM-stage II-III). All statistical analyses were performed using IBM SPSS 
version 21. All P values <0.05 were considered statistically significant.
Results
Study population
A total of 1066 patients underwent neoadjuvant chemotherapy and gastrectomy for non-cardia 
gastric adenocarcinoma with curative intent. After excluding patients who underwent (neo)
adjuvant (chemo)radiotherapy (n=146), with incomplete data (n=15), or who did not undergo 
aCTx (n=341), 474 patients remained. Of these 474 patients, 463 (98%) patients started aCTx 
within 12 weeks and were included for the analysis (Appendix 2).
Patient characteristics 
The majority of the 463 patients completed all 3 cycles of neoadjuvant chemotherapy (91%), and 
had a stage II or III tumour (69%). The median hospital stay was 8 days (interquartile range (IQR) 
7-11 days), and all patients had a hospital stay ≤30 days. Some 351 patients (76%) who started 
with aCTx completed all 3 cycles. More patient characteristics are presented in appendix 1.
Timing of adjuvant chemotherapy
The median timing of start of aCTx was 6.1 weeks after gastrectomy (IQR 4.9-7.7 weeks) (Figure 
1). The groups of timing of aCTx (<6 weeks, 6-8 weeks, and >8 weeks) consisted of 208 (45%), 
155 (33%), and 100 (22%) patients, respectively (Table 1). Patients in the early timing groups 
more frequently underwent a partial gastrectomy (P=0.006), and had a shorter hospital stay 
(P<0.001). Furthermore, patients in the earlier timing groups more frequently completed all 3 
cycles of aCTx (81% <6 weeks, 73% 6-8 weeks, 69% >8 weeks, P=0.007) (Table 2). In multivariable 
logistic regression analysis, a longer hospital stay was an independent predictor of late start of 
aCTx (each additional day OR=1.15, 95% CI  1.08-1.23, P<0.001; Table 2).
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Figure 1 Histogram of the timing of aCTx in weeks (n=463).
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Table 1 Baseline characteristics of 463 patients according to timing of aCTx.
< 6 weeks 
   n = 208
6 – 8 weeks 
   n = 155
> 8 weeks
   n = 100
n (%) n (%) n (%) P value
Age in years (mean, SD) 61.0 10.0 62.0 ±11.0 61.8 10.3 0.616
Gender 0.494
Male 130 (63) 103 (66) 69 (69)
Female 78 (37) 52 (44) 31 (31)
Year of diagnosis 0.061
2010 41 (20) 18 (12) 22 (22)
2011 44 (21) 34 (22) 16 (16)
2012 44 (21) 29 (19) 18 (18)
2013 46 (22) 36 (23) 28 (28)
2014 33 (16) 38 (24) 16 (16)
cT stage 0.433
T1  3 (2) 0 (0) 1 (1)
T2 57 (27) 52 (33) 31 (31)
T3 44 (21) 31 (20) 24 (24)
T4a 4 (2) 7 (5) 6 (6)
Unknown 100 (48) 65 (42) 38 (38)
cN stage 0.823
N0 126 (61) 96 (62) 58 (58)
N1 40 (19) 37 (24) 23 (23)
N2 20 (10) 19 (12) 16 (16)
N3 1 (<1) 1 (1) 1 (1)
Unknown 21 (10) 2 (1) 2 (2)
Cycles of neoadjuvant CTx 0.259
1 cycle 0 (0) 0 (0) 3 (3)
2 cycles 19 (9) 7 (5) 5 (5)
3 cycles 187 (90) 143 (92) 89 (89)
Unknown* 2 (1) 5 (315) 3 (3)
Surgical type 0.006
Partial gastrectomy 133 (64) 77 (50) 47 (47)
Total gastrectomy 75 (36) 77 (50) 51 (51)
Multi-organ surgery* 0 (0) 1 (<1) 2 (2)
Surgical approach 0.108
Open 171 (82) 117 (75) 72 (72)
Laparoscopic 34 (16) 34 (22) 26 (26)
Unknown* 3 (1) 4 (3) 2 (2)
Radicality 0.616
R0 184 (89) 143 (92) 90 (90)
R+ 15 (7) 8 (5) 8 (8)
Unknown* 9 (4) 4 (3) 2 (2)
Table 1 continues on next page.
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< 6 weeks 
   n = 208
6 – 8 weeks 
   n = 155
> 8 weeks
   n = 100
n (%) n (%) n (%) P value
ypT stage 0.164
T0 15 (7) 16 (10) 1 (1)
T1  28 (14) 20 (13) 17 (17)
T2 39 (19) 25 (16) 15 (15)
T3 102 (49) 70 (45) 51 (51)
T4a 21 (10) 23 (15) 15 (15)
Unknown* 3 (1) 1 (1) 1 (1)
ypN stage 0.414
N0 94 (45) 76 (49) 41 (41)
N1 47 (23) 33 (21) 19 (19)
N2 27 (13) 22 (14) 19 (19)
N3 39 (19) 23 (15) 21 (21)
Unknown* 1 (<1) 1 (1) 0 (0)
Pathological tumour stage 0.191
0 15 (7) 15 (10) 1 (1)
I 48 (23) 33 (21) 22 (22)
II 77 (37) 61 (39) 39 (39)
III 64 (31) 44 (28) 37 (37)
Unknown* 4 (2) 2 (1) 1 (1)
Tumour location 0.760
Proximal/middle 80 (38) 59 (38) 43 (43)
Antrum 68 (33) 46 (30) 30 (30)
Pyloric 16 (8) 9 (6) 4 (4)
Overlapping or not  otherwise 
specified
44 (21) 41 (26) 23 (23)
Tumour differentiation 0.287
Well 1 (1) 2 (1) 1 (2)
Moderate 29 (14) 13 (8) 8 (8)
Poor 82 (39) 67 (43) 47 (47)
Unknown* 96 (46) 73 (47) 44 (44)
Hospital stay (median, IQR) 8 (6-10) 9 (7-12) 9 (7-14) <0.001
Cycles of aCTx 0.007
1 cycle 11 (5) 11 (7) 8 (8)
2 cycles 20 (10) 28 (18) 23 (23)
3 cycles 169 (81) 113 (73) 69 (69)
Unknown* 8 (4) 3 (2) 0 (0)
Referral for aCTx to other 
hospital as surgical hospital 
147 (71) 106 (68) 71 (71) 0.747
*Excluded from statistical analysis in this table. Percentages may not add up to 100 due to rounding.
Continuation of Table 1.
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Table 2 Univariable and multivariable logistic regression analysis on risk factors for late start (≥6 weeks) 
of adjuvant chemotherapy (n=463).
Univariable Multivariable
OR 95% CI P value OR 95% CI P value
Gender
Male ref ref
 Female 0.80 0.55-1.18 0.266 0.72 0.48-1.10 0.131
Additional year of age 1.01 0.99-1.03 0.328 1.01 0.99-1.03 0.520
Additional year of diagnosis 1.13 0.99-1.29 0.071 1.15 0.98-1.36 0.087
Surgical approach
Open ref ref
Minimally invasive 1.60 1.00-2.55 0.050 1.40 0.82-2.40 0.221
Surgical extent
Partial gastrectomy ref ref
Total gastrectomy 1.91 1.32-2.75 0.001 1.40 0.91-2.15 0.123
Tumour differentiation
Well-moderate ref ref
Poor-undifferentiated 1.74 0.95-3.19 0.074 1.80 0.93-3.35 0.082
ypT-stage
T0-2 ref ref
 T3-4 1.13 0.77-1.65 0.534 1.02 0.66-1.59 0.929
ypN-stage
N0 ref ref
N+ 0.97 0.67-1.41 0.889 0.81 0.53-1.25 0.347
Radicality
R0 ref ref
R+ 0.84 0.41-1.75 0.645 0.80 0.36-1.78 0.585
Additional day of hospital stay 1.15 1.09-1.22 <0.001 1.15 1.08-1.23 <0.001
Referral for aCTx
Surgical hospital ref ref
Other hospital 0.94 0.62-1.40 0.744 0.95 0.63-1.56 0.954
HR: Hazard ratio, CI: confidence interval.
Overall survival
Median follow-up length after gastrectomy of all patients treated with aCTx was 34.1 months 
(IQR 20.9 – 53.0 months), and the 1- and 3-year survival rates were 80% and 62%, respectively. The 
landmark at 5 months after surgery to compare OS between different timing of aCTx, excluded 4 
patients (aCTx <6 weeks n=3, aCTx 6-8 weeks n=1). Kaplan-Meier survival curves demonstrated 
that timing of aCTx was not associated with OS (P=0.199, Figure 2). In multivariable survival 
analysis, timing of aCTx did not significantly influence OS using both timing as categorised 
variable (6-8 weeks vs. <6 weeks, HR=1.14, 95% CI 0.79-1.65, P=0.471; >8 weeks vs. <6 weeks, 
HR=1.04, 95% CI 0.68-1.57, P =0.872) and as linear variable (per additional week of timing, 
HR=1.02, 95% CI 0.95-1.11, P =0.549; Table 3). Sensitivity analyses demonstrated that the 
association between timing of aCTx and OS was non-significant for both early gastric cancer 
and advanced gastric cancer (stage II and III, data not shown).
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Figure 2 Kaplan-Meier survival curves according to timing of aCTx (n=459; P=0.199). 
*Survival was defined as time from five months after surgery to death or 1nd of February 2017 for patients who were still alive. 
Patients who died within 5 months after surgery were excluded from the analysis (n=4).
Table 3 Univariable and multivariable Cox regression analyses on the influence of timing of aCTx on overall 
survival in patients treated with gastrectomy for cancer (n=459).
Univariable Multivariable*
HR 95% CI P value HR 95% CI P value
Each additional week 1.06 0.99 – 1.13 0.114 1.02 0.95 – 1.11 0.549
<6 weeks (n = 205) ref ref
6-8 weeks (n = 154) 1.02 0.73 – 1.43 0.914 1.14 0.79 – 1.65 0.471
>8 weeks (n = 100) 1.36 0.95 – 1.94 0.092 1.04 0.68 – 1.57 0.872
*Adjusted for age, gender, year of diagnosis, number of neoadjuvant CTx cycles, type of surgery, surgical approach, 
tumour differentiation, radicality, ypT-stage, ypN-stage, length of hospital stay, and number of aCTx cycles. HR: Hazard 
ratio, CI: confidence interval. Patients who died within 5 months after surgery were excluded from the analysis (n=4).
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Discussion
This population-based study among patients with gastric cancer who received perioperative 
chemotherapy and gastrectomy with curative intent demonstrated that the timing of aCTx was 
not associated with overall survival. Patients who started within 6 weeks had a comparable 
survival compared to patients who started between 6-8 weeks and >8 weeks after surgery. 
Furthermore, a later start of aCTx was associated with a longer hospital stay and completion 
of less aCTx cycles. 
Value of adjuvant therapy 
Only 76% of patients who started aCTx were able to complete all 3 cycles in the present 
study. These numbers are similar to the MAGIC-trial.1 In the MAGIC-trial, discontinuation of 
perioperative chemotherapy was mostly observed after surgery, indicating that patients do 
not start with aCTx. This led to a discussion about the relevance of aCTx in the perioperative 
chemotherapy regimen. Although there is evidence that omitting aCTx impairs oncologic 
outcomes in patients receiving aCTx after gastrectomy without neoadjuvant chemotherapy18, 
there is limited evidence in patients who received neoadjuvant chemotherapy. In a recent 
study from our group, a propensity score matched analysis was performed to compare 
patients who received the complete perioperative chemotherapy and patients who received 
only the neoadjuvant component (chapter 6). This study demonstrated that patients who 
received perioperative chemotherapy had a better OS compared to patients who only received 
neoadjuvant chemotherapy. However, even after propensity score matching it is still possible 
that patient groups were not completely comparable due to selection bias. In continuation of 
this study, the question raised whether the timing of aCTx was of importance for oncological 
outcomes.
Optimal timing of adjuvant therapy
For patients who qualify for aCTx after gastrectomy, the optimal timing of aCTx is under 
debate. On the one hand, it seems rational to start with aCTx as early as possible for an optimal 
oncological result. The goal of aCTx is to eradicate microscopic disease that may exist after 
neoadjuvant treatment and gastrectomy. Previous translational research has demonstrated that 
surgical resection may enhance growth of remaining tumour cells, thus early start of treatment 
may be favourable.19,20 For colon and breast cancer, early timing of aCTx has indeed proven to 
benefit oncological outcomes.6-8 However, these tumours have a relatively higher response rate 
to chemotherapy than gastric cancer, which may increase the importance for early timing of 
aCTx.20-22 Moreover, these tumours generally only receive aCTx, whereas patients in this study 
already received neoadjuvant treatment. 
On the other hand, late start of aCTx might even be favourable. Gastrectomy is considered 
as a major surgical procedure, and patients need time to recover from surgery, which may take 
up to several months depending on the postoperative course.5 Indeed, the present study found 
a longer hospital stay to be an independent factor associated with a late start of aCTx. Hospital 
stay was used as a proxy for a complicated postoperative course, indicating that patients who 
experience complications have a higher risk for later start of aCTx. There may be more factors 
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related to a late start of aCTx, which were not taken into account in this study, such as dietary 
problems after surgery.23,24 Furthermore, patients need to be fit for the start of aCTx, since the 
chemotherapy regimen is associated with considerable toxicity.1 Last, it is questionable whether 
the time frames (weeks) of the delay in start of aCTx are relevant for oncologic outcomes. Cancer 
development generally involves months to years, which are longer than the time frames that 
delay the start of aCTx.
Comparison to other studies 
To our knowledge, no studies evaluated the impact of timing of aCTx on OS in patients who 
received perioperative chemotherapy and gastrectomy for cancer. Our group previously 
demonstrated that the time between diagnosis and start of neoadjuvant treatment was not 
associated with worse OS for gastric cancer.25 Other studies have focused on the timing of aCTx 
in patients receiving gastrectomy and aCTx only.9-11 Two Korean studies demonstrated that OS 
of patients was impaired if aCTx was not started within 4 and 8 weeks after surgery.9,10 On the 
contrary, a more recent American study found no relation between timing of aCTx and OS in 
patients starting aCTx up to 6 months after surgery.11 These studies differed from each other and 
the present study. The Korean studies included only stage 2-3 tumours, and the American study 
also included stage 1 tumours. The present study included all tumour stages and performed 
sensitivity analyses in order to detect a difference between early and advanced tumours. As no 
difference was seen between tumour stages, taking the American study into account, it seems 
that in Western countries timing of aCTx does not impair survival for any tumour stage, and in 
any chemotherapeutic setting.
Guidelines
Dutch guidelines advise to start treatment within 5-6 weeks after diagnosis, but there is no 
advice for the start of adjuvant therapy for gastric cancer.26,27 In the MAGIC-trial however, 
which led to the introduction of perioperative treatment in most European countries, aCTx 
was administered within 12 weeks after surgery.1 The present study demonstrates that in the 
Netherlands only 45% of the patients received aCTx within 6 weeks, and in 98% of the patients 
aCTx was administered within 12 weeks after surgery. Possibly, physicians may have omitted 
aCTx in patients who were unable to start aCTx within 12 weeks after surgery due to limited 
evidence of the effect on survival.1 The results of this study are therefore restricted to the time 
frame of 12 weeks after gastrectomy. 
Limitations
This study has some limitations that need to be addressed. First, performance status, 
comorbidities and data on postoperative complications and recurrence patterns were not 
available in the NCR. However, age and duration of postoperative hospital stay may be proxies 
for comorbidities and postoperative complications, respectively. The use of hospital stay as a 
proxy for complications has probably worked well, since including this variable in multivariable 
analysis affected the association between timing of aCTx and OS demonstrated in univariable 
analysis, indicating that it is a confounder. Secondly, the study is limited by its observational 
design; the results may be highly susceptible to selection bias, e.g. fragile patients receiving aCTx 
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later. Although we adjusted for several confounding factors, results may be subjected to residual 
confounding. Nevertheless, a strong bias most likely would have led to significant differences 
in OS between the groups. As this was not the case, the data used for this study is probably of 
high quality. Moreover, the current study may have used the best available methodology, as a 
randomised trial for this type of research would face ethical problems. Strengths of this study 
include its large nationwide population-based design and being the first study to examine the 
effect of timing of adjuvant chemotherapy on survival in patients treated with perioperative 
chemotherapy and gastrectomy for gastric cancer. 
Conclusion
If started within 12 weeks after surgery, timing of aCTx is not associated with overall survival 
in patients undergoing perioperative chemotherapy and gastrectomy for gastric cancer. These 
results suggest that the early period after surgery may be safely used for recovery and optimising 
patients for the start of aCTx.
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Appendix 1 Baseline characteristics of 463 patients with gastric cancer who underwent perioperative 
chemotherapy and gastrectomy in the period 2010-2014.
All patients
n = 463
n (%)
Age in years (mean, SD) 61.5 10.4
Gender
Male 302 (65)
Female 161 (35)
Year of diagnosis
2010 81 (17)
2011 94 (20)
2012 91 (20)
2013 111 (24)
2014 87 (19)
cT stage
T1  4 (1)
T2 140 (30)
T3 99 (21)
T4a 17 (3)
Unknown 203 (44)
cN stage
N0 280 (60)
N1 100 (22)
N2 55 (12)
N3 3 (1)
Unknown 25 (5)
Cycles of neoadjuvant CTx
1 cycle 3 (1)
2 cycles 31 (7)
3 cycles 419 (90)
Unknown 10 (2)
Surgical type
Partial gastrectomy 257 (55)
Total gastrectomy 203 (44)
Multi-organ surgery 3 (1)
Surgical approach
Open 360 (78)
Laparoscopic 94 (20)
Unknown 9 (2)
Radicality
R0 417 (90)
R+ 31 (7)
Unknown 15 (3)
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ypT stage
T0 32 (7)
T1  65 (14)
T2 79 (17)
T3 223 (48)
T4a 59 (13)
Unknown 5 (1)
ypN stage
N0 211 (46)
N1 99 (21)
N2 68 (15)
N3 83 (18)
Unknown 2 (<1)
Pathological tumour stage
0 31 (7)
I 103 (22)
II 177 (38)
III 145 (31)
Unknown 7 (2)
Tumour location
Proximal/middle (fundus/corpus/curvatures) 182 (39)
Antrum 144 (31)
Pyloric 29 (6)
Overlapping or not otherwise specified 108 (23)
Tumour differentiation
Well 4 (1)
Moderate 50 (11)
Poor 196 (42)
Unknown 213 (46)
Duration of hospital stay (median, IQR) 8 (7-11)
Cycles of aCTx
1 cycle 30 (7)
2 cycles 71 (15)
3 cycles 351 (76)
Unknown 11 (2)
Referral for aCTx to other hospital as surgical hospital 324 (70)
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Appendix 2 Flowchart of the study population.
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Abstract
Background 
Definitive chemoradiotherapy is an alternative treatment option in patients with potentially 
curable oesophageal cancer who are not eligible for surgery. The aim of this study was to assess 
the impact of age and comorbidity on choice and outcome of two different types of curative 
treatment and long-term survival among these patients.
Methods
All patients with potentially curable oesophageal cancer (cT1N+/cT2-3,TX, any cN, cM0) 
diagnosed in the South East of the Netherlands between 2004 and 2014 treated with 
definitive chemoradiotherapy or neoadjuvant chemoradiotherapy plus surgery were included. 
Multivariable logistic regression analysis was used to examine the probability to undergo 
definitive chemoradiotherapy or neoadjuvant chemoradiotherapy plus surgery. Kaplan-Meier 
method with log-rank tests and multivariable Cox regression analysis were used to compare 
overall survival.
Results
A total of 702 patients was included. Age ≥75 years and multiple comorbidities were associated 
with a higher probability for definitive chemoradiotherapy (OR=8.58; 95% CI 4.72-15.58; 
and OR=3.09; 95% CI 1.93-4.93, respectively). The strongest associations were found for the 
combination of hypertension plus diabetes (OR=3.80; 95% Cl 1.97-7.32) and the combination 
of cardiovascular with pulmonary co-morbidity (OR=3.18; 95% Cl 1.57-6.46). Patients with 
oesophageal cancer who underwent definitive chemoradiotherapy had a poorer prognosis 
than those who underwent neoadjuvant chemoradiotherapy plus surgery, irrespective of age, 
number and type of co-morbidities . In contrast, for patients with squamous cell carcinoma 
having ≥2 comorbidities or being ≥75 years of age, overall survival was comparable between 
both groups (HR=1.52; 95% CI 0.78-2.97; and HR=0.73; 95% CI 0.13-4.14, respectively).
Conclusions
Histological tumour type should be acknowledged in treatment choices for patients with 
oesophageal cancer. Neoadjuvant chemoradiotherapy plus surgery should be the choice of 
treatment for operable oesophageal adenocarcinoma patients, regardless of age, number 
and type of comorbidity. For patients with oesophageal squamous cell carcinoma having ≥2 
comorbidities or being 75 years or older, definitive chemoradiotherapy may be the preferred 
strategy.
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Introduction
For potentially curable oesophageal cancer, radical surgery after neoadjuvant chemoradiotherapy 
is standard of care in the Netherlands since 2008.1 However, surgery is associated with 
postoperative morbidity in up to 60% of patients and a 90-day mortality rate of 7-13%.2-
6 In general, comorbidity and older age are related to early postoperative mortality after 
gastrointestinal cancer surgery.7 A less aggressive treatment approach may well be considered 
in these patients.8 Definitive chemoradiotherapy is an alternative treatment option in elderly 
patients and in patients with severe comorbidities.3,9-11 Similar survival rates have been reported 
after chemoradiotherapy with or without surgery for patients with oesophageal squamous 
cell carcinoma (OSCC).11,12 In patients with oesophageal adenocarcinoma (OAC), surgery is 
recommended unless there is a high risk for postoperative complications and/or mortality.13-16
Long-term outcome data following definitive chemoradiotherapy for potentially curable 
oesophageal cancer are scarce and guidelines for selecting the appropriate treatment in 
patients with severe comorbidity and older age are not available.13,17 Therefore, the aim of this 
retrospective observational study was to assess the impact of age and comorbidity on the 
choice of treatment and long-term overall survival among patients with potentially curable 
oesophageal cancer.  
Methods
Data from all patients with a primary oesophageal cancer (C15.1-C15.9), diagnosed between 
2004 and 2014 in the South East of the Netherlands were obtained from the population-
based nationwide Netherlands Cancer Registry (NCR). Data from this region was used, as data 
on comorbidities was not routinely registered in other parts of the Netherlands during the 
study period. Trained data managers of the NCR routinely extract information on diagnosis, 
tumour stage, comorbidity and treatment from the medical hospital records, using a strict 
registration and coding manual. Tumours were clinically staged according to the UICC/AJCC 
TNM classification that was valid at the time of diagnosis. 
Patients with potentially curable oesophageal cancer (cT1N+/cT2-3,TX, any cN , cM0) and 
treated with definitive chemoradiotherapy or neoadjuvant chemoradiotherapy plus surgery 
were eligible for this study (Figure 1). Patient were classified as cTX when the tumour could 
not be adequately subcategorised, for example due to an obstructing tumour that could not 
be passed during endoscopic ultrasonography. Patients were considered potentially curable if 
they had no clinically distant metastasis (cM0 and cM1a i.e. positive coeliac nodes, according 
to TNM-6 and cM0 according to TNM-7) and no tumour invasion into surrounding organs (no 
cT4 according to TNM-6 and no cT4a or cT4b according to TNM-7). Although patients with a 
cT4a tumour could theoretically be treated with curative intent, all cT4 tumours were excluded, 
as T4a and T4b were only distinguished after 2010 by TNM-7. For the analysis, patients with 
a cM1a tumour according to TNM-6 were categorised as having cN+ according to TNM-7. As 
of 2010, coding regulations to register a cM0 or cM1 status into the NCR were less strict than 
prior to 2010. As a consequence, since 2010, relatively more patients were registered with no 
(cM0) rather than unknown (cMX) clinical distant metastases into the NCR. To account for this, 
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we decided to include all patients with cMX. Patients with cancer of the cervical oesophagus 
(C15.0) as well as patients with a cT1N0 tumour were excluded as surgery was not standard of 
care in these patients. 
Definitive chemoradiotherapy was defined as concurrent chemotherapy and radiotherapy 
not followed by surgical resection. Neoadjuvant chemoradiotherapy, which was introduced 
more recently, was usually given according to the CROSS regimen.1 Patients who underwent 
palliative or other treatment were excluded from the analysis (Figure 1). 
In the NCR, comorbidities are registered according to a slightly modified version of the 
Charlson Co-morbidity index.18 The Charlson comorbidity index is most widely used for 
recording comorbidity and was validated in various studies. Comorbidity was defined as life-
shortening diseases that were present at the time of cancer diagnosis.19,20 The following groups 
of comorbidities were included in our analyses: pulmonary disease (COPD, emphysema, chronic 
bronchitis), cardiovascular disease (vascular disease, angina pectoris, myocardial infarction, 
cardiomyopathy, myocarditis, TIA, CVA), hypertension, diabetes mellitus (non-insulin-dependent, 
insulin-dependent) and previous malignancies. Patients with no serious co-morbidity in the 
medical file were registered as having no co-morbidity. Patients were excluded if comorbidity 
status was not registered. 
Statistics Netherlands developed an indicator of Socio-Economic Status Score (SES), using 
individual fiscal data based on the economic value of the home and household income.21 This 
SES indicator is provided at an aggregated level for each postal code (covering an average of 
17 households). SES was categorised as low (deciles 1–3), medium (deciles 4–7) or high (deciles 
8–10). A separate category was made for postal codes of care-providing institutions because 
assigning SES for those living in nursing home or other care providing institutions is difficult.
Statistical analysis
Differences between patient groups were analysed by using Chi-square tests. Multivariable 
logistic regression analyses were performed to examine the impact of clinicopathological 
factors on the choice of treatment (definitive chemoradiotherapy versus neoadjuvant 
chemoradiotherapy followed by surgery). Survival time was defined as time from 6 months after 
diagnosis until death or until February 2017 for patients who were still alive. Thus, patients who 
died within 6 months after diagnosis were excluded from survival analysis. This was done in order 
to deal with immortal time bias of patients undergoing neoadjuvant treatment plus surgery, 
as total treatment duration for those who underwent definitive chemoradiotherapy is shorter. 
Overall survival was calculated with the Kaplan Meier analysis and log-rank tests were performed 
to test for differences between groups. Multivariable survival analyses were performed using the 
Cox proportional hazards model (HR and 95% confidence intervals) to investigate the prognosis 
after definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy plus surgery after 
adjustment for confounders. According to histological tumour type separate models were 
performed for age categories, number of comorbidities and for each type of comorbidity.  All 
analyses were performed in SAS version 9.4 and 2-sided P values of <0.05 were considered 
statistically significant.
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Results
Clinicopathological characteristics  
A total of 702 patients was included in the study (Figure 1). Neoadjuvant chemoradiotherapy 
with surgery was performed in 386 patients (55%) and definitive chemoradiotherapy in 
316 patients (45%). Frequently reported comorbidities were cardiovascular disease (33%), 
hypertension (33%), pulmonary disease (15%) and diabetes (15%) (Table 1). Most tumours 
were adenocarcinomas (65%) and in a locally advanced stage with cT3 (65%) and cN1-3 (60%). 
About 81% of the patients were treated after 2008. 
Figure 1 Flowchart of study population. 
*The sum of excluded patients per exclusion criteria is larger than the total number of excluded patients because some 
patients met 2 exclusion criteria. ** Lymphoma, melanoma were already excluded. ***Not eligible for surgery. ****Eligible 
for  endoscopic resection. ***** 74% underwent radiotherapy only.
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Table 1 Characteristics of oesophageal cancer patients (cT1N+/cT2-3,TX, any cN , cM0) treated with 
definitive chemoradiotherapy  or neoadjuvant chemoradiotherapy followed by surgery diagnosed in the 
South East of the Netherlands in the period 2004-2014 (n=702).
All patients
(n=702)
n %
Treatment
Definitive chemoradiotherapy 316 45%
Neoadjuvant chemoradiotherapy followed by surgery 386 55%
Gender
Male 535 76%
Female 167 24%
Age (in years)
< 60 184 26%
60-74 387 55%
≥75  131 19%
Number of comorbidities
0 211 30%
1 218 31%
≥2 273 39%
Type of comorbidity
Cardiovascular 231 33%
Pulmonary 108 15%
Hypertension 232 33%
Previous malignancies 72 10%
Diabetes 102 15%
Socio-economic status
Low 153 22%
Intermediate 277 39%
High 219 31%
Care providing institution 21 3%
Unknown 32 5%
Tumour Localisation 
Proximal 38 5%
Mid 92 13%
Distal 544 77%
Overlapping/ not otherwise specified 28 4%
Histology 
OAC 457 65%
OSCC 230 33%
Other/unknown 15 2%
Table 1 continues on next page
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All patients
(n=702)
n %
cT classification
T1 6 <1%
T2 138 20%
T3 455 65%
TX 103 15%
cN classification
N0 259 37%
N+ 423 60%
NX 20 3%
Period of diagnosis
2004 – 2008 133 19%
2009 – 2014 569 81%
OAC= oesophageal adenocarcinoma, OSSC=oesophageal squamous cell carcinoma
dCRT = definitive chemoradiotherapy, nCRT=neoadjuvant chemoradiotherapy
Continuation of table 1
The association between age and treatment 
Of the patients treated with neoadjuvant chemoradiotherapy and surgery less than 8% (29 
of 386 patients) were 75 years or older (Table 2). On the other hand, of the patients who were 
treated with definitive chemoradiotherapy, 19% (60 of 316 patients) were younger than 60 years. 
About 78% (102 of 131 patients) of the elderly (≥75 years) patients were treated with definitive 
chemoradiotherapy, whereas only 33% (60 of 184 patients) of the patients younger than 60 
years underwent definitive chemoradiotherapy.
The association between comorbidity and treatment 
Patients with multiple comorbidities underwent more often definitive chemoradiotherapy 
(160 of 273 patients; 59%) whereas patients without comorbidities underwent more often 
neoadjuvant chemoradiotherapy plus surgery (142 of 211 patients; 67%; Table 2). Multivariable 
logistic regression analysis confirmed the associations of age and comorbidities with type of 
treatment. Patients ≥75 years of age (OR=8.58; 95% CI 4.72-15.58) and patients with multiple 
comorbidities (OR=3.09; 95%CI 1.93-4.93) had a higher probability to receive definitive 
chemoradiotherapy than neoadjuvant chemoradiotherapy plus surgery. Regarding type of 
comorbidity and the likelihood to receive definitive chemoradiotherapy, the association was 
higher for the combination hypertension and diabetes (OR=3.80; 95% Cl 1.97-7.32) and for 
cardiovascular and pulmonary comorbidity (OR=3.18; 95% Cl 1.57-6.46) (Table 2). 
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Table 2 Multivariable logistic regression analysis of clinicopathological factors upon the likelihood of 
treatment with definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery 
among patients with potentially curable oesophageal cancer (cT1N+/cT2-3,Tx, any cN , cM0) diagnosed in 
the South East of the Netherlands in the period 2004-2014 (n=702).
Patients Multivariable analysis
Definitive 
chemoradiotherapy 
(n=316)
Neoadjuvant 
chemoradiotherapy 
+ surgery 
(n=386)
Definitive 
chemoradiotherapy 
vs. neoadjuvant 
chemoradiotherapy + 
surgery
n % n % P value OR 95% CI
Gender <0.01
Male 218  69% 317 82% 1.0
Female 98 31% 69 18% 1.38 0.88-2.17
Age (in years) <0.01
< 60 60 19% 124 32% 1.0
60-74 154 49% 233 60% 1.08 0.69-1.68
≥75 102 32% 29 8% 8.58 4.72-15.58
Number of comorbidities <0.01
0 69 22% 142 37% 1.0
1 87 28% 131 34% 1.34 0.84-2.15
≥2 160 51% 113 29% 3.09 1.93-4.93
Type of comorbidity a
Cardiovascular 132 42% 99 26% <0.01 1.74 1.18-2.57
Pulmonary 63 20% 45 12% <0.01 2.08 1.28-3.38
Hypertension 118 37% 114 30% 0.03 1.40 0.95-2.06
Previous malignancies 44 14% 28 7% <0.01 1.55 0.86-2.80
Diabetes 60 19% 42 11% <0.01 2.39 1.45-3.92
Cardiovascular and 
pulmonary 
34 11% 17 4% <0.01 3.18 1.57-6.46
Hypertension and diabetes 40 13% 18 5% <0.01 3.80 1.97-7.32
Socio-economic status 0.05
Low 79 25% 74 19% 1.0
Intermediate 125 40% 152 39% 0.67 0.42-1.06
High 84 27% 135 35% 0.57 0.35-0.93
Care providing institution / 
unknown
28 9% 25 6% 0.72 0.34-1.55
Tumour Localisation <0.01
Proximal/ Mid 98 31% 32 8% 1.0
Distal 204 65% 340 88% 0.23 0.13-0.40
Overlapping/ not otherwise 
specified 
14 4% 14 4% 0.37 0.14-0.98
Histology b <0.01
OAC 158 50% 299 77% 1.0
OSCC 149 47% 81 21% 1.95 1.24-3.06
Table 2 continues on next page
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Patients Multivariable analysis
Definitive 
chemoradiotherapy 
(n=316)
Neoadjuvant 
chemoradiotherapy 
+ surgery 
(n=386)
Definitive 
chemoradiotherapy 
vs. neoadjuvant 
chemoradiotherapy + 
surgery
n % n % P value OR 95% CI
cT classification <0.01
cT1-2 70 22% 74 19% 1.0
cT3 184 58% 271 70% 0.66 0.42-1.03
cTX 62 20% 41 11% 1.34 0.72-2.48
cN classification 0.07
cN0 112 35% 147 38% 1.0
cN+ 190 60% 233 60% 1.76 1.17-2.66
cNX 14 4% 6 2% 3.36 1.03-10.97
Period of diagnosis 0.01
2004 – 2008 60 23% 73 16% 1.0
2009 – 2014 326 77% 243 84% 0.48 0.35-0.76
OAC= oesophageal adenocarcinomas, OSSC=oesophageal squamous cell carcinoma
a The effects of type of comorbidity on treatment allocation were evaluated in separated models, which are 
adjusted for all variables in Table 2 expect number of comorbidities. Reference category for effects of type of 
co-morbidity: No co-morbidity.
b Category unknown is not shown.
Continuation of table 2
Long-term overall survival
Two-year overall survival of all patients was significantly better following neoadjuvant 
chemoradiotherapy plus surgery compared to definitive chemoradiotherapy (61% versus 
38% P <0.01). Even after stratification for histological tumour type, the survival differences 
remained statistically significant (OAC: 60% versus 33% respectively P <0.01; OSSC: 68% versus 
42% respectively P<0.01; Figure 2a). 
Impact of age and comorbidity on long-term overall survival 
Kaplan Meier survival analysis showed that the 2-year overall survival was worse among patients 
with OAC who underwent definitive chemoradiotherapy compared to those who underwent 
neoadjuvant chemoradiotherapy plus surgery, regardless of the number of comorbidities 
(Figure 2b). In contrast, the 2-year overall survival for OSCC patients with multiple comorbidities 
after definitive chemoradiotherapy (46%) was comparable to the 2-year overall survival (51%) 
following neoadjuvant chemoradiotherapy plus surgery (Figure 2c). 
Multivariable Cox regression analyses showed that OAC patients had a poorer prognosis 
following definitive chemoradiotherapy compared to neoadjuvant chemoradiotherapy plus 
surgery, irrespective of age and number of comorbidities (Table 3). Especially, among patients 
with cardiovascular diseases, hypertension or diabetes survival was poorer after definitive 
chemoradiotherapy. 
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In contrast, among OSCC patients with at least 2 comorbidities or being 75 years or older, 
overall survival after definitive chemoradiotherapy was comparable to the overall survival 
after neoadjuvant chemoradiotherapy plus surgery. This was especially the case among OSCC 
patients  with cardiovascular diseases or previous malignancies. However, OSCC patients with 
hypertension had a poorer overall survival after definitive chemoradiotherapy compared to 
neoadjuvant chemoradiotherapy plus surgery. The impact of pulmonary diseases or diabetes 
could not be assessed accurately due to the small number of patients (Table 3).
Figure 2a Overall survival of oesophageal cancer patients (cT1N+/cT2-3,Tx, any cN , cM0) according to 
morphology following definitive chemoradiotherapy or neoadjuvant chemoradiotherapy plus surgery. 
Patients who died within the first 6 months after diagnosis were excluded from the analysis.
OAC= oesophageal adenocarcinomas, OSSC=oesophageal squamous cell carcinoma
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Figure 2b and c Overall survival of oesophageal cancer patients (cT1N+/cT2-3,Tx, any cN , cM0) according 
to number of comorbidities following definitive chemoradiotherapy or neoadjuvant chemoradiotherapy 
plus surgery, stratified for morphology (b; n=424 and c; n=205).
Discussion
The results of this population-based study support the use of neoadjuvant chemoradiotherapy 
plus surgery in operable patients with OAC, regardless of age, number and type of comorbidity. 
The administration of definitive chemoradiotherapy was preferable in patients with OSCC having 
at least 2 comorbidities or being 75 years or older. This was seen particularly among those 
with cardiovascular disease or previous malignancies as their overall survival after definitive 
chemoradiotherapy was comparable to the overall survival of patients after neoadjuvant 
chemoradiotherapy plus surgery. 
"&"'&(',!+
.
*
%%+
-*.
".
%







	
	(&(*"",/
(&(*"","+
	(&(*"",/

(&(*"","+
(&(*"","+
(&(*"","+
(#-.',
!&(*"(,!*)/
+-* */
"'",".
!&(*"(,!*)/
 
(,*"+$
(
(
	(

	


 	

	






(
	( 
 
  
 	
 
 

(

(



	
	


	
	

/*(.*%%
+-*.".%
(#-.',
!&(*
+-* */
"'",".
!&(*"(,!*)/
.%-
(&(*
	(&(*

(&(*





 	
	
	
"&"'&(',!+
.
*
%%+
-*.
".
%







	
 
 	
 
 
(,*"+$
(
(
	(




	 	

	



	




	
	
(
	(  
 	 		

(

(
	
 
 
 	
	  

/*(.*%%
+-*.".%
(#-.',
!&(*
+-* */
"'",".
!&(*"(,!*)/
.%-
(&(*
	(&(*

(&(*


	


 	




144 Chapter 8|
8
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   144 20-3-2018   22:25:45
Table 3 Multivariable Cox regression analyses to examine overall survival differences among patients who 
underwent definitive chemoradiotherapy versus patients who underwent neoadjuvant chemoradiotherapy 
followed by surgery according to age, number and type of comorbidity, stratified for histology.
OAC OSSC
Definitive chemoradiotherapy 
vs. neoadjuvant chemoradiotherapy 
+ surgery
Definitive chemoradiotherapy 
vs. neoadjuvant chemoradiotherapy 
+ surgery
n HR 95% CI n HR 95% CI
Patients who died within 6 months after diagnosis were excluded to reduce immortal time bias.
Number of 
comorbidities *
0 comorbidities 134 3.21 1.85-5.57 64 4.14 1.80-9.52
1 comorbidity 130 2.99 1.73-5.19 65 2.31 1.10-4.89
≥2 comorbidities 160 2.67 1.75-4.09 76 1.52 0.78-2.97
Age (in years) **
< 60 116 4.95 2.63-9.32 55 2.30 1.09-4.85
60-74 230 2.33 1.63-3.34 117 2.72 1.58-4.69
75 + 78 2.17 1.09-4.30 33 0.73 0.13-4.14
Type of comorbidity a
Cardiovascular diseases 131 2.32 1.42-3.77 67 1.68 0.83-3.40
Pulmonary 64 1.84 0.90-3.78 32 n.a.
Hypertension 142 3.34 2.10-5.34 62 3.22 1.22-8.50
Previous malignancies 33 1.30 0.36-4.67 28 0.98 0.25-3.90
Diabetes 69 2.95 1.50-5.81 16 n.a.
OAC= oesophageal adenocarcinomas, OSSC=oesophageal squamous cell carcinoma, n.a. =not assessed (too small 
number of patients).
 * Adjusted for gender, age, tumour stage and period of diagnosis. 
** Adjusted for gender, tumour stage, number of comorbidities and period of diagnosis 
a Models for type of comorbidity were adjusted for gender, age, tumour stage, period of diagnosis and number of 
comorbidities.
In the Netherlands, neoadjuvant chemoradiotherapy in combination with surgery is the 
standard potentially curative treatment for locally advanced oesophageal cancer. This treatment 
potentially downstages the tumour and increases the radical resectability rate, which in turn 
reduces locoregional recurrences with improved long-term survival.1 Moreover, the CROSS 
trial also showed a distant disease control beyond the first 24 months after neoadjuvant 
chemoradiotherapy followed by surgery, supporting a direct systemic effect of this regimen.22 
Of great importance for a prolonged survival is a pathological complete response following 
neoadjuvant chemoradiotherapy, which occurred in about 49% of the patients with OSSC 
included in the CROSS trial and in 23% of those with OAC.22 
In our study, 78% of the elderly patients were treated with definitive chemoradiotherapy 
and survival in elderly patients with OSCC was equal for both treatment modalities. Elderly 
patients are generally regarded as less suitable for surgery because of an advanced age, severe 
comorbidity or decreased performance status. Moreover, definitive chemoradiotherapy seems 
a well-tolerated alternative for patients with oesophageal cancer who are not fit enough to 
8
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undergo surgery.11,12,23-24 Nevertheless, selecting the appropriate treatment for elderly patients 
requires an adequate multidisciplinary board with the presence and consultation of a geriatric 
physician.25 
Several studies have reported relatively good outcome after definitive chemoradiotherapy 
in a selected groups of patients.11,12,26-27 Two previous studies have found a comparable overall 
survival after definitive chemoradiotherapy compared with surgery alone for patients with 
resectable OSCC.11,12 However, in these studies, survival differences were not investigated 
according to number and type of comorbidities. In our study no significant difference was found 
in overall survival following definitive chemoradiotherapy or neoadjuvant chemoradiotherapy 
plus surgery in patients with OSCC having at least 2 comorbidities. This suggests that patients 
derive the same benefits from both treatment methods, although the type of comorbidity may 
have an impact on the outcome. 
In patients with OAC, the standard approach of neoadjuvant chemoradiotherapy followed by 
surgery indeed resulted in a better survival. A better overall survival was found for OAC patients 
with diabetes mellitus, hypertension or cardiovascular disease. Tougeron et al. reported a more 
frequent use of definitive chemoradiotherapy in advanced staged OAC, in elderly patients and 
patients with comorbidities of ≥ Charlson score 2.13 Although selection bias may be present 
in this previous study, survival after surgery was better compared to survival after definitive 
chemoradiotherapy (median overall survival 36.2 months vs. 16.5 months; P=0.02). Another 
study has also found a significant improvement in median survival for patients with locally 
advanced OAC treated with neoadjuvant chemoradiotherapy followed by surgery compared 
to definitive chemoradiotherapy.14 
The differences in treatment response between patients with OAC and OSCC may be 
associated with tumour aggressiveness and different carcinogenesis pathways.13  Moreover, 
tumour site (distal versus proximal) and pulmonary based differences with a larger field of 
radiotherapy in lower oesophageal tumours, may also play a role in the different outcomes 
between OAC and OSCC following definitive chemoradiotherapy.28 With current radiation 
techniques, including intensity-modulated radiotherapy, respiratory gated radiotherapy and 
intensity-modulated proton therapy the radiation dose can be delivered more accurately with 
less damage to normal tissue.15,29-31 Moreover, in diminishing toxicity of chemotherapy regimens, 
the combination of carboplatin/paclitaxel can be a good alternative or even standard approach, 
especially in patients with cardiovascular and pulmonary comorbidities.32 
Our study has some limitations. First, the intent of  treatment with chemoradiotherapy 
(curative or palliative) was unknown. As only potentially curable oesophageal cancer patients 
were included it was assumed that these patients underwent chemoradiotherapy with curative 
intent (neoadjuvant or definitive). Second, the group of patients who underwent definitive 
chemoradiotherapy may be heterogeneous as patients who were unable to undergo surgery 
after neoadjuvant chemoradiotherapy were allocated to this group. Furthermore, patients in 
this group may also had a complete clinical response after chemoradiotherapy and may have 
refused surgery. Third, little information was given about the radiotherapy techniques and 
schedule of the given chemoradiotherapy. Fourth, the impact of type of some comorbidities 
could not be assessed accurately due to a small number of patients. Moreover, information 
about performance status was not registered for the study period. Finally, because endoscopic 
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ultrasonography was not always performed in patients with oesophageal cancer, clinical T-stage 
was unknown in 15% of the patients. A strength of this population-based study is that the results 
are based on patients diagnosed in ten hospitals providing an overview of everyday clinical 
practice, rather than in a single institution in which patients are possibly more carefully selected, 
In conclusion, neoadjuvant chemoradiotherapy plus surgery should be performed in 
operable patients with oesophageal adenocarcinoma regardless of age, number and type of 
comorbidities. Definitive chemoradiotherapy may be preferred in patients with oesophageal 
squamous cell carcinoma having  at least 2 comorbidities or being older than 75 years. 
Prospective studies are needed to assess more accurately which patients may benefit from 
definitive chemoradiotherapy.
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Abstract
Background
The aim of our study was to describe treatment patterns and the impact on overall survival 
among elderly patients (75 years and older) with potentially curable oesophageal cancer.
Methods
Between 2003 and 2013, 13 244 patients from the nationwide population-based Netherlands 
Cancer Registry  were diagnosed with potentially curable oesophageal cancer (cT2-3,X, any cN, 
cM0,X) of which 34% were elderly patients (n=4501). 
Results
Surgical treatment with or without neoadjuvant treatment remained stable among elderly 
patients (around the 16% between 2003-2013). However, among younger patients surgical 
treatment increased from 60.2% to 67.0%. The use of definitive chemoradiation (dCRT) increased 
in elderly patients from 1.9% to 19.5% and in younger patients from 5.2% to 17.2%. Due to the 
increase in dCRT, treatment with curative intent doubled in the elderly from 17% to 37.1%. 
Multivariable Cox regression revealed that elderly patients with an adenocarcinoma receiving 
surgery alone or dCRT had a significantly worse overall survival compared to those receiving 
surgery with neoadjuvant chemo(radio)therapy (nCRT/CT)(HR: 1.7 95%CI 1.4-2.0 and HR=1.9 
95%CI 1.5-2.3). However, among elderly with squamous cell carcinoma overall survival was 
comparable between dCRT, surgery alone and surgery with nCRT/CT.
Conclusions
Survival was comparable among elderly patients with squamous cell carcinoma who 
underwent surgery with nCRT/CT, surgery alone or received dCRT, while elderly patients with 
an adenocarcinoma who underwent surgery with nCRT/CT had a better overall survival, when 
compared with surgery alone or dCRT. Therefore, dCRT can be considered as a reasonable 
alternative for surgery among potentially curable elderly patients with oesophageal squamous 
cell carcinoma. However in elderly patients with oesophageal adenocarcinoma surgery with 
nCRT/CT is still preferable regarding overall survival.
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Introduction
The incidence of oesophageal cancer, especially adenocarcinoma, has increased dramatically 
over the past four decades in the Western world and is still rising but at a slower rate than 
previously.1,2 Oesophageal cancer is mainly a disease of the elderly as a significant number of 
patients is aged between 60 and 85 year at time of diagnosis.3,4 In the Netherlands approximately 
30% of all newly diagnosed patients with oesophageal cancer is 75 years or older.5
According to the Dutch clinical practice guidelines, the preferred treatment for patients 
with potentially curable oesophageal cancer is neoadjuvant chemoradiation followed by a 
subsequent oesophagectomy. Early oesophageal cancer (T1a) can be treated with Endoscopic 
Mucosal Resection (EMR).6 Frail patients unfit for surgery, such as some elderly patients, can 
be treated alternatively with a curative intention using definitive chemoradiation (dCRT).7,8 
Furthermore, histological subtype plays a role in treatment of patients with potentially curable 
oesophageal cancer. For example, patients with squamous cell carcinoma seem to have a better 
response to dCRT compared to patients with an adenocarcinoma.9-11 
Surgical treatment of oesophageal cancer is complex with a high post-operative complication 
rate, especially in elderly patients with multiple co-morbidities, which might be an argument 
to withhold some patients from surgical treatment.12,13 A previous study has shown an increase 
in 30-day postoperative mortality from 4.9% in patients younger than 65 years to 10.3% in 
patients older than 75 years.14
However, most treatment strategies and guidelines are based on clinical trials in which 
elderly patients are excluded. Therefore, it is of significant importance to investigate the effect 
of different treatment options on survival in this specific group of patients. The aim of our study 
was to describe treatment patterns and the impact on overall survival in elderly patients (75 
years and older) with potentially curable oesophageal cancer (adenocarcinoma or squamous 
cell carcinoma) in the Netherlands.  
Methods
Data collection
Nationwide population-based data from the Netherlands Cancer Registry (NCR) were used. The 
NCR is based on notification of all newly diagnosed malignancies in the Netherlands by the 
national automated pathological archive (PALGA). Additional sources are the national registry of 
hospital discharge, radiotherapy institutions and diagnosis therapy combinations (specific codes 
for reimbursement purposes). Specially trained data managers of the NCR routinely extracted 
information on diagnosis, tumour stage and treatment from the medical records. Information on 
vital status was obtained through an annual linkage with the Municipal Administrative Database, 
in which all deceased and emigrated persons in the Netherlands were registered.  Institutional 
Review Board approval was obtained from the NCR.
Patients
Between January 2003 and December 2013, 25 638 patients were diagnosed with an 
adenocarcinoma or squamous cell carcinoma of the oesophagus or gastro-oesophageal junction 
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in the Netherlands. The topography and morphology of the tumours were coded according to 
the International Classification of Diseases for Oncology (ICD-O-3).15 Subsite distribution was 
divided as: proximal (C15.0, C15.3), mid (C15.4), distal (C15.5), overlapping or not otherwise 
specified (C15.8, C15.9) and gastro-oesophageal junction (GEJ) (C16.0). Patients diagnosed from 
2003 to 2009 were staged according to TNM-6, whereas patients diagnosed from 2010-2013 
were staged according to TNM-7.16,17 
Patients with potentially curable oesophageal tumours were eligible for this study 
(Figure 1). Patients were considered potentially curable in this study if they had no clinically 
distant metastasis (cM1b for TNM-6 and cM1 for TNM 7) (n=8009) and no tumours infiltrating 
surrounding organs (cT4 according to TNM-6 and cT4A and cT4B according to TNM-7) (n=1368). 
We excluded patients with tumours infiltrating surrounding organs since it was uncertain 
whether or not these patients were eligible for curative treatment. For the analyses, patients 
with a cM1A tumour according to TNM-6 were categorized as having cN+ as most patients 
with a cM1A tumour had a distal tumour with coeliac lymph nodes which can be considered as 
having cN+ according to TNM-7. Furthermore, patients with unknown clinical distant metastases 
(cMX) were included. It should be noted that as of 2010 coding regulations to register a cM0 
or cM1 status into the NCR were less strict than before 2010, and therefore as of 2010 relatively 
more patients were registered with a cM0 rather than a cMX into the NCR. To account for this, 
we decided to include all patients with cMX. Patients with an in-situ or a cT1 tumour (n=1002) 
were also excluded since these tumours are treated predominantly with an Endoscopic Mucosal 
Resection (EMR) rather than surgical treatment. In addition, patients with missing/unknown 
treatment (n=92) and patients receiving EMR alone (n=350) were excluded. This resulted in 
13244 patients with a potentially curable oesophageal carcinoma (cT2, 3, X, any cN, cM0, X). Of 
these patients 4501 (34%) were elderly patients being 75 years and older (Figure 1).
Treatment
Surgery with potentially curative intent was defined as an transhiatal oesophagectomy 
or transthoracic oesophagectomy. Definitive chemoradiation (dCRT) was defined as the 
combination of radiotherapy and chemotherapy as primary treatment without surgery. Curative 
treatment was defined as dCRT, surgery alone or surgery with neoadjuvant chemoradiotherapy 
or chemotherapy (nCRT/CT). All other treatments were defined as “other” therapy.
Statistical analysis
Differences in patient and tumour characteristics between elderly patients with an 
adenocarcinoma and squamous cell carcinoma were described and compared using the Pearson’s 
chi-square test for nominal data. For differences in continuous variables, the independent T-test 
was used. Survival time was defined as time from diagnosis to death or until February 1st 2016 
for patients who were still alive. Survival curves per treatment option were obtained using the 
Kaplan-Meier method for elderly patients according to histology. Differences in overall survival 
according to treatment were assessed by using log-rank tests. Multivariable Cox regression 
analyses were performed to evaluate independent prognostic factors for overall survival. All 
statistical analyses were performed using Statistical Package for Social Sciences version 22.0 
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(IBM Corporation, Armonk, NY, USA) and P-values less than 0.05 were considered statistically 
significant.
Figure 1 Flowchart of the study population.
*cT4 according to TNM-6 and cT4a and cT4b according to TNM-7. 
**cT1 according to TNM-6 and cT1a and cT1b according to TNM-7.
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Results
Patient characteristics
Of the potentially curable elderly patients of 75 years and older diagnosed with a oesophageal 
carcinoma, 75.6% (n=3402) was diagnosed with an adenocarcinoma and 24.4% (n=1099) with 
a squamous cell carcinoma. There were no significant differences in age, cT- stage, cN-stage 
and cM-stage between both histology groups. However, patients with an adenocarcinoma had 
more often a distally located tumour and a poor tumour differentiation. Furthermore, elderly 
patients with an adenocarcinoma more often received surgical treatment (21.3%) than dCRT 
(7.7%), whereas patients with a squamous cell carcinoma more often received dCRT (13.1%) 
than surgery (10.4%) (Table 1). 
Of all elderly patients diagnosed with potentially curable oesophageal carcinoma, 6.9% 
received surgery with nCRT/CT, 11.8% received surgery alone, 18.6% received surgery, 9.0% 
received dCRT and 72.4% received other/no treatment.
Trends in treatment
From 2003 until 2013, the use of surgery with nCRT/CT among the elderly (≥75 years) and the 
younger patients (<75 years) increased over time from 0.5% to 13.5% and from 14.4% to 63.3% 
respectively. In line with these findings, the proportion of patients with underwent surgery 
alone decreased among both the elderly and the younger patients from respectively 14.5% to 
4.2% and from 45.8% to 3.7%. The use of surgical treatment (surgery with nCRT/CT or surgery 
alone) among all elderly patients (≥75 years) remained relatively stable over time from 15.0% 
in 2003 to 17.7% in 2013, whereas among the younger patients (≥75 years) the use of surgical 
treatment increased over time from 60.2% in 2003 to 67.0% in 2013. Furthermore, there was 
an increase in administration of dCRT in elderly patients from 1.9% to 19.5% as well as in the 
younger patients from 5.2% to 17.2% (Figure 2a).
The increase in dCRT was most prominent among elderly patients with a squamous cell 
carcinoma in which treatment with dCRT increased from 3.5% to 30.7%, while among younger 
patients with squamous cell carcinoma an increase from 9.5% to 29.3% was observed (Figure 
2b). In patients with an adenocarcinoma, the increase in use of dCRT was comparable in the 
elderly patients compared to the increase among younger patients (Figure 2c). Mainly due to 
the increase in dCRT, the administration of treatment with curative intent (surgery or dCRT) 
doubled over time in all elderly patient from 17% to 37.1%. The increase of treatment with a 
curative intent quadrupled over time in the elderly patient with squamous cell carcinoma from 
10.5% to 41.2%. However, the increase in the use of treatment with curative intent was less 
prominent in the younger patients (Figure 2).
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Table 1 Patient characteristics of the elderly patient (≥75 years) diagnosed with potentially curable 
oesophageal cancer in the period 2003-2013 (n=4501).
Adenocarcinoma Squamous cell carcinoma 
n (%) n (%) P value
Total 3402 (75.6) 1099 (24.4)
Age in years (mean, SD) 81.6 (4.9) 81.3 (5.0) 0.051
Gender <0.001
Male 2374 (69.8) 514 (46.8)
Female 1028 (30.2) 585 (53.2)
cT-stage 0.163
T2 582 (17.1) 171 (15.6)
T3 863 (25.4) 308 (28.0)
Unknown 1957 (57.5) 620 (56.4)
cN-stage 0.302
N0 1167 (34.3) 388 (35.3)
N+ 1173 (34.5) 395 (35.9)
Unknown 1062 (31.2) 316 (28.8)
cM-stage 0.174
M0 2790 (82.0) 921 (83.8)
Unknown 612 (18.0) 178 (16.2)
Tumour location <0.001
Proximal 38 (1.1) 164 (14.9)
Mid 208 (6.1) 398 (36.2)
Distal 1983 (58.3) 454 (41.3)
GOJ 1040 (30.6) 7 (0.6)
Overlapping/NOS 133 (3.9) 76 (6.9)
Tumour differentiation <0.001
Well 67 (2.0) 31 (2.8)
Moderate 677 (19.9) 296 (26.9)
Poor 1147 (33.7) 254 (23.1)
Unknown 1511 (44.4) 518 (47.1)
Type of treatment <0.001
Surgery with nCRT/CT * 250 (7.3) 59 (5.4)
Surgery alone 475 (14.0) 55 (5.0)
Definitive chemoradiation 261 (7.7) 144 (13.1)
Other/no treatment 2416 (71.0) 841 (76.5)
GOJ: Gastro-oesophageal junction. NOS: Not otherwise specified.
* Among this group of patients 77.3% received nCRT and 22.7% received nCT. Two patients received chemoradiation 
postoperatively.
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Figure 2 Trends in treatment for oesophageal cancer according to age for a all patients (n=4501), b 
squamous cell carcinoma (n=3402) and c adenocarcinoma (n=1099).
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Survival
Overall, elderly patients with a potentially curable adenocarcinoma had a comparable 1- and 
3-year overall survival rate compared to elderly patients with a potentially curable squamous 
cell carcinoma with 1-year overall survival rates of 40.8% vs. 36.5% and 3-year survival rates of 
12.0% vs. 14.1%, respectively (log rank P=0.621). Furthermore, the 1- year overall survival in 
elderly patients with an adenocarcinoma treated with surgery and nCRT/CT was 79.6% which 
was comparable to the overall survival of patients treated with surgery alone (64.8%) or dCRT 
(72.4%) whereas 3-year overall survival was significantly better for patients who underwent 
surgery with nCRT/CT (51.2%) compared to patients receiving surgery alone (29.5%) or dCRT 
(11.6%)(P<0.001)(Figure 3a). Among elderly patients with a squamous cell carcinoma, patients 
receiving surgery with nCRT/CT had a better 3-year overall survival (50.2%) compared to surgery 
alone (40.0%) and dCRT (36.8%) however this difference was not statistically significant (P=0.267) 
(Figure 3b). 
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Figure 3 Kaplan-Meier survival analysis among elderly patients with oesophageal cancer according to 
treatment, stratified for histology; a adenocarcinoma (n=3402), b squamous cell carcinoma (n=1099).
Multivariable Cox regression analyses showed that patients with male gender, a poor tumour 
differentiation, an overlapping tumour/not otherwise specified tumour location, cT3 tumours, 
regional lymph nodes metastasis and a squamous cell histology had a significantly worse 
overall survival. Regarding the treatment strategy, the multivariable Cox regression analysis 
which included both histology groups showed that elderly patients who received surgery alone 
(HR=1.6, 95%CI 1.3-1.9), dCRT (HR=1.7, 95%CI 1.4-2.0) or other/no treatment (HR=4.1, 95%CI 
3.5-4.8) had a significantly worse overall survival compared to patients who underwent surgery 
with nCRT/CT (Table 2).
Comparable results were found for elderly patients with an adenocarcinoma. Among elderly 
patients with an adenocarcinoma, patients receiving surgery alone (HR=1.7, 95%CI 1.4-2.0), 
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dCRT (HR=1.9, 95%CI 1.5-2.3) or other/no treatment (HR=4.3, 95%CI 3.6-5.1) had a significantly 
worse overall survival compared to patients receiving surgery with nCRT/CT. However, among 
elderly patients with a squamous cell carcinoma overall survival was comparable for patients 
who underwent surgery alone (HR=1.3, 95%CI 0.8-2.1), dCRT (HR=1.4, 95%CI 0.9-2.0) or surgery 
with nCRT/CT (Table 2).
Table 2 Multivariable Cox regression analysis for all elderly patients and stratified for histology.
All elderly patients
n=4501
Adenocarcinoma
n=3402
Squamous cell carcinoma 
n=1099
HR* 95%CI P value HR* 95%CI P value HR* 95%CI P value
Gender
Male 1.0 1.0 1.0
Female 0.9 0.8-1.0 0.001 0.9 0.8-1.0 0.015 0.8 0.7-0.9 0.003
Period of diagnosis
2003-2006 0.9 0.9-1.0 0.084 0.9 0.9-1.0 0.058 1.0 0.8-1.1 0.581
2007-2010 0.9 0.9-1.0 0.085 1.0 0.9-1.0 0.304 0.9 0.8-1.0 0.132
2011-2013 1.0 1.0 1.0
Tumour differentiation
Well 0.8 0.6-1.0 0.031 0.6 0.5-0.8 0.001 1.7 1.1-2.5 0.009
Moderate 0.9 0.8-0.9 <0.001 0.8 0.7-0.9 <0.001 1.1 0.9-1.3 0.269
Poor 1.0 1.0 1.0
Unknown 0.8 0.7-0.9 <0.001 0.8 0.7-0.8 <0.001 1.0 0.8-1.2 0.922
Tumour location
Proximal 0.8 0.7-0.9 0.008 1.0 0.7-1.4 0.954 0.7 0.6-0.9 0.002
Mid 0.9 0.8-1.0 0.041 1.0 0.8-1.1 0.721 0.9 0.7-1.0 0.030
Distal 1.0 1.0 1.0
GOJ 1.0 0.9-1.1 0.828 1.0 0.9-1.1 0.997 1.9 0.9-4.0 0.104
Overlapping/ NOS 1.3 1.1-1.5 0.001 1.2 1.0-1.4 0.042 1.4 1.1-1.8 0.008
cT-stage
cT2 0.9 0.8-1.0 0.019 0.9 0.8-1.0 0.019 0.9 0.7-1.1 0.411
cT3 1.0 1.0 1.0
Unknown 1.2 1.1-1.3 <0.001 1.2 1.1-1.3 0.002 1.4 1.2-1.7 <0.001
cN-stage
cN0 1.0 1.0 1.0
cN+ 1.2 1.1-1.3 <0.001 1.2 1.1-1.3 <0.001 1.2 1.0-1.4 0.057
Unknown 1.6 1.4-1.7 <0.001 1.5 1.4-1.7 <0.001 1.8 1.5-2.1 <0.001
Type of treatment
Surgery with nCRT/CT 1.0 1.0 1.0
Surgery alone 1.6 1.3-1.9 <0.001 1.7 1.4-2.0 <0.001 1.3 0.8-2.1 0.222
Definitive chemoradiation 1.7 1.4-2.0 <0.001 1.9 1.5-2.3 <0.001 1.4 0.9-2.0 0.123
Other/no treatment 4.1 3.5-4.8 <0.001 4.3 3.6-5.1 <0.001 3.8 2.7-5.4 <0.001
Histology
Squamous cell 1.1 1.0-1.2 0.037 n.a. n.a.
Adenocarcinoma 1.0
* Adjusted for all variables listed in table 2. GOJ: Gastro-oesophageal junction. NOS: Not otherwise specified. HR=Hazard 
ratio. CI=confidence interval. n.a.= non-applicable.
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Discussion
This large nationwide population-based study among elderly patients with potentially curable 
oesophageal cancer who were 75 years or older revealed an increase in treatment with a curative 
intent, with a consistent use of surgical treatment and a significant increase in the use of dCRT 
among all elderly patients in the period 2003-2013. The increase in administration of dCRT was 
most prominent in elderly patients with a squamous cell carcinoma. Furthermore, multivariable 
analysis showed no difference in overall survival for elderly patients with a squamous cell 
carcinoma who received surgery with nCRT/CT or surgery alone or dCRT. However, elderly 
patients with an adenocarcinoma who underwent surgery with nCRT/CT had a significantly 
better overall survival compared to patients who underwent surgery alone or dCRT.  
Despite the increase in the use of treatment with curative intent among potentially curable 
elderly patients, explained by the increase in dCRT, there is still a large proportion of patients 
that were not treated with curative intent (72.4%).This study demonstrates that the elderly 
patients with potentially curable tumours received less often surgical treatment compared to 
younger patients (17.7% vs. 67.0%), whereas the use of dCRT was slightly higher in the elderly 
patients compared to the younger patients (19.5% vs. 17.2%). These findings may be explained 
by the fact that an older age is a risk factor for post-operative morbidity and mortality after 
oesophagectomy.12,18-20 Although, other studies have shown that age alone should not be 
regarded as a predictor for worse overall survival after oesophagectomy, in daily practice it 
appears that advanced age is a significant factor in decision making whether or not patients 
are proposed for surgery.12,13 
Our study revealed a relatively stable use of surgical treatment and a significant increase in 
use of dCRT among all elderly patients during the study period especially after 2010. This striking 
increase in administration of dCRT is higher compared to another study in the Netherlands in an 
earlier period (1989-2008) in which they reported an increase from 0.2% to 2.2%.21 The increase in 
use of dCRT is probably caused by the increasing awareness that dCRT has a favourable survival, 
especially among patients with squamous cell carcinoma, and is often well tolerated, even in 
patients with considerable co-morbidity.7,8 Although toxicity after chemoradiation is occurring 
frequently, with 75% of the patients experiencing toxicity of grade 3 or greater, especially in the 
elderly patients, it is often manageable.22,23  
This study showed that elderly patients with an adenocarcinoma received more often 
surgical treatment compared to patients with a squamous cell carcinoma which received more 
often dCRT especially after 2010. These result are in line with result from a large population based 
study in the United States.9 The observed difference in treatment could be explained by the fact 
that most studies show a better response to dCRT of squamous cell carcinomas when compared 
to adenocarcinoma, with a better overall survival and disease free survival in good responders.10 
On the other hand, a study from the United Kingdom on dCRT revealed a comparable overall 
survival and disease free survival between both histological subtypes. However patients with 
squamous cell carcinoma had significantly more advanced stages of disease.24 Furthermore, a 
significant difference in relapse pattern has been described, with adenocarcinomas being more 
likely to relapse in distant sites and squamous cell carcinoma more likely to recur locally.8,24
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The multivariable Cox survival analysis revealed that elderly patients with an adenocarcinoma 
who received  surgery with nCRT/CT have a better overall survival compared to the patients 
receiving surgery alone or dCRT. However, among elderly patient with squamous cell carcinomas 
there was no significant difference in overall survival between patients who underwent surgery 
with nCRT/CT, surgery alone or patients who received dCRT. Currently, there are only three 
randomised control trials which have directly compared dCRT with surgical treatment in patients 
with squamous cell carcinoma. These trials have shown comparable survival rates in patients 
treated with definitive chemoradiation or chemoradiation followed by surgery.11,25,26 However, in 
two of the three trials elderly patients were excluded and in the third trial results were not reported 
for elderly patients as a separate group. Furthermore, a recent Cochrane review states that there 
is only low quality evidence in the literature which showed that chemoradiation appears to 
be equivalent to surgery in squamous cell carcinoma who are responsive to chemoradiation, 
however in adenocarcinoma there is uncertainty whether or not patients receiving definitive 
chemoradiation benefit compared to surgery.27 Our results provide more arguments for the 
equivalence of definitive chemoradiation to surgery in squamous cell carcinoma and confirm 
their statement on adenocarcinoma. The results of our study advocate for further research in 
which the use of dCRT and surgery are compared for disease free survival and quality of life. 
Univariable and multivariable survival analysis also revealed a similar overall survival for 
patients with oesophageal squamous cell carcinoma who underwent surgery with or without 
nCRT/CT. Although there seems to be immortal time bias, the Kaplan-Meier curves for these 
treatment groups were parallel, assuming overall survival is comparable (Figure 3b). Immortal 
time bias exists of patients receiving nCRT/CT which takes more time to receive than surgery 
alone. However, no landmark analysis was performed as this would result in exclusion of many 
patients in the ‘other/no treatment’ group. Multivariable analysis confirmed the non-significant 
difference in overall survival between squamous cell carcinoma patients with and without 
nCRT/CT. These results are in contrast with results from the CROSS trial28,29, which showed an 
improved survival for patients who received surgery with nCRT compared to patients who 
received surgery alone. Moreover, the difference in overall survival was higher for squamous 
cell carcinoma compared to adenocarcinoma. However, most elderly patients did not meet 
the eligibility criteria from the CROSS trial. Therefore, further research should investigate the 
difference in outcomes between surgery with or without nCRT/CT among elderly patients with 
oesophageal squamous cell carcinoma.
A limitation of this study is that the NCR did not register nationwide information on 
comorbidity or performance status during the study period. This might have influenced the 
survival analyses since comorbidity and performance status play an important role in the clinical 
decision making, especially among the elderly patients and has a significant influence on overall 
survival. However, the survival benefit for dCRT might even be more than observed, because 
especially unfit patients with multiple comorbidities and an a priori unfavourable prognosis 
receive dCRT. Thus, the lack of comorbidity data might even lead to an underestimation of the 
potential favourable impact of dCRT on overall survival. This study has also several strengths, 
such as its observational nature resulting in a representative nationwide population and 
therefore enabling the demonstration of current patterns of care and its impact on overall 
survival among elderly patients with oesophageal cancer in daily clinical practice. 
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In conclusion, this large nationwide population-based study revealed that there was a 
consistent use of surgical treatment and a major increase in use of dCRT among all elderly 
patients with potentially curable oesophageal cancer in the period 2003 to 2013. The increase 
in dCRT was most prominent among patients with squamous cell carcinoma. Survival was 
comparable among elderly patients with squamous cell carcinoma who underwent surgery with 
nCRT/CT, surgery alone or received dCRT, while elderly patients with an adenocarcinoma who 
underwent surgery with nCRT/CT had a better overall survival, when compared with surgery 
alone or dCRT. Therefore, dCRT can be considered as a reasonable alternative for surgery among 
potentially curable elderly patients with oesophageal squamous cell carcinoma. However in 
elderly patients with oesophageal adenocarcinoma surgery with nCRT/CT is still preferable 
regarding overall survival.
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Abstract
Background
This study assessed trends in the treatment and survival of palliatively treated patients with 
gastric cancer, with a focus on age-related differences.
Methods
For this retrospective, population-based, nationwide cohort study, all patients diagnosed 
between 1989 and 2013 with non-cardia gastric cancer with metastasised disease or invasion 
into adjacent structures were selected from the Netherlands Cancer Registry. Trends in treatment 
and 2-year overall survival were analysed and compared between younger (age less than 70 
years) and older (aged 70 years or more) patients. Analyses were done for five consecutive 
periods of 5 years, from 1989–1993 to 2009–2013. Multivariable logistic regression analysis was 
used to examine the probability of undergoing surgery. Multivariable Cox regression analysis 
was used to identify independent risk factors for death.
Results
Palliative resection rates decreased significantly in both younger and older patients, from 24.5 
and 26.2 per cent to 3.0 and 5.0 per cent respectively. Compared with patients who received 
chemotherapy alone, both younger (21.6 versus 6.3 per cent respectively; P < 0.001) and older 
(14.7 versus 4.6 per cent; P < 0.001) patients who underwent surgery had better 2-year overall 
survival rates. Multivariable analysis demonstrated that younger and older patients who received 
chemotherapy alone had worse overall survival than patients who had surgery only (younger: 
hazard ratio (HR) 1.22, 95 per cent c.i. 1.12 to 1.33; older: HR 1.12, 1.01 to 1.24). After 2003 there 
was no association between period of diagnosis and overall survival in younger or older patients.
Conclusion
Despite changes in the use of resection and chemotherapy as palliative treatment, overall 
survival rates of patients with advanced and metastatic gastric cancer did not improve.
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Introduction
Gastric cancer incidence rates are declining in the western world, including the Netherlands.1 
Survival rates of patients with gastric cancer have remained dismal through the years, despite 
developments in treatment.1 One important reason for the generally poor prognosis is that a 
considerable proportion of patients (45 per cent) are diagnosed with metastatic disease (stage 
IV).1,2 With a median overall survival of less than 4 months for patients with stage IV gastric 
cancer, their survival rate is amongst the lowest in gastrointestinal oncology.3,4
The preferred treatment approach for patients with stage IV or locally advanced gastric 
cancer is debated worldwide. In particular, the effect of palliative gastrectomy on survival and 
quality of life remains unclear.5–7 This is particularly relevant as postoperative mortality rates in 
gastric cancer are amongst the highest of all gastrointestinal cancers.8 In addition, the effect of 
palliative chemotherapy on survival and quality of life is debated.4
According to the national clinical practice guideline for treatment of gastric cancer9, palliative 
gastrectomy can be performed to improve quality of life and/or survival. This guideline9 and 
some previous studies5,6 suggest that palliative resection should be performed only in patients 
aged less than 70 years. Although surgical morbidity and mortality are indeed higher in older 
patients with gastric cancer, palliative resection is suggested to have an equally positive effect 
on survival in both younger and older patients.10–13
The aim of the present study was to investigate trends and the incidence of palliative 
treatment among younger and older patients in a nationwide setting, and assess which patient, 
tumour and treatment characteristics are related to the likelihood of having a palliative resection. 
The study also investigated the survival of younger and older patients according to the type 
of treatment.
Methods
Data source
Data were obtained from the population-based Netherlands Cancer Registry (NCR). This registry 
serves the total Dutch population of almost 17 million. The NCR is based on notification of all 
newly diagnosed malignancies in the Netherlands by the national automated pathological 
archive (PALGA). Additional sources are the national registry of hospital discharge and 
radiotherapy institutions. Information on diagnosis, staging and treatment is extracted routinely 
from the medical records by specially trained data managers of the NCR. The information on 
vital status is obtained by annual linkage with the municipal administrative databases, which 
register all deceased and emigrated persons in the Netherlands. The study period was from 
January 1989 to December 2013.
Ethical approval
According to the Netherlands Central Committee on Research involving Human Subjects, this 
type of study does not require approval from an ethics committee in the Netherlands. This 
study was approved by the Privacy Review Board of the NCR. All procedures followed were in 
accordance with the Helsinki Declaration of 1964 and later versions.14
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Patient selection criteria
The reporting of this study followed the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) guidelines.15 For this retrospective, population-based, nationwide cohort 
study, patients with non-cardia gastric cancer who received palliative treatment for clinically 
distant metastases or a tumour infiltrating surrounding organs were selected. Topography and 
morphology of the disease were coded according to ICD-O-3.16
Tumour location and stage
The distribution of the location in the stomach was considered as follows: proximal/middle 
(fundus, corpus and lesser and greater curvature: C16.1, C16.2, C16.5 and C16.6), pylorus and 
antrum (C16.3, C16.4), and overlapping or not otherwise specified (C16.8, C16.9).
Tumour staging was performed according to the fourth, fifth, sixth or seventh edition of the 
UICC TNM classification, as was valid at the time of diagnosis. An important change was made in 
the seventh UICC TNM classification. Before TNM-7 (which was implemented in the NCR in 2010) 
malignancies infiltrating surrounding organs were categorised as cT4, and since TNM-7 tumours 
infiltrating surrounding organs have been categorised as cT4B. cT4A in TNM-7 corresponds to 
tumours that perforate the gastric serosa, which were previously coded as cT3. Therefore, the 
present study included all cT4 tumours before 2010 and only cT4B tumours after 2010.
Hospital type
The three types of hospital in which diagnosis was made were academic, teaching and non-
teaching hospitals. A hospital was considered a teaching hospital if it offered (part of ) a surgical 
residency programme.
Age groups
Patients were analysed according to age (less than 70 years versus 70 years or above), in 
accordance with the guidelines proposed by the European Society of Medical Oncology and 
the Dutch clinical guideline.8,9
Statistical analysis
All analyses were conducted using SPSS® version 23 (IBM, Armonk, New York, USA). Analyses 
were performed for five consecutive periods of 5 years, from 1989–1993 to 2009–2013. To 
investigate trends over time in the proportion of patients treated with palliative intent, ratios 
of palliative patients for sequential time periods were calculated for all patients, and for both 
younger and older patients. 
Descriptive statistics were used to characterise patients younger or older than 70 years, 
and compared using χ2 test. Bar graphs were used to assess differences in treatment modalities 
throughout the years for the two groups of patients, and compared with the χ2 test. Postoperative 
30-day mortality rates were available in the NCR from 2005, and were calculated and compared 
using the χ2 test. Univariable and multivariable logistic regression analyses were performed for 
younger and older patients to examine the influence of different clinicopathological factors 
associated with the receipt of palliative surgery. Results of these analyses were reported as odds 
ratios (ORs) with 95 per cent confidence intervals.
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Survival time was defined as time from diagnosis to death, or until 1 January 2015 for patients 
who were still alive. Kaplan–Meier curves were generated and compared by log-rank testing to 
examine overall survival in younger and older patients according to treatment.
Multivariable Cox regression analyses were performed to investigate the prognostic impact 
of palliative treatment options on overall survival in both groups of patients after adjustment 
for patient, tumour and treatment characteristics. Results of survival analyses using Cox 
regression were reported as hazard ratios (HRs) with 95 per cent confidence intervals. P < 
0.050 was considered statistically significant.
Results
A total of 38 004 patients were diagnosed with non-cardia gastric cancer, of whom 15 011 
were included in the study as they had clinically distant metastasis or a tumour infiltrating 
surrounding organs, and therefore were considered to have been treated with palliative intent 
(Figure 1; Appendix 1). The mean (s.d.) age was 58.2 (9.5) years for younger patients and 77.8(5.4) 
years for older patients. Median duration of follow-up was 4.4 (interquartile range 1.8–9.5) and 
2.9 (1.2–6.6) months for younger and older patients respectively. The percentage of patients 
treated with palliative intent increased significantly over the years for both age groups (P < 
0.001) (Figure 1).
Some 8108 patients (51 per cent) were aged at least 70 years, and 6903 (49 per cent) patients 
were less than 70 years of age. The two groups were comparable (Table 1), except for more 
younger patients presenting with signet-ring cell carcinomas (23.1 versus 13.2 per cent; P < 
0.001). Younger patients were significantly more often treated with chemotherapy compared 
with older patients (28.0 versus 7.9 per cent respectively; P < 0.001). Older patients more often 
received supportive care alone (no surgery or chemotherapy) than younger patients (73.9 versus 
52.5 per cent respectively; P < 0.001). Surgery alone was performed in 16.0 per cent of the 
younger patients and among 17.5 per cent of older patients (P = 0.018).
During the study interval, the proportion of patients undergoing palliative surgery decreased 
significantly in both younger and older patients, from 24.5 per cent in 1989–1993 to 3.0 per 
cent in 2009–2013 (P < 0.001), and from 26.2 per cent to 5.0 per cent, respectively (P < 0.001). 
Postoperative 30-day mortality rates in 2005–2008 and 2009–2013 were 12.1 and 11.3 per cent 
respectively (P = 0.781) (7.5 and 8.0 per cent for younger patients (P = 0.896) and 16.6 and 15.2 
per cent for older patients (P = 0.129), respectively). 
There was a significant increase in the proportion of patients treated with chemotherapy 
alone over the study interval (Figure 2). In 1989 –1993, 15.0 and 2.1 per cent of younger and 
older patients respectively received chemotherapy alone, compared with 51.3 and 20.8 per cent 
respectively in 2009–2013 (P < 0.001).
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Figure 1 Proportions of a younger (aged less than 70 years), b older (aged 70 years or more) and c all 
patients, with non-cardia gastric cancer having a palliative disease (cT4(b) or cM1) according to period of 
diagnosis. 
Probability of surgery
Multivariable logistic regression analyses showed that both younger and older patients with 
a more recent diagnosis had a significantly lower likelihood of having surgery: OR 0.42 (95 
per cent c.i. 0.33 to 0.54) and 0.22 (0.17 to 0.28) respectively. Among younger patients, sex, 
period of diagnosis, tumour morphology, tumour differentiation, tumour location, cTNM status, 
chemotherapy, radiotherapy and type of diagnosing hospital were associated with a higher 
probability of undergoing surgery. In contrast, in older patients sex, tumour morphology and 
type of diagnosing hospital did not influence the probability of having surgery, but age did 
(Table 2).
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   175 20-3-2018   22:26:03
10
176 Chapter 10|
Table 1 Characteristics of younger and older patients diagnosed between 1989 and 2013 who received 
palliative treatment (cM1 and cT4(b)).
Younger patients 
(age < 70 years) 
n = 6903
Older patients 
(age ≥ 70 years) 
n = 8108
Sex ratio (M : F) 4347 : 2556 4832 : 3276
Period of diagnosis
1989–1993 1589 (23.0) 1929 (23.8)
1994–1998 1400 (20.3) 1669 (20.6)
1999–2003 1393 (20.2) 1528 (18.8)
2004–2008 1268 (18.4) 1526 (18.8)
2009–2013 1253 (18.2) 1456 (18.0)
cT status
0–3 926 (13.4) 1021 (12.6)
4 2515 (36.4) 2905 (35.8)
Unknown 3462 (50.2) 4182 (51.6)
cN status
N0 703 (10.2) 897 (11.1)
N+ 2757 (39.9) 2761 (34.1)
Unknown 3443 (49.9) 4450 (54.9)
cM status
M0 973 (14.1) 1232 (15.2)
M1 5602 (81.2) 6452 (79.6)
Unknown 328 (4.8) 424 (5.2)
Tumour location
Proximal and middle 1972 (28.6) 2139 (26.4)
Pyloric and antrum 1693 (24.5) 2444 (30.1)
Overlapping or unspecified 3238 (46.9) 3525 (43.5)
Tumour differentiation
Well 111 (1.6) 148 (1.8)
Moderate 936 (13.6) 1495 (18.4)
Poor/undifferentiated 3524 (51.1) 3768 (46.5)
Unknown 2332 (33.8) 2697 (33.3)
Tumour morphology
Adenocarcinoma 4274 (61.9) 6130 (75.6)
Non-adenocarcinoma 405 (5.9) 421 (5.2)
Linitis plastica 632 (9.2) 489 (6.0)
Signet-ring cell carcinoma 1592 (23.1) 1068 (13.2)
Hospital type
Academic 571 (8.3) 460 (5.7)
Teaching 4067 (58.9) 4778 (58.9)
Non-teaching 2256 (32.7) 2867 (35.4)
Unknown 9 (0.1) 3 (0.0)
Table 1 continues on the next page
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Treatment
No resection or CT 3627 (52.5) 5995 (73.9)
Chemotherapy 1935 (28.0) 640 (7.9)
Resection 1106 (16.0) 1415 (17.5)
Resection + CT 235 (3.4) 58 (0.7)
Values in parentheses are percentages. CT= chemotherapy.
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Figure 2 Treatment modality according to period of diagnosis for a younger (aged less than 70 years) and 
b older (aged 70 years or more) patients with non-cardia gastric cancer who received palliative treatment.
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Table 2 Multivariable logistic regression analysis of factors related to the likelihood of having palliative 
surgery.
Younger patients (age < 70 years) 
n = 6903
Older patients (age ≥ 70 years) 
n = 8108
Odds ratio P value Odds ratio P value
Age 0.99 (0.99, 1.00) 0.066 0.97 (0.90, 0.98) < 0.001
Sex
M 1.00 (reference) 1.00 (reference)
F 1.21 (1.05, 1.40) 0.007 1.13 (0.99, 1.29) 0.068
Period of diagnosis
1989–1993 1.00 (reference) 1.00 (reference)
1994–1998 0.94 (0.78, 1.14) 0.538 0.78 (0.65, 0.92) 0.004
1999–2003 0.66 (0.55, 0.81) < 0.001 0.57 (0.47, 0.69) < 0.001
2004–2008 0.58 (0.47, 0.73) < 0.001 0.40 (0.33, 0.50) < 0.001
2009–2013 0.42 (0.33, 0.54) < 0.001 0.22 (0.17, 0.28) < 0.001
Tumour morphology
Adenocarcinoma 1.00 (reference) 1.00 (reference)
Non-adenocarcinoma 0.93 (0.67, 1.29) 0.662 0.83 (0.59, 1.18) 0.303
Linitis plastica 1.51 (1.15, 1.98) 0.003 1.16 (0.85, 1.59) 0.343
Signet ring cell carcinoma 1.52 (1.28, 1.80) < 0.001 1.12 (0.93, 1.36) 0.237
Tumour differentiation
Well 1.37 (0.87, 2.16) 0.176 0.99 (0.65, 1.49) 0.946
Moderate 1.24 (1.02, 1.49) 0.029 0.89 (0.76, 1.05) 0.157
Poor/undifferentiated 1.00 (reference) 1.00 (reference)
Unknown 0.37 (0.31, 0.44) < 0.001 0.23 (0.19, 0.28) < 0.001
Tumour location
Proximal and middle 1.00 (reference) 1.00 (reference)
Pylorus and antrum 1.49 (1.26, 1.77) < 0.001 2.10 (1.78, 2.47) < 0.001
Overlapping/unspecified 0.59 (0.50, 0.70) < 0.001 0.89 (0.75, 1.05) 0.177
cT status
0–3 1.62 (1.24, 2.11) < 0.001 1.77 (1.37, 2.28) < 0.001
4 1.00 (reference) 1.00 (reference)
Unknown 1.32 (1.08, 1.62) 0.008 1.16 (0.95, 1.42) 0.152
cN status
N0 1.46 (1.18, 1.81) 0.001 1.52 (1.24, 1.86) < 0.001
N+ 1.00 (reference) 1.00 (reference)
Unknown 0.56 (0.48, 0.65) < 0.001 0.44 (0.39, 0.51) < 0.001
cM status
M0 6.58 (5.24, 8.25) < 0.001 4.91 (3.95, 6.10) < 0.001
M1 1.00 (reference) 1.00 (reference)
Unknown 2.91 (2.13, 3.98) < 0.001 1.89 (1.40, 2.56) < 0.001
Chemotherapy
No 1.00 (reference) 1.00 (reference)
Yes 0.48 (0.41, 0.57) < 0.001 0.58 (0.43, 0.79) < 0.001
Table 2 continues on the next page
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Radiotherapy
No 1.00 (reference) 1.00 (reference)
Yes 0.53 (0.32, 0.89) 0.017 0.18 (0.08, 0.39) < 0.001
Hospital type
Academic 0.96 (0.74, 1.23) 0.736 1.07 (0.81, 1.41) 0.650
Teaching 1.00 (reference) 1.00 (reference)
Non-Teaching 0.86 (0.74, 1.00) 0.045 1.08 (0.95, 1.24) 0.256
Unknown 1.59 (0.17, 14.40) 0.681 4.27 (0.25, 71.80) 0.313
Values in parentheses are 95 per cent confidence intervals.
Survival
Survival analyses showed that both younger and older patients who underwent surgery had 
better 2-year overall survival than those who received chemotherapy alone (younger group: 
21.6 versus 6.3 per cent respectively, P < 0.001; older group: 14.7 versus 4.6 per cent, P < 0.001) 
(Figure 3). Overall survival at 2 years was lowest among patients who received only supportive 
care. Patients who had both surgery and chemotherapy had the most favourable survival.
Multivariable Cox regression analyses confirmed that younger and older patients who did 
not have chemotherapy or surgery had a worse overall survival than patients who had surgery 
alone (HR 2.77, 95 per cent c.i. 2.57 to 2.98, and 2.29, 2.15 to 2.45, respectively). Younger and 
older patients treated with chemotherapy had a worse overall survival than those treated with 
surgery (HR 1.22, 95 per cent c.i.1.12 to 1.33, and 1.12, 1.01 to 1.24). Survival was best among 
patients who received both chemotherapy and surgery versus surgery only (younger group: HR 
0.76, 95 per cent 0.66 to 0.88; older group: HR 0.74, 0.57 to 0.97) (Table 3). Period of diagnosis was 
not associated with survival in older patients. Among younger patients, survival was better in 
1994–1998 than in 1989–1993 (HR 0.92, 95 per cent c.i. 0.85 to 0.98). For all other periods there 
was no statistically significant difference in survival (Table 3). A subgroup analysis, in which 
multivariable Cox regression analysis was performed in younger patients who did not receive 
surgery, found no significant survival difference over the years, whereas the same analysis in 
younger patients who did have surgery showed a significant survival improvement in 2009–2013 
compared with 1989–1993 (HR 0.71, 95 per cent 0.54 to 0.93) (Appendix 2). The same subgroup 
analysis in older patients treated with palliative intent who did or did not receive surgery showed 
no significant differences in survival over time.
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Figure 3 Kaplan–Meier 2-year survival curves according to treatment method in a younger (aged less 
than 70 years) and b older (aged 70 years or more) patients with non-cardia gastric cancer who received 
palliative treatment
Table 3 continues on the next page
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Table 3 Multivariable Cox regression analysis of factors related to overall survival.
Younger patients (age < 70 years) 
n = 6903
Older patients (age ≥ 70 years) 
n = 8108
Hazard ratio P value Hazard ratio P value
Age 1.00 (1.00, 1.01) 0.036 1.01 (1.01, 1.02) < 0.001
Sex
M 1.00 (reference) 1.00 (reference)
F 0.89 (0.84, 0.93) < 0.001 0.91 (0.87, 0.95) < 0.001
Period of diagnosis
1989–1993 1.00 (reference) 1.00 (reference)
1994–1998 0.92 (0.85, 0.98) 0.018 1.05 (0.98, 1.12) 0.173
1999–2003 0.93 (0.86, 1.00) 0.054 0.98 (0.92, 1.05) 0.632
2004–2008 0.99 (0.91, 1.07) 0.756 0.96 (0.89, 1.03) 0.224
2009–2013 1.03 (0.95, 1.12) 0.459 1.00 (0.93, 1.08) 0.981
Tumour location
Proximal and middle 1.00 (reference) 1.00 (reference)
Pylorus and antrum 1.01 (0.95, 1.08) 0.683 1.05 (0.99, 1.12) 0.084
Overlapping/unspecified 1.11 (1.05, 1.18) < 0.001 1.14 (1.08, 1.21) < 0.001
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Tumour morphology
Adenocarcinoma 1.00 (reference) 1.00 (reference)
Non-adenocarcinoma 1.05 (0.94, 1.16) 0.384 1.33 (1.21, 1.47) < 0.001
Linitis plastica 1.03 (0.94, 1.13) 0.483 1.07 (0.97. 1.17) 0.205
Signet-ring cell carcinoma 1.02 (0.96, 1.08) 0.551 1.04 (0.97, 1.11) 0.291
Tumour differentiation
Well 0.76 (0.62, 0.92) 0.004 0.88 (0.74, 1.04) 0.130
Moderate 0.90 (0.84, 0.97) 0.008 0.82 (0.78, 0.88) < 0.001
Poor/undifferentiated 1.00 (reference) 1.00 (reference)
Unknown 0.98 (0.93, 1.04) 0.563 0.89 (0.85, 0.94) < 0.001
cT status
0–3 0.93 (0.85, 1.02) 0.105 0.96 (0.88, 1.04) 0.336
4 1.00 (reference) 1.00 (reference)
Unknown 1.11 (1.04, 1.19) 0.002 1.11 (1.04, 1.18) 0.001
cN status
N0 0.91 (0.83, 0.99) 0.023 0.81 (0.75, 0.88) < 0.001
N+ 1.00 (reference) 1.00 (reference)
Unknown 1.09 (1.04, 1.15) 0.001 1.13 (1.08, 1.19) < 0.001
cM status
M0 0.64 (0.59, 0.70) < 0.001 0.65 (0.60, 0.70) < 0.001
M1 1.00 (reference) 1.00 (reference)
Unknown 0.84 (0.74, 0.95) 0.006 0.89 (0.79, 0.99) 0.036
Hospital type
Academic 1.06 (0.97, 1.16) 0.202 0.97 (0.88, 1.07) 0.537
Teaching 1.00 (reference) 1.00 (reference)
Non-teaching 1.07 (1.02, 1.13) 0.011 1.04 (0.99, 1.09) 0.117
Unknown 0.93 (0.48, 1.80) 0.830 0.57 (0.18, 1.77) 0.328
Treatment
Resection 1.00 (reference) 1.00 (reference)
Chemotherapy 1.22 (1.12, 1.33) < 0.001 1.12 (1.01, 1.24) 0.030
Resection + CT 0.76 (0.66, 0.88) < 0.001 0.74 (0.57, 0.97) 0.027
No resection or CT 2.77 (2.57, 2.98) < 0.001 2.29 (2.15, 2.45) < 0.001
Values in parentheses are 95 per cent confidence intervals. CT= chemotherapy.
Discussion
In this population-based nationwide study, 45.2 per cent of younger patients and 35.7 per cent 
of older patients presented with locally advanced or metastasised gastric cancer at diagnosis. 
During the study interval, the proportion undergoing palliative surgery reduced significantly. 
However, both younger and older patients who underwent gastrectomy had a significantly 
better survival compared with patients treated with chemotherapy or supportive care alone.
An increased incidence of stage IV disease and decreased resection rates have been 
shown for other gastrointestinal cancers in the Netherlands.17–19 This decrease in palliative 
resection suggests a better selection of patients as a result of improved diagnostic accuracy 
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and preoperative staging, and the availability of systemic treatment options.18 The latter was 
also demonstrated in the present study, by a significant increase in use of chemotherapy, 
especially from 2005 onwards. In addition, the Dutch clinical guideline9 on treatment of gastric 
cancer, implemented in 2009, advises that palliative gastrectomy should be performed only 
in patients under 70 years of age, who have no more than one item of incurability – either 
distant metastasis (M1 disease) or tumour infiltrating the surrounding organs (cT4 disease). 
This could also have led to a decrease in palliative gastrectomy. Finally, better understanding 
of postoperative morbidity and mortality in patients with stage IV gastric cancer may have 
led physicians to refrain from a surgical approach.5,6 In the present study, especially in older 
patients, 30-day postoperative mortality rates were high, despite a substantial improvement 
in postoperative mortality compared with that in previous Dutch studies.5,6 A Dutch study5 of 
palliative gastrectomy reported a 30-day postoperative mortality rate of 20 per cent in 1989–
1993, considerably higher than the 15.2 per cent found in the present study.
Despite increased use of chemotherapy, survival of all patients receiving palliative care for 
gastric cancer did not improve after adjustment for clinicopathological factors. However, in 
multivariable analysis overall survival increased between 2010 and 2013 for younger patients 
treated with gastrectomy, which may be due to centralisation of gastric cancer surgery as of 2012 
in the Netherlands. An additional explanation may be better selection of younger patients with 
cancer, who are relatively fit for palliative surgery. The present study also showed that younger 
patients diagnosed in teaching hospitals had a significantly better overall survival than those 
diagnosed in non-teaching hospitals.
Previous studies from Germany20,21 have suggested that tumour resection should be part of 
palliative therapy in gastric cancer, with prolongation of median survival up to 5 months, and 
acceptable perioperative morbidity and mortality rates of 47.7 and 11.6 per cent respectively. 
Other studies have shown a positive effect of palliative gastrectomy on overall survival in smaller 
groups and in a meta-analysis.22 In line with this, the present study showed that survival of 
patients who had a palliative resection was higher than that in those receiving chemotherapy 
alone. The 2-year survival rate was 21.6 and 14.7 per cent in younger and older patients who 
underwent palliative surgery, compared with 6.3 and 4.6 per cent in patients who received 
chemotherapy alone . A positive effect of palliative resection on survival has been reported for 
various malignancies, although there has been no explanation as to why palliative resection is 
associated with improved overall survival.23–28
There are studies that have suggested a more positive or equal effect   on survival compared 
with palliative surgery in patients with gastric cancer treated with palliative chemotherapy.7,29,30 
Recently an RCT comparing palliative gastrectomy and chemotherapy with chemotherapy alone 
(REGATTA trial)29 showed no benefit for palliative gastrectomy. However, this trial involved an 
Asian population and, because of well known differences between Asian and European patients 
with gastric cancer, this finding should be treated with care.31–33 Furthermore, the REGATTA 
trial included only patients with liver, peritoneal or para-aortic lymph node metastases, and 
thus the effect of palliative surgery on survival of patients with gastric cancer and a locally 
advanced (T4b) tumour remains unclear. The difference in survival between patients treated 
with chemotherapy alone and those who had surgery and chemotherapy in the present study 
is, however, noteworthy, and not in line with the findings of the REGATTA trial. An European 
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RCT evaluating the effect of palliative gastrectomy versus palliative chemotherapy on overall 
survival is thus needed.
The present study has some limitations. This was a retrospective cohort study in which there 
is a likelihood of selection bias. The survival difference between various treatment groups may 
be caused by selecting fitter patients for palliative gastrectomy. The absence of information on 
clinical symptoms, comorbidity, hospital resection volume, ASA fitness grade and therapeutic 
complication rates is another limitation. These data have only recently been included entirely 
in the NCR, and could therefore not be included in the present study. Furthermore, information 
regarding adherence to multidisciplinary team meetings, intention of treatment and therapeutic 
plans was not available. There was also a relatively large proportion of unknown characteristics 
(for instance cTNM status, tumour location and differentiation). This was because in the earlier 
periods clinical staging was not always available and a high proportion of patients did not 
undergo surgery. Finally, no adjustment was made for immortal time bias – the period during 
follow-up in which death cannot occur. For example, in the present study, patients who had 
been treated with chemotherapy and resection could not die within the first few weeks after 
diagnosis as otherwise they would not have been able to receive these treatments. However, 
taking immortal time bias into account would have meant excluding patients  who had died in 
the initial months after diagnosis - mainly those treated with neither chemotherapy nor with 
resection. As these patients generally have the worst prognosis, skewness would have been 
created in the study population.  
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Appendix 1 Proportions of patients with non-cardia gastric cancer having a palliative disease (cT4(b) or 
cM1) according to age group and period of diagnosis.
Younger patients 
(age < 70 years)
Older patients 
( ≥ 70 years)
Total
All Pall. Percent All Pall. Percent All Pall. Percent
Period of 
diagnosis
1989-1993 3825 1589 42% 5482 1929 35% 9307 3518 38%
1994-1998 3209 1400 44% 4881 1669 34% 8090 3069 38%
1999-2003 2916 1393 48% 4425 1528 35% 7341 2921 40%
2004-2008 2657 1268 48% 4038 1526 38% 6695 2794 42%
2009-2013 2676 1253 47% 3895 1456 37% 6571 2709 41%
Total 15283 6903 45% 22721 8108 36% 38004 15011 39%
Appendix 2 Cox regression analysis of the influence of different clinicopathological factors on survival of 
younger and older patients who underwent palliative surgical resection.
Younger patients (age < 70 years)
n=1341
Older patients ( ≥ 70 years)
n=1473
Hazard ratio P value Hazard ratio P value
Period of diagnosis
1989-1993 1.00 (reference)   1.00 (reference)
1994-1998 0.81 (0.07, 0.94) 0.006 0.97 (0.85, 1.12) 0.710
1999-2003 0.81 (0.69, 0.95) 0.010 0.90 (0.77, 1.05) 0.193
2004-2008 0.81 (0.67, 0.97) 0.026 0.92 (0.78, 1.10) 0.353
2009-2013 0.71 (0.54, 0.93) 0.013 0.86 (0.67, 1.11) 0.245
Values in parentheses are 95 per cent confidence intervals.
* Adjusted for age, sex, tumor location, tumor morphology, tumor grade, cTNM-stage and type of diagnosing hospital.
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Abstract
Background
Treatment for oesophageal cancer has evolved due to developments including the centralisation 
of surgery and introduction of neoadjuvant treatment. Therefore, this study evaluated trends 
in stage distribution, treatment and survival of oesophageal cancer patients in the last 26 years 
in the Netherlands.
Patients and methods
Patients with oesophageal cancer diagnosed in the period 1989-2014 were selected from the 
Netherlands Cancer Registry. Patients were divided into two groups: non-metastatic (M0) and 
metastatic (M1). Trends in stage distribution, treatment and relative survival rates were evaluated 
according to histology.
Results
Among all 35,760 patients the percentage of an unknown tumour stage decreased from 34% to 
10% during the study period, while the percentage of patients with metastatic disease increased 
from 21% to 34%. Among surgically treated patients 32% underwent a resection in a high-
volume hospital in 2005 which increased to 92% in 2014. Use of neoadjuvant chemoradiotherapy 
increased in non-metastatic oesophageal adenocarcinoma (OAC) and squamous cell carcinoma 
(OSCC) patients from respectively 4% and 2% in 2000-2004 to 43% and 26% in 2010-2014. 
Five-year relative survival increased from 8% to 22% for all patients; from 12% to 36% for non-
metastatic OAC and from 9% to 27% for non-metastatic OSCC over 26 years. Median overall 
survival of metastatic patients improved from 18 to 22 weeks.
Conclusion
In the Netherlands, survival for oesophageal cancer patients improved significantly, especially in 
the period 2005-2014 which might be the result of better treatment related to the centralisation 
of surgery and introduction of neoadjuvant chemoradiotherapy. 
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Introduction
Oesophageal cancer is the sixth leading cause of cancer-related mortality and eight most 
common cancer worldwide.1,2 It affects 456,000 people worldwide annually and the incidence 
is increasing rapidly.1 There are two major histological types, oesophageal adenocarcinoma 
(OAC) and oesophageal squamous cell carcinoma (OSCC) each with a distinct aetiology and 
specific risk factors.3 Although OSCC accounts for approximately 90% of all cases of oesophageal 
cancer worldwide, OAC has become the predominant type of oesophageal cancer in Europe 
and Northern America during the past decades.1,4
Treatment of oesophageal cancer has been subjected to paradigm shifts in the last two 
decades. Long term results from the CROSS trial confirmed the clinical value of multimodality 
treatment for oesophageal cancer with a 5-year overall survival difference of 14% in favour of 
patients who underwent neoadjuvant chemoradiotherapy followed by surgery compared to 
surgery alone.5,6 Furthermore, endoscopic treatment was introduced for treatment of early 
stage tumours and definitive chemoradiotherapy is increasingly considered as a well-tolerated 
alternative for surgery in inoperable patients and especially in squamous cell oesophageal 
cancer.7-10 Besides these major changes in treatment, improved diagnostic procedures facilitated 
a better patient selection.11-14
Oesophageal cancer surgery has been increasingly centralised in the Netherlands. As of 2006, 
surgical treatment for oesophageal cancer was centralised in hospitals performing a minimum 
of 10 resections per year and since 2011 a minimum of 20. Concentration of oesophageal cancer 
surgery has been shown to be associated with improved long-term overall survival for surgically 
and non-surgically treated patients.15, 16 As treatment for oesophageal cancer has evolved over 
the last few decades due to several developments such as centralisation of surgery and new 
treatment approaches, the aim of this study was to evaluate trends in treatment and survival 
of patients with oesophageal cancer in the Netherlands. 
Methods
Netherlands Cancer Registry
Data were obtained from the Netherlands Cancer Registry (NCR). This registry serves the total 
Dutch population of 16.9 million inhabitants. The NCR is based on the inclusion of all newly 
diagnosed malignancies in the Netherlands by the national automated pathological archive 
(PALGA). Additional sources are the national registry of hospital discharge and radiotherapy 
institutions. Specially trained data managers of the NCR routinely extract information on 
diagnosis, tumour stage and treatment from the medical records. Information on vital status 
is obtained through annual linkage with the Municipal Administrative Database, in which all 
deceased and emigrated persons in the Netherlands are registered. 
Patients with oesophageal cancer (C15.0-C15.9) diagnosed in the period 1989-2014 were 
selected. Topography and morphology were coded according to the International Classification 
of Diseases for Oncology (ICD-O).17 ICD-O morphology codes were used to classify tumours as 
adenocarcinoma, squamous cell carcinoma and other or unknown histology. Subsite distribution 
was divided as: cervical (C15.0), proximal 1/3 (C15.3), middle 1/3 (C15.4), distal 1/3 (C15.5) and 
overlapping or not otherwise specified (C15.8, C15.9).
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Tumour staging was performed according to the Union for International Cancer Control 
(UICC) TNM classification that was valid at the time of diagnosis. As tumour stage classification 
was comparable from TNM-4 to -6, but changed with the introduction of TNM-7, all patients 
were recoded (stage I to IV and unknown) according to TNM-6 in this study. Furthermore, M1a 
tumours according to TNM-5 and 6 were categorised as N+ as most patients with a M1a tumour 
had a distal tumour with coeliac lymph nodes which can be considered N+ according to TNM-7. 
Pathologic tumour stage was assessed for stage distribution, or if not available, clinical tumour 
stage was noted. Patients with a cM1 or pM1 stage were classified as metastatic and all other 
patients as non-metastatic. 
Treatment
For non-metastatic patients, neoadjuvant chemoradiotherapy was defined as chemoradiotherapy 
followed by surgery. Definitive chemoradiotherapy was defined as chemoradiotherapy without 
a surgical resection as the intention of chemoradiotherapy was not registered during the study 
period. An endoscopic resection was defined as a local tumour excision, endoscopic mucosal 
resection or an endoscopic submucosal dissection.
For metastatic patients, a distinction was made between chemoradiotherapy, systemic 
treatment or radiotherapy as single modality. Systemic treatment included chemotherapy 
and targeted therapy. Symptom-related treatment was classified as no treatment. All other 
treatments were grouped as ‘other’ therapy and were described below figure 3 and 4.
Statistical analysis
Differences in characteristics between patients were described according to period of diagnosis. 
Incidence and mortality rates were calculated as the number of new patients per 100,000 
inhabitants per year, and age-standardized to European Standardised Rates (ESR). Survival time 
was defined as time from diagnosis to death or until February 1st 2017 for patients who were 
still alive. The median overall survival was estimated by using the Kaplan Meier method for 
metastatic patients. Relative survival was estimated by using life tables of the general population 
to correct for age- and gender specific background mortality. The Ederer II method with age 
standardisation to the most recent time period was used to compare relative survival between 
time periods.18, 19 STATA version 14.1 was used for the survival analyses and all other analyses 
were conducted using SAS version 9.4. P values of <0.05 were considered statistically significant. 
Results
Between January 1989 and December 2014, 35,760 patients were diagnosed with oesophageal 
cancer in the Netherlands. Age-standardised incidence rates increased from 5 per 100,000 
inhabitants in 1989 to 9 in 2014, while mortality rates increased to a lesser extent from 5 to 7 
(Figure 1). The incidence of OAC increased especially in males, from 3 per 100,000 inhabitants 
in 1989 to 10 in 2014. Corresponding to the increase of OAC, the number of patients with a 
distal tumour increased. The median age was 69 (interquartile range 60-77) in 1989-1994 and 
remained similar over time (Table 1). 
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Figure 1 Incidence and mortality of oesophageal cancer in the Netherlands, 1989-2014.
Table 1 Characteristics of patients with oesophageal cancer in the Netherlands 1989-2014 (n=35 670).
1989-1994 1995-1999 2000-2004 2005-2009 2010-2014
n % n % n % n % n %
All patients 4999 100% 5299 100% 6722 100% 8554 100% 10096 100%
Gender
Male 3312 66% 3633 69% 4790 71% 6256 73% 7484 74%
Female 1687 34% 1666 31% 1932 29% 2298 27% 2612 26%
Age (median yrs., IQR) 69 60-77 68 59-77 68 58-77 68 60-76 68 61-76
Age (yrs.)
< 60 1233 25% 1386 26% 1860 28% 2115 25% 2171 22%
60-74 2201 44% 2296 43% 2783 41% 3804 44% 4941 49%
≥ 75 1565 31% 1617 31% 2079 31% 2635 31% 2984 30%
Tumour location
Cervical 135 3% 138 3% 154 2% 125 1% 92 <1%
Upper thoracic 338 7% 353 7% 396 6% 447 5% 559 6%
Mid-thoracic 1147 23% 1189 22% 1241 18% 1382 16% 1512 15%
Lower thoracic  2769 55% 3146 59% 4443 66% 6043 71% 7243 72%
Overlapping, unknown 610 12% 473 9% 488 7% 557 7% 690 7%
Morphology
Squamous cell carcinoma 2614 52% 2358 44% 2479 37% 2750 32% 3101 31%
Adenocarcinoma 2097 42% 2593 49% 3837 57% 5377 63% 6696 66%
Other/unknown 288 6% 348 7% 406 6% 427 5% 299 3%
IQR=interquartile range
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The proportion of patients with an unknown tumour stage decreased from 34% to 10% in 
1989-1994 and 2010-2014, with a corresponding decrease in the proportion of patients with a 
metastatic disease from 21% to 34% (Figure 2). Furthermore, the percentage of patients with 
a stage 0 tumour (pathologic or if not available clinical stage T0,N0,M0 or T0,NX,M0) increased 
from 0% in 2000-2004 to 6% in 2010-2014.
Trends in treatment
Among all patients, resection rates remained relatively stable with approximately 25% between 
1989-2004 and 29% between 2010-2014. Among non-metastatic OAC the use of neoadjuvant 
chemoradiotherapy and surgery increased significantly from 4% in 2000-2004 to 43% in 2010-
2014 and from 2% to 26% for non-metastatic OSCC (Figure 3a and 3b). During the same period 
the use of definitive chemoradiotherapy increased as well from 8% in 2000-2004 to 31% in 
2010-2014 for non-metastatic OSCC, while this increase was less prominent for non-metastatic 
OAC (3% to 14%). The use of endoscopic resection hardly increased for non-metastatic OSCC but 
increased for non-metastatic OAC from 2% in 2000-2004 to 10% in 2010-2014. Furthermore, in 
2005 32% of all resected patients underwent a resection in a high-volume hospital (performing 
≥20 procedures per year) which increased to 92% in 2014 (Appendix 1).
The proportion of patients with metastatic OAC who received systemic treatment as 
a single modality increased from 11% in 1989-1994 to 28% in 2010-2014 and the use of 
chemoradiotherapy increased from 1% to 15% in these time periods (Figure 4a). In contrast, 
the increase in chemoradiotherapy was more prominent among patients with metastatic OSCC 
(3% in 1989-1994 and 21% in 2010-2014), while the use of chemotherapy remained stable 
(approximately 11%); Figure 4b). 
Figure 2 Stage distribution of all patients with oesophageal cancer according to period of diagnosis (n=35 670). 
Pathological tumour stage was assessed, or if not available, clinical tumour stage was noted.
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Figure 3 Treatment of patients with non-metastatic (M0) oesophageal cancer in the Netherlands, according 
to histology and period of diagnosis,1989-2014 (a; n=13 854, b; n=10 125).
OAC= oesophageal adenocarcinoma OSCC= oesophageal squamous cell carcinoma.
Other treatment mainly included: systemic treatment as a single modality, and chemotherapy combined with surgery.
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Figure 4 Treatment of patients with metastatic (M1) oesophageal cancer in the Netherlands, according to 
histology and period of diagnosis,1989-2014 (a; n=6746, b; n=3177). 
OAC= oesophageal adenocarcinoma OSCC= oesophageal squamous cell carcinoma.
Other treatment mainly included: radiotherapy for metastases, metastasectomy and surgery alone, the latter especially 
in the earlier periods.
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Survival
The 5-year relative survival for all patients with oesophageal cancer increased from 8% to 22% 
in 1989-2014 (Figure 5; Table 2a). The largest increases were observed in the last two periods. 
During these periods survival improved by 7% and 9% compared to the period before. Five-
year relative survival tripled for both patients with non-metastatic OAC and OSCC, from 12% to 
36% and 9% to 27% in 1989-1994 and 2010-2014, respectively (Figure 6a and 6b and Table 2b). 
One-year relative survival for all patients with metastatic oesophageal cancer increased 
from 15% to 22% in 1989-2014 (Table 2c). The one-year relative survival increased with 3% in 
2000-2004 for patients with metastatic OSCC and with 5% in 2005-2009 for metastatic OAC. 
After these periods relative survival remained stable (Figure 6c and 6d and Table 2c). Median 
overall survival for all metastatic patients increased with 4 weeks from 18 weeks in 1989-1994 
to 22 weeks in 2010-2014.
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Figure 5 Relative survival of all patients with oesophageal cancer (n=35 670). 
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Table 2a Five-year relative survival for all patients with oesophageal carcinoma.
All oesophageal cancer 
n=35 670
All OAC
n=20 600
All OSCC
n=13 302
Point estimate (%) SE Point estimate (%) SE Point estimate (%) SE
Period of diagnosis
1989-1994 8 0.4 9 0.7 8 0.6
1995-1999 10 0.5 11 0.7 10 0.7
2000-2004 12 0.4 13 0.6 11 0.7
2005-2009 16 0.4 18 0.6 15 0.7
2010-2014 22 0.5 23 0.6 20 0.9
SE= standard error.
OAC= oesophageal adenocarcinoma OSCC= oesophageal squamous cell carcinoma.
Table 2b Five-year relative survival for patients with non-metastatic (M0) oesophageal carcinoma.
M0 oesophageal cancer 
n=25 214
M0 OAC
n=13 854
M0 OSCC
n=10 125
Point estimate (%) SE Point estimate (%) SE Point estimate (%) SE
Period of diagnosis
1989-1994 10 0.5 12 0.9 9 0.7
1995-1999 13 0.6 15 1.0 12 0.9
2000-2004 16 0.6 18 0.8 14 0.9
2005-2009 23 0.6 27 0.8 19 1.0
2010-2014 32 0.7 36 0.9 27 1.2
SE= standard error.
OAC= oesophageal adenocarcinoma OSCC= oesophageal squamous cell carcinoma.
Table 2c One-year relative survival for patients with metastatic (M1) oesophageal carcinoma.
M1 oesophageal cancer 
n=10 456
M1 OAC
n=6746
M1 OSCC
n=3177
Point estimate (%) SE Point estimate (%) SE Point estimate (%) SE
Period of diagnosis
1989-1994 15 1.1 14 1.5 16 1.7
1995-1999 14 1.0 14 1.3 17 1.9
2000-2004 17 0.9 16 1.1 22 1.8
2005-2009 21 0.8 22 1.0 22 1.5
2010-2014 22 0.7 22 0.8 23 1.4
SE= standard error.
OAC= oesophageal adenocarcinoma OSCC= oesophageal squamous cell carcinoma.
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Discussion
This large population-based nationwide study observed progress against oesophageal cancer 
in the last 26 years in the Netherlands, as the incidence increased and mortality decreased, 
suggesting an improvement in survival. Relative survival rates more than doubled for all patients 
and tripled for non-metastatic patients, particularly in the last two study periods. Moreover, an 
improvement in survival of metastatic patients was also observed. 
The rising incidence in oesophageal cancer can be attributed to a rise in OAC, especially 
among males. OAC and OSCC have a distinct aetiology and specific risk factors. OSCC has been 
associated with tobacco smoking, overconsumption of alcohol and low intake of fruit and 
vegetables, whereas OAC has been associated with obesity, gastro-oesophageal reflux disease 
and Barrett’s oesophagus.2, 20 The increase in OAC among males may be attributed to the increase 
in obesity and especially abdominal (visceral) fat, which is more common among males and 
the strongest risk factor for Barrett’s oesophagus and OAC.2 Globally, the incidence of OAC is 
highest in Western industrialised countries, while the incidence of OSCC is highest in Asia, East 
Africa and South America.4
The widening gap between incidence and mortality for oesophageal cancer suggesting an 
improvement in survival.21 There are several reasons why survival may artificially increase, such 
as improved detection (i.e. screening) and changes in incidence and underlying proportional 
changes in age, morphology and stage distribution. As screening programs are not the case for 
oesophageal cancer in the Netherlands and survival improved for non-metastatic and metastatic 
patients as well as for both morphology subgroups, changes in survival may reflect improved 
staging and treatment. 
During the study period, relative survival also increased for patients with gastric cardia cancer, 
which is related to distal OAC,  from 11% in 1989-1994 to 17% in 2010-2014. Survival especially 
improved in the last two periods. However, survival for gastric cardia cancer increased to a lesser 
extent compared to oesophageal cancer. An explanation may be that multimodality treatment 
has been administered less frequently in gastric cardia cancer as compared to oesophageal 
cancer.22 Moreover, gastric cardia cancer patients can be treated with an oesophagectomy or 
gastrectomy which latter procedure is centralised more recently. Therefore, it is expected that 
survival will further increase in the next decade.
There are several possible explanations for the improvement in survival of patients with 
non-metastatic oesophageal cancer. First, the introduction of neoadjuvant chemoradiotherapy 
in a multimodality treatment for oesophageal cancer has contributed to better survival rates 
for resected patients by downstaging of the tumour and an improved locoregional and distant 
disease control.5, 6 The results from the CROSS trial have led to a successful implementation 
of neoadjuvant chemoradiotherapy as preferred treatment for resectable patients with 
oesophageal cancer in the Netherlands. Nowadays, nearly all Dutch patients that undergo 
surgery receive neoadjuvant chemoradiotherapy. The downstaging effect of chemoradiotherapy 
possibly resulted in an increasing number of patients with a pathological complete response 
(stage 0) or stage I and II as shown in Figure 2.
Second, centralisation of oesophageal cancer surgery may have further contributed to the 
improved survival in the most recent periods for non-metastatic patients. Many population-based 
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studies have shown that centralisation improves surgical experience, decreases postoperative 
complications and mortality.15, 23-26 Furthermore, centralisation also seems to improve patient 
selection as survival also improved for non-surgically treated patients.15, 27  
Third, survival may have improved due to better diagnostic procedures, resulting in improved 
patient selection. With the introduction of high-quality computed tomography (CT) scanners, 
endoscopic ultrasonography (EUS), endobronchial ultrasonography (EBUS) and Positron 
Emission Tomography-Computed Tomography (PET-CT), staging has become more accurate.13, 
14, 28, 29 The higher proportion of patients diagnosed with an advanced tumour stage over time – 
instead of unknown - in the present study indicates stage migration due to improved diagnostic 
techniques. However, since the survival of all patients increased the influence of stage migration 
can only partly explain the increased survival. 
Finally, the increased use of definitive chemoradiotherapy might have improved survival 
especially for patients with OSCC. Compared with neoadjuvant chemoradiotherapy followed 
by surgery, definitive chemoradiotherapy has been associated with an equivalent survival of 
patients with OSCC but higher rates of local relapse in two RCTs.10, 30 As not each patient is fit for 
surgery, definitive chemoradiotherapy can be a well-tolerated alternative, especially in OSCC 
patients.31
The median overall survival of metastatic oesophageal cancer patients improved from 18 to 
22 weeks (22%) during the last 26 years. Similar findings have been reported by two other Dutch 
studies.32, 33 The prolonged survival in metastatic patients may be the result of major changes in 
treatment but also of stage migration due to improved diagnostic techniques, which facilitates 
detection of metastases at an earlier stage.12 
Survival of patients with oesophageal cancer also improved in countries outside the 
Netherlands. The EUROCARE-5 study showed that the largest improvements in 5-year relative 
survival were observed in Ireland, the UK and Central Europe in the period 2005-2007 compared 
to 1999-2001 ranging from 4 to 5%.34 The changes in survival between Belgium and the 
Netherlands are comparable. 35 Limited improvements were observed in Eastern and Southern 
Europe.34 The average European 5-year relative survival of 12% in 2000-2007 was somewhat lower 
compared to the 5-year relative survival of 16% in 2005-2009 in the Netherlands. Furthermore, 
the improvement in five-year relative survival rates in the Netherlands was comparable to the 
improvement seen in the United states.36
This study has some limitations. First, information about the intention of chemoradiotherapy 
(curative or palliative) was not available. Therefore, among non-metastatic oesophageal cancer 
patients it was assumed that patients underwent chemoradiotherapy with curative intention 
(neoadjuvant or definitive). Second, the group of M0 patients who underwent definitive 
chemoradiotherapy may be heterogeneous, consisting of patients who indeed underwent 
definitive chemoradiotherapy, patients not fit enough to undergo surgery after neoadjuvant 
chemoradiotherapy and some patients with a complete clinical response after neoadjuvant 
chemoradiotherapy who may have refused surgery. Third, possible incompleteness of 
registration of endoscopic resections in the earlier period could have led to an underestimation 
of endoscopically treated patients. The strength of this study is its unique nationwide population-
based design resulting in a large and representative study population with real world data about 
treatment patterns and survival in the past 26 years in the Netherlands.
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In conclusion, the significant improvement in survival of oesophageal cancer patients 
especially after 2005 reflects the possibly improved staging, better patient selection and evolving 
therapeutic options including neoadjuvant treatment and centralisation of oesophageal cancer 
surgery. Further improvement may be achieved by earlier detection and treatment of (pre)
malignant lesions and by use of more effective personalised systemic treatment.37
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Appendix 1 Number of oesophageal cancer resections per hospital volume category in the period 2005-
2014.
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Discussion
In this chapter the results observed in this thesis will be discussed in a broader context. 
Centralisation of surgery
Improving quality of care for patients with oesophageal and gastric cancer is a major challenge as 
the incidence is relatively low and most patients have an advanced disease at time of diagnosis. 
Therefore, like in many other European countries, surgery is centralised in the Netherlands and 
now mainly performed in high-volume hospitals.1 In the Netherlands, since 2006, hospitals 
should perform a minimum of 10 oesophagectomies per year and since 2012 a minimum 
of 10 gastrectomies per year which increased to 20 in 2011 and 2013 for oesophageal and 
gastric cancer, respectively. Currently, a large number of studies has been published on the 
impact of centralisation on outcomes after oesophagectomy and gastrectomy, showing short-
term improved perioperative and oncologic results.2-5 This thesis confirmed the reduction of 
postoperative mortality and showed also an improved long-term survival for surgically treated 
patients and all patients with gastric cancer in the period after centralisation. 
An explanation for improved survival after centralisation could be the ‘practice makes 
perfect’ concept. This suggests that more experience is gained in hospitals that treat a greater 
number of patients, which could lead to improvements in the management of patients across 
the whole treatment pathway.6 For example, specialisation of a surgeon should increase their 
experience and technical abilities. Moreover, the greater exposure of medical specialists and 
nurses to patients after Upper GI cancer surgery increases their ability to timely recognise and 
treat complications at an earlier stage and by doing so decreases postoperative mortality and 
failure to rescue.7,8 Furthermore, a better patient selection by appropriate preoperative staging 
using endoscopic ultrasound and PET performed by experienced radiation oncologists and 
gastroenterologists is likely to play a significant role in improving overall survival.9,10 In addition, 
medical oncologists and radiotherapists may be more aware of the possibilities of chemotherapy 
and radiotherapy when treating more patients. Finally, several studies have observed that 
pathological examination improves with growing experience, resulting in better staging.11 
Many previous studies only included surgically treated patients to assess the influence of 
centralisation on the outcome of patients with upper gastrointestinal tumours.12-15 However, 
improvement in survival after surgery observed by these studies may be explained by patient 
selection rather than by better care. Medical specialists may perform a more critical pre-operative 
selection withholding the less fit patients from surgical treatment. As a result, overall survival 
may be worse for all patients as improvement in survival is only the case in the selected group 
of patients.6 Therefore, it is important to evaluate the impact of centralising treatment for all 
patients, irrespective of treatment, in a population-based setting as performed in this thesis.
Centralisation of surgery has enforced regionalisation of oncological care for oesophageal 
and gastric cancer within the Netherlands. Centralisation of surgery imposed by the Health 
Care Inspectorate and the Association of Surgeons in the Netherlands by defining a minimum 
number of procedures per year, resulted in an increasing number of hospitals starting to create 
regional agreements on referral of oesophageal and gastric cancer patients for surgery. Within 
these regions patients can be referred to high volume hospitals for surgery or discussed within 
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a multidisciplinary team (MDT’s) meeting. Moreover, it avoids that low volume hospitals are 
confronted with complex patients and poor outcomes.16 Currently multiple collaborative regions 
exists in the Netherlands. Sharing knowledge and experiences and making formal agreements 
on their specific role in the clinical pathway within these regional collaborations is of paramount 
importance as oncological care, like for oesophageal and gastric cancer, is increasingly complex.
Hospital of diagnosis and impact on treatment selection
Surgical treatment of both oesophageal and gastric cancer is nowadays centralised in the 
Netherlands, but the initial decision which treatment modality to perform, including the 
decision whether or not to refer patients for a curative treatment option is made in all hospitals, 
sometimes by consulting medical specialists from other hospitals. This thesis showed a large 
inter-hospital variation in the use of curative treatment options for patients with oesophageal 
and gastric cancer. Large differences between hospitals of diagnosis existed varying from 50% 
to 82% and from 48% to 78% for patients with oesophageal and gastric cancer, respectively. 
Moreover, patients diagnosed in hospitals with a low probability of undergoing curative 
treatment had a worse overall survival, even after adjustment for case-mix factors.
The variation between hospitals indicates that decision-making in oesophageal and gastric 
cancer can be improved. Due to centralisation of complex surgery an increasing number of 
patients are referred to another hospital for treatment by the hospital of diagnosis. Centralisation 
of surgery may have led to a “brain drain” of knowledge and experience of treatment options 
for these tumours among hospitals which do not perform these procedures (anymore). This 
possible downside of centralisation could have influenced the selection of patients for curative 
treatment and subsequently referral and overall survival.  
Differences in the composition of a MDT meeting may explain variation in curative treatment 
between hospitals of diagnosis. According to the guidelines, all oesophageal and gastric cancer 
patients should be discussed in a MDT meeting for a consensus-based treatment decision before 
starting treatment in the Netherlands. Previous studies have found that MDTs improve diagnostic 
work-up and significantly influenced treatment decisions in oesophageal and gastric cancer.17-19 
However, no information is available as to which expertise in treatment of oesophageal and 
gastric cancer is present in this MDT. Differences in the presence of experienced specialists in 
these MDT meetings might explain differences between hospitals in the proportion of patients 
undergoing treatment with curative intent. Therefore, regional expert MDT meetings with 
involvement of experienced specialists in this field, for example by means of video conferencing, 
may improve treatment selection for patients with oesophageal and gastric cancer. 
Early diagnosis of oesophageal cancer
Survival for patients with oesophageal cancer improved the last decades, probably related to 
the introduction of neoadjuvant chemoradiotherapy and centralisation of surgery. Further 
improvement may be achieved by earlier detection and treatment of premalignant and 
malignant lesions like Barrett’s oesophagus.
This thesis showed that oesophageal adenocarcinoma and high-grade dysplasia was ‘missed’ 
at index Barrett’s oesophagus endoscopy in up to 13% of the Barrett’s oesophagus patients in 
Northern Ireland, who were subsequently diagnosed with one of these (pre)malignant diseases. 
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This percentage was significant but substantially lower than previously reported estimates 
by a systematic review (25%). However, this systematic review was severely lacking inclusion 
of robust, population-based data. Moreover, this review defined ‘missed’ as being diagnosed 
with oesophageal malignant or premalignant lesion within one year after Barrett’s oesophagus 
diagnosis. However, a diagnosis less than three months after diagnosis of Barrett’s oesophagus 
may be part of the diagnostic work-up.20 
There could be two overarching explanations for the ‘missed’ (pre)malignant lesions. First, 
the missed cancers may be truly missed, which means that the cancer or premalignant lesions 
were already present at index endoscopy but not detected.21 It is possible that cancer or 
premalignant lesions were not detected due to features that make them less likely to be seen 
by the endoscopist such as oesophagitis, oesophageal stricture and ulceration.21 Methods to 
increase detection of cancer and premalignant lesions such as advanced endoscopic imaging 
techniques22, greater time examining Barrett’s oesophagus segments23 and greater number 
of targeted biopsies21 may decrease the burden of missed (pre)malignant lesions.24 Second, 
it is plausible that the missed cancers may be more aggressive cancers which have no visible 
evidence at time of index Barrett’s oesophagus endoscopy but develop rapidly afterward. 
Therefore, biomarkers could assist in determining the risk of progression at Barrett’s oesophagus 
diagnosis and guide the targeting of endoscopic surveillance.25-27 Nevertheless, it is important 
to put the ‘missed’ oesophageal (pre)malignant rate of 13%, into context of the total Barrett’s 
oesophagus population. This figure represents only 0.26% of all Barrett’s oesophagus patients 
diagnosed in Northern Ireland in the period 1993-2000, and so the ever-important question of 
identifying the very small proportion of high-risk patients remains a considerable challenge.
Perioperative treatment for gastric cancer
While survival of the total group of patients with oesophageal cancer showed major improvement 
during the last two decades as shown by this thesis, survival of patients with gastric cancer 
only improved for patients with a potentially curable disease.28 As of 2006, perioperative 
chemotherapy for gastric cancer patients is recommended in several European countries based 
on results of the UK MAGIC trial.29 However, a study in this thesis, based on real-world data, 
highlights that a more than expected proportion of the patients did not receive perioperative 
treatment in daily clinical practice. 
In the MAGIC-trial, the French FNCLCC/FFCD, the CRITICS I trial and a study in this thesis, 
discontinuation of perioperative chemotherapy was mostly observed after surgery.29-31 Therefore, 
research is necessary to elucidate the importance of the individual components of perioperative 
treatment. Although there is evidence that the omission of postoperative chemotherapy 
impairs oncologic outcomes in patients that did not receive neoadjuvant chemotherapy,32 
there is limited evidence for omission of postoperative chemotherapy in patients who received 
neoadjuvant chemotherapy.
There are several reasons that may explain why resectable gastric cancer patients do 
not receive perioperative treatment. Many patients with gastric cancer have an older age, 
comorbidities and suffer from malnutrition and weight loss which could preclude them from 
starting with the perioperative treatment regimen.33 After preoperative chemotherapy there 
could be several reasons for not undergoing surgery such as disease progression, toxicity from 
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chemotherapy, patient request and death.29,34 Moreover, gastric cancer surgery is associated 
with substantial morbidity and postoperative complications which could interfere with receiving 
postoperative treatment.29,35-37 As only a minority of the patients is actually capable of receiving 
the full regimen, one could argue about the appropriateness of the current perioperative 
chemotherapy as a reference regime for patients with resectable gastric cancer.
If gastric cancer patients are able to undergo perioperative chemotherapy the optimal timing 
of chemotherapy after surgery seems equivocal. On one hand, it seems rational to start with 
postoperative chemotherapy as early as possible to eradicate microscopic disease that may 
exist after neoadjuvant treatment and gastrectomy. For colon and breast cancer, early timing of 
postoperative chemotherapy has indeed proven to benefit oncological outcomes.38-41 However, 
these tumours have a relatively higher response rate to chemotherapy than gastric cancer, which 
may increase the importance for early timing of postoperative chemotherapy.42-44 On the other 
hand, a gastrectomy is considered as a major surgical procedure, and patients need time to 
recover from surgery, which may take up to several months depending on the postoperative 
course.45 Moreover, a study in this thesis showed that timing of the adjuvant component of 
perioperative treatment in gastric cancer was not associated with overall survival indicating 
that the early postoperative period may be safely used for recovery and optimising patients for 
the start of adjuvant chemotherapy
Nevertheless, results from a recent randomised controlled trial investigating different 
perioperative treatment regimens seem promising at first sight. This trial, the FLOT4-AIO trial, 
investigated whether perioperative chemotherapy with 5-Fluorouracil (5-FU), Leucovorin, 
Oxaliplatin and Docetaxel (FLOT regime) leads to improved survival compared with Epirubicin, 
Cisplatin and 5-FU/Capecitabine (ECF/ECX; MAGIC regime).46 In the ECF/ECX arm, 37% of patients 
completed the planned postoperative treatment, whereas 46% of the patients allocated to the 
FLOT arm completed postoperative treatment. Three-year overall survival was 48% for ECF/ECX 
and 57% for FLOT (P=0.01). Perioperative complications were similar across the 2 arms of the 
FLOT. The FLOT seems superior to ECF/ECX and may be the new standard of care in perioperative 
treatment of patients with adenocarcinomas of the stomach or gastro-oesophageal junction. 
However, it should be noted that the patients included in the aforementioned trials which are 
relatively healthy, may not represent all gastric cancer patients seen in daily clinical practice.47 
Age and treatment
Elderly patients represent a substantial proportion of the patients with oesophageal and gastric 
cancer. However, most treatment strategies and guidelines are based on clinical trials in which 
elderly patients are largely excluded.48 Population-based studies are therefore needed to bridge 
the gap of knowledge between clinical trials in selected patients and unselected patients in 
daily clinical practice.47,49
Population-based studies in this thesis showed that the proportion of patients that received 
treatment declined with age. For example, as shown by this thesis, elderly patients with 
potentially curable oesophageal cancer underwent less often curative treatment compared to 
their younger counterparts. Reasons to withhold patients from treatment with curative intent 
could be comorbidity, bad general health condition of the patients, short life expectancy and 
refusal by the patients and/or family.33,50 Nevertheless, cancer within the elderly is subject to 
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ageist stereotypes, with elderly cancer patients considered as frail and by some not as likely to 
recover as younger patients with cancer.51 However, elderly patients may be very heterogeneous 
with respect to their underlying health status. Therefore, the use of biological age as opposed 
to chronological age is desirable in deciding on treatment.52
Medical specialists have to deal with elderly patients who are very heterogeneous with 
respect to their underlying health status. The variation in treatment between hospitals after 
adjustment for case-mix in this thesis shows the complexity of adequate selection of patients 
that will benefit from a specific treatment. Also shown by this thesis, older metastatic gastric 
cancer patients derived the same benefits from chemotherapy compared to their younger 
counterparts with regard to survival, but received chemotherapy far less often. Another 
study in this thesis demonstrated that elderly patients with oesophageal squamous cell 
carcinoma derived the same benefits, regarding survival, from definitive chemoradiotherapy 
as compared to chemoradiotherapy followed by surgery. Two randomised controlled trials 
support these findings. Results showed that patients with oesophageal cancer, especially 
squamous cell carcinoma, who are not fit enough to undergo surgery may benefit from definitive 
chemoradiotherapy which is regarded as a well-tolerated alternative.53-55 However, treatment 
efficacy and toxicity should be balanced especially when selecting treatment in older patients. 
The inclusion of geriatrics and geriatric assessment may provide additional opportunities for 
refinement of treatment selection in older patients.56-58
Methodological considerations
Study design
The studies in this thesis are of an observational design and based on real-world data. While 
randomised clinical trials are considered the gold standard in evaluating the efficacy of 
treatments, observational studies based on real-world data have the ability to provide a broader 
insight of how treatment may be applied in daily clinical practice. Especially for subsets of 
patients who do not meet the eligibility criteria from randomised controlled trials, like relatively 
unhealthy patients, observational studies are of paramount importance because it provide an 
unique insight into the use and effectiveness of treatment in daily practice. Nevertheless, bias 
due to confounding factors is an important issue in population-based observational studies 
and should be carefully considered when interpreting the results of the studies in this thesis. 
Selection bias
Selection bias was present in many studies included in this thesis. In these studies, baseline 
characteristics were different between groups as patients were grouped according to treatment 
based on clinical decisions. For example, patients treated with perioperative chemotherapy, 
preoperative chemotherapy or surgery alone differed for several patient and tumour 
characteristics such as age, cT stage and cN stage (chapter 6). We used propensity score matching 
to adjust for imbalances between treatment groups based on known and observed patients and 
tumour characteristics. However, even after propensity score matching, patients groups may 
still not be completely comparable and confounding due to non-randomised assignment may 
still exists. Moreover, one should consider the use of propensity score matching  if variables that 
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affected treatment assignment were imbalanced between treated and untreated subjects. In 
that case propensity score matching may increase imbalance and bias.59
Immortal time bias 
Some studies in this thesis have been exposed to immortal time bias (chapter 6 and 7). Immortal 
time bias arises when determination of a patient’s treatment status involves a delay or wait 
period during which follow-up time is accrued. In this period death can not occur as patients 
must have been alive to receive the treatment. This kind of bias can generate an illusion of 
treatment effectiveness and often occurs when studies compare against patients who did not 
underwent treatment. To minimise the immortal time bias we defined survival time as of a 
certain starting point. For example, overall survival was defined as of four months after surgery 
for all patients irrespective of adjuvant treatment (chapter 6). 
Stage migration
Stage migration should be taken into account when interpreting treatment and survival trends. 
Improved diagnostic techniques have led to the detection of smaller metastases that would have 
been missed in the earlier time period. Patients who previously might have been classified with 
non-metastasised disease may now have been classified with metastasised disease. Because 
of the migration of these patients, survival rates improve in each group even though no actual 
improvement has taken place. In chapter 11 survival improved for oesophageal cancer patients 
with and without metastasis. However, since survival of all patients combined also increased, 
stage migration can only partly explain the improved survival. Interestingly, in chapter 10 
survival remained stable for patients with metastatic gastric cancer despite improved diagnostic 
techniques and an increased use of systemic therapy. An explanation may be that the proportion 
of the more aggressive diffuse tumour type increased and the proportion of the more indolent 
intestinal tumour type decreased. 
Residual confounding
The studies that are described in this thesis are based on data from the Netherlands Cancer 
Registry. The data for studies in this thesis were collected independent of the research 
question. As a result, some information was lacking. For example, no information was available 
on performance status and nutritional status. So, we were only able to adjust for known and 
registered characteristics in our statistical analyses. However, even if we had all the information 
about known characteristics, there could still be unknown characteristics resulting in residual 
confounding.
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What does the future hold?
Since the last two decades, survival improved for patients with oesophageal cancer in the 
Netherlands, probably due to the introduction of neoadjuvant chemoradiotherapy and 
centralisation of surgery. With the increasing incidence of oesophageal adenocarcinoma, 
combined with improvements in survival, more patients will be subjected to long-term follow-
up and quality of life issues will become more important. Moreover, treatment for oesophageal 
adenocarcinoma and oesophageal squamous cell carcinoma will further diverge. The distinction 
of these two subtypes by TNM-8 for tumour staging may support this expectation together 
with a different treatment response to neoadjuvant chemoradiotherapy, a different aetiology, 
pathogenesis and different molecular characters.  
Neoadjuvant chemoradiotherapy followed by surgery is the preferred treatment for 
resectable oesophageal cancer in the Netherlands. Chemoradiotherapy appears to be an 
effective preoperative treatment especially for oesophageal squamous cell carcinoma as 
these patients show excellent histological responses associated with radiotherapy.60 Moreover, 
results from the CROSS trial showed that 49% of the patients with oesophageal squamous 
cell carcinoma compared to 23% of the patients with oesophageal adenocarcinoma had a 
pathological complete response after chemoradiotherapy.61 These findings raise the question 
whether or not an oesophagectomy following chemoradiotherapy should be performed for 
these patients as an oesophagectomy is associated with severe postoperative morbidity and a 
substantial impact on the quality of life.62-64 Therefore, the SANO trial, which is a phase III trial, 
will investigate neoadjuvant chemoradiotherapy plus surgery versus active surveillance after 
chemoradiotherapy for clinically complete responders  with oesophageal cancer.
Trends in survival of gastric cancer may be explained by the differential response to treatment 
according to the Laurén classification and changes in the distribution of subgroups within this 
classification over time. According to the Laurén classification gastric adenocarcinoma can be 
subdivided in two major histological subtypes; the intestinal and diffuse tumour type.65 The 
diffuse type is considered as more aggressive with a worse prognosis compared to the intestinal 
type. The studies in this thesis did not incorporate the Laurén classification as this information 
was not available in the Netherlands Cancer Registry at time of performing these studies. The 
Laurén classification is one of the factors that may support individualised treatment for gastric 
cancer, which is increasingly gaining attention in the scientific field. Moreover, trends in survival 
of gastric cancer may be explained by changes in the distribution of subgroups within the 
Laurén classification. Future studies should investigate trends and the effect of treatment among 
patients with gastric cancer according to the Laurén classification.
Survival for oesophageal and gastric cancer may further improve by minimising variation 
in curative treatment between hospitals for patients with oesophageal and gastric cancer. 
Therefore, regional expert MDT meetings with involvement of experienced specialists may 
improve treatment selection for patients with oesophageal and gastric cancer, for example 
by using video conferencing. However, studies that directly link the organisation of MDTs to 
variation between hospitals are lacking. Moreover, there is a lack of knowledge on amendable 
factors, such as behavioural and other organisational aspects, that influence variation in 
treatment decision. Therefore, a recently started project, funded by the Dutch Cancer Society, 
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will attempt to identify these factors. This project will use qualitative and quantitative methods 
to in-depth assess which factors influence the probability that a patient is treated with curative 
intent. In addition, the effect of reducing variation in treatment on survival, health-related quality 
of life and health economics will be assessed. More understanding and insight in these factors 
will aid patients and physicians in their treatment decision.
Many gastric cancer patients that are eligible for perioperative treatment do not receive 
the adjuvant component of perioperative treatment or they do not receive chemotherapy at 
all in addition to surgery. Future population-based studies should investigate why patients do 
not undergo chemotherapy at all or why they fail to undergo adjuvant treatment in clinical 
practice. These information may aid to assess the feasibility and importance of the individual 
components of perioperative chemotherapy. The CRITICS-II trial will hopefully evaluate 
three different neoadjuvant strategies: chemotherapy, chemoradiotherapy and combination 
chemotherapy and chemoradiotherapy. Furthermore, as of 2015 more information is registered 
in the Netherlands Cancer Registry for patients with oesophageal and gastric cancer, for example 
the type of systemic treatment, number of cycles received, response on chemotherapy, and 
reasons for not undergoing surgery or chemotherapy. This information will shed some more light 
on the use, feasibility and importance of the individual components of perioperative treatment 
for patients with gastric cancer.
Palliative treatment of oesophageal and gastric cancer remains a challenge for clinicians. 
The optimal therapeutic approach for patients with metastatic oesophageal and gastric cancer 
is not well defined. Moreover, about 40% of the patients have a metastatic disease at time of 
diagnosis. Therefore, a project started aiming to investigate the currently used palliative care 
modalities and the association with survival and toxicity in a population-based setting among 
patients with metastasised oesophageal and gastric cancer. 
Concluding remarks
The studies in this thesis aimed to give more insight in the provided care and outcomes for 
patients with oesophageal and gastric cancer in daily clinical practice. Survival improved 
for patients with oesophageal cancer the last 26 years, probably due to the introduction of 
neoadjuvant chemoradiotherapy and centralisation of surgery. Survival of patients with gastric 
cancer improved as well in the period after centralisation of surgery. Nevertheless, still a more 
than expected proportion of patients with resectable gastric cancer do not receive perioperative 
chemotherapy. The large variation between hospitals of diagnosis in curative treatment rates 
suggest that there is room for further improvement in survival. Moreover, it is highly desirable 
to move from a ‘one-size-fits all’ approach to a more tailored MDT based treatment approach for 
the individual patient with maximisation of treatment efficacy and minimisation of treatment-
related morbidity and mortality. 
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   218 20-3-2018   22:26:24
12
219Discussion and future perspectives |
References
1.  Strong VE. Gastric Cancer: Principles and 
Practice, 2015ed.: Springer International 
Publishing.
2.  Anderson O, Ni Z, Moller H, Coupland VH, 
Davies EA, Allum WH, Hanna GB. Hospital 
volume and survival in oesophagectomy 
and gastrectomy for cancer, 2011. Eur J 
Cancer;47:2408-2414.
3.  Jensen LS, Nielsen H, Mortensen PB, Pilegaard 
HK, Johnsen SP. Enforcing centralization for 
gastric cancer in Denmark, 2010. Eur J Surg 
Oncol;36 Suppl 1:S50-54.
4.  Lemmens VE, Bosscha K, van der Schelling 
G, Brenninkmeijer S, Coebergh JW, de Hingh 
IH. Improving outcome for patients with 
pancreatic cancer through centralization, 
2011. Br J Surg;98:1455-1462.
5.  van de Poll-Franse LV, Lemmens VE, 
Roukema JA, Coebergh JW, Nieuwenhuijzen 
GA. Impact of concentration of oesophageal 
and gastric cardia cancer surgery on long-
term population-based survival, 2011. Br J 
Surg;98:956-963.
6.  Luft HS, Hunt SS, Maerki SC. The volume-
outcome relationship: practice-makes-
perfect or selective-referral patterns?, 1987. 
Health Serv Res;22:157-182.
7.  Ghaferi AA, Birkmeyer JD, Dimick JB. Hospital 
volume and failure to rescue with high-risk 
surgery, 2011. Med Care;49:1076-1081.
8.  Needleman J, Buerhaus P, Mattke S, Stewart 
M, Zelevinsky K. Nurse-staffing levels and 
the quality of care in hospitals, 2002. N Engl 
J Med;346:1715-1722.
9.  Birkmeyer JD, Sun Y, Goldfaden A, Birkmeyer 
NJ, Stukel TA. Volume and process of 
care in high-risk cancer surgery, 2006. 
Cancer;106:2476-2481.
10.  van Vliet EP, Hermans JJ, De Wever W, 
Eijkemans MJ, Steyerberg EW, Faasse C, van 
Helmond EP, de Leeuw AM, Sikkenk AC, de 
Vries AR, de Vries EH, Kuipers EJ, Siersema PD. 
Radiologist experience and CT examination 
quality determine metastasis detection in 
patients with esophageal or gastric cardia 
cancer, 2008. Eur Radiol;18:2475-2484.
11.  Bilimoria KY, Talamonti MS, Wayne JD, 
Tomlinson JS, Stewart AK, Winchester DP, 
Ko CY, Bentrem DJ. Effect of hospital type 
and volume on lymph node evaluation for 
gastric and pancreatic cancer, 2008. Arch 
Surg;143:671-678; discussion 678.
12.  Coupland VH, Lagergren J, Luchtenborg 
M, Jack RH, Allum W, Holmberg L, Hanna 
GB, Pearce N, Moller H. Hospital volume, 
proportion resected and mortality 
from oesophageal and gastric cancer: a 
population-based study in England, 2004-
2008, 2013. Gut;62:961-966.
13.  Wouters MW, Karim-Kos HE, le Cessie 
S, Wijnhoven BP, Stassen LP, Steup WH, 
Tilanus HW, Tollenaar RA. Centralization 
of esophageal cancer surgery: does it 
improve clinical outcome?, 2009. Ann Surg 
Oncol;16:1789-1798.
14.  Boddy AP, Williamson JM, Vipond MN. The 
effect of centralisation on the outcomes of 
oesophagogastric surgery--a fifteen year 
audit, 2012. Int J Surg;10:360-363.
15.  Gooiker GA, Lemmens VE, Besselink MG, 
Busch OR, Bonsing BA, Molenaar IQ, Tollenaar 
RA, de Hingh IH, Wouters MW. Impact of 
centralization of pancreatic cancer surgery 
on resection rates and survival, 2014. Br J 
Surg;101:1000-1005.
16. van Erning FN, van Steenbergen LN, van 
den Broek WT, Rutten HJ, Lemmens VE. No 
difference between lowest and highest 
volume hospitals in outcome after colorectal 
cancer surgery in the southern Netherlands, 
2013. Eur J Surg Oncol;39:1199-1206.
17.  Davies AR, Deans DA, Penman I, Plevris 
JN, Fletcher J, Wall L, Phillips H, Gilmour H, 
Patel D, de Beaux A, Paterson-Brown S. The 
multidisciplinary team meeting improves 
staging accuracy and treatment selection 
for gastro-esophageal cancer, 2006. Dis 
Esophagus;19:496-503.
18.  Du CZ, Li J, Cai Y, Sun YS, Xue WC, Gu J. 
Effect of multidisciplinary team 
treatment on outcomes of patients with 
gastrointestinal malignancy, 2011. World J 
Gastroenterol;17:2013-2018.
19.  van Hagen P, Spaander MC, van der Gaast 
A, van Rij CM, Tilanus HW, van Lanschot JJ, 
Wijnhoven BP. Impact of a multidisciplinary 
tumour board meeting for upper-GI 
malignancies on clinical decision making: 
a prospective cohort study, 2013. Int J Clin 
Oncol;18:214-219.
20.  Chadwick G, Groene O, Hoare J, Hardwick 
RH, Riley S, Crosby TD, Hanna GB, Cromwell 
DA. A population-based, retrospective, 
cohort study of esophageal cancer missed 
at endoscopy, 2014. Endoscopy;46:553-560.
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   219 20-3-2018   22:26:25
220 Chapter 12|
12
21.  Yalamarthi S, Witherspoon P, McCole D, 
Auld CD. Missed diagnoses in patients 
with upper gastrointestinal cancers, 2004. 
Endoscopy;36:874-879.
22.  Fitzgerald RC, di Pietro M, Ragunath K, Ang 
Y, Kang JY, Watson P, Trudgill N, Patel P, Kaye 
PV, Sanders S, O'Donovan M, Bird-Lieberman 
E, Bhandari P, Jankowski JA, Attwood S, 
Parsons SL, Loft D, Lagergren J, Moayyedi 
P, Lyratzopoulos G, de Caestecker J. British 
Society of Gastroenterology guidelines on 
the diagnosis and management of Barrett's 
oesophagus, 2014. Gut;63:7-42.
23.  Gupta N, Gaddam S, Wani SB, Bansal A, 
Rastogi A, Sharma P. Longer inspection 
time is associated with increased detection 
of high-grade dysplasia and esophageal 
adenocarcinoma in Barrett's esophagus, 
2012. Gastrointest Endosc;76:531-538.
24.  Bhat SK, McManus DT, Coleman HG, 
Johnston BT, Cardwell CR, McMenamin U, 
Bannon F, Hicks B, Kennedy G, Gavin AT, 
Murray LJ. Oesophageal adenocarcinoma 
and prior diagnosis of Barrett's oesophagus: 
a population-based study, 2015. Gut;64:20-
25.
25.  Bird-Lieberman EL, Dunn JM, Coleman HG, 
Lao-Sirieix P, Oukrif D, Moore CE, Varghese S, 
Johnston BT, Arthur K, McManus DT, Novelli 
MR, O'Donovan M, Cardwell CR, Lovat 
LB, Murray LJ, Fitzgerald RC. Population-
based study reveals new risk-stratification 
biomarker panel for Barrett's esophagus, 
2012. Gastroenterology;143:927-935.e923.
26.  Martinez P, Timmer MR, Lau CT, Calpe S, 
Sancho-Serra Mdel C, Straub D, Baker AM, 
Meijer SL, Kate FJ, Mallant-Hent RC, Naber 
AH, van Oijen AH, Baak LC, Scholten P, 
Bohmer CJ, Fockens P, Bergman JJ, Maley 
CC, Graham TA, Krishnadath KK. Dynamic 
clonal equilibrium and predetermined 
cancer risk in Barrett's oesophagus, 2016. 
Nat Commun;7:12158.
27.  Stachler MD, Taylor-Weiner A, Peng S, 
McKenna A, Agoston AT, Odze RD, Davison 
JM, Nason KS, Loda M, Leshchiner I, Stewart 
C, Stojanov P, Seepo S, Lawrence MS, Ferrer-
Torres D, Lin J, Chang AC, Gabriel SB, Lander 
ES, Beer DG. Paired exome analysis of 
Barrett's esophagus and adenocarcinoma, 
2015;47:1047-1055.
28.  Nelen SD, Verhoeven RH, Lemmens VE, de 
Wilt JH, Bosscha K. Increasing survival gap 
between young and elderly gastric cancer 
patients, 2017. Gastric Cancer.
29.  Cunningham D, Allum WH, Stenning SP, 
Thompson JN, Van de Velde CJ, Nicolson 
M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, 
Smith DB, Langley RE, Verma M, Weeden 
S, Chua YJ, Participants MT. Perioperative 
chemotherapy versus surgery alone for 
resectable gastroesophageal cancer, 2006. 
N Engl J Med;355:11-20.
30.  Verheij M, Jansen E, Cats A. A multicenter 
randomized phase III trial of neo-adjuvant 
chemotherapy followed by surgery 
and chemotherapy or by surgery and 
chemoradiotherapy in resectable gastric 
cancer: First results from the CRITICS study., 
2016, ed.  Oral presentation at ASCO 2016 
Annual Meeting; June 3-7, 2016; Chicago. 
Abstract no. 4000.
31.  Ychou M, Boige V, Pignon JP, Conroy T, Bouche 
O, Lebreton G, Ducourtieux M, Bedenne L, 
Fabre JM, Saint-Aubert B, Geneve J, Lasser 
P, Rougier P. Perioperative chemotherapy 
compared with surgery alone for resectable 
gastroesophageal adenocarcinoma: an 
FNCLCC and FFCD multicenter phase III trial, 
2011. J Clin Oncol;29:1715-1721.
32.  Jin LX, Sanford DE, Squires MH, 3rd, Moses 
LE, Yan Y, Poultsides GA, Votanopoulos KI, 
Weber SM, Bloomston M, Pawlik TM, Hawkins 
WG, Linehan DC, Schmidt C, Worhunsky 
DJ, Acher AW, Cardona K, Cho CS, Kooby 
DA, Levine EA, Winslow E, Saunders N, 
Spolverato G, Colditz GA, Maithel SK, Fields 
RC. Interaction of Postoperative Morbidity 
and Receipt of Adjuvant Therapy on Long-
Term Survival After Resection for Gastric 
Adenocarcinoma: Results From the U.S. 
Gastric Cancer Collaborative, 2016. Ann Surg 
Oncol;23:2398-2408.
33.  Deans DA, Tan BH, Wigmore SJ, Ross JA, de 
Beaux AC, Paterson-Brown S, Fearon KC. The 
influence of systemic inflammation, dietary 
intake and stage of disease on rate of weight 
loss in patients with gastro-oesophageal 
cancer, 2009. Br J Cancer;100:63-69.
34.  Reece-Smith AM, Saha S, Cunnell ML, 
Hameed K, Bessell EM, Duffy JP, Madhusudan 
S, Parsons SL. MAGIC in practice: experience 
of peri-operative ECF/X chemotherapy in 
gastro-esophageal adenocarcinomas, 2012. 
J Surg Oncol;106:748-752.
35.  Luc G, Gersen-Cherdieu H, Degrandi O, 
Terrebonne E, Chiche L, Collet D. Impact of 
postoperative chemotherapy in patients 
with locally advanced gastroesophageal 
adenocarcinoma treated with perioperative 
chemotherapy strategy, 2015. Am J 
Surg;210:15-23.
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   220 20-3-2018   22:26:25
12
221Discussion and future perspectives |
36.  Bartlett EK, Roses RE, Kelz RR, Drebin JA, 
Fraker DL, Karakousis GC. Morbidity and 
mortality after total gastrectomy for gastric 
malignancy using the American College 
of Surgeons National Surgical Quality 
Improvement Program database, 2014. 
Surgery;156:298-304.
37.  Luc G, Durand M, Chiche L, Collet D. Major 
post-operative complications predict 
long-term survival after esophagectomy 
in patients with adenocarcinoma of the 
esophagus, 2015. World J Surg;39:216-222.
38.  Czaykowski PM, Gill S, Kennecke HF, Gordon 
VL, Turner D. Adjuvant chemotherapy for 
stage III colon cancer: does timing matter?, 
2011. Dis Colon Rectum;54:1082-1089.
39.  Hershman D, Hall MJ, Wang X, Jacobson 
JS, McBride R, Grann VR, Neugut AI. Timing 
of adjuvant chemotherapy initiation after 
surgery for stage III colon cancer, 2006. 
Cancer;107:2581-2588.
40.  Lohrisch C, Paltiel C, Gelmon K, Speers C, 
Taylor S, Barnett J, Olivotto IA. Impact on 
survival of time from definitive surgery 
to initiation of adjuvant chemotherapy 
for early-stage breast cancer, 2006. J Clin 
Oncol;24:4888-4894.
41.  Bos AC, van Erning FN, van Gestel YR, 
Creemers GJ, Punt CJ, van Oijen MG, 
Lemmens VE. Timing of adjuvant 
chemotherapy and its relation to survival 
among patients with stage III colon cancer, 
2015. Eur J Cancer;51:2553-2561.
42.  Adlard JW, Richman SD, Seymour MT, Quirke 
P. Prediction of the response of colorectal 
cancer to systemic therapy, 2002. Lancet 
Oncol;3:75-82.
43.  Fisher B, Gunduz N, Saffer EA. Influence of 
the interval between primary tumor removal 
and chemotherapy on kinetics and growth 
of metastases, 1983. Cancer Res;43:1488-
1492.
44.  Mansour JC, Tang L, Shah M, Bentrem D, 
Klimstra DS, Gonen M, Kelsen DP, Brennan 
MF, Coit DG. Does graded histologic response 
after neoadjuvant chemotherapy predict 
survival for completely resected gastric 
cancer?, 2007. Ann Surg Oncol;14:3412-3418.
45.  Brenkman HJ, Ruurda JP, Verhoeven RH, van 
Hillegersberg R. Safety and feasibility of 
minimally invasive gastrectomy during the 
early introduction in the Netherlands: short-
term oncological outcomes comparable to 
open gastrectomy, 2017. Gastric Cancer.
46.  Al-Batran S, Homann N, Schmalemberg H. 
Perioperative chemotherapy with docetaxel, 
oxaliplatin, and fluorouracil/leucovorin 
(FLOT) versus epirubicin, cisplatin, and 
fluorouracil or capecitabine (ECF/ECX) for 
resectable gastric or gastroesophageal 
junction (GEJ) adenocarcinoma (FLOT4-
AIO): a multicenter, randomized phase 3 trial, 
2017, ed.  ASCO 2017 Annual Meeting; June 
2-6, 2017; Chicago. Abstract no. 4004.
47.  Booth CM, Tannock IF. Randomised 
controlled trials and population-based 
observational research: partners in the 
evolution of medical evidence, 2014. Br J 
Cancer;110:551-555.
48.  Rothwell PM. External validity of randomised 
controlled trials: "to whom do the results of 
this trial apply?", 2005. Lancet;365:82-93.
49.  Booth CM, Mackillop WJ. Translating new 
medical therapies into societal benefit: the 
role of population-based outcome studies, 
2008. JAMA;300:2177-2179.
50.  van Erning FN, Janssen-Heijnen ML, 
Creemers GJ, Pruijt HF, Maas HA, Lemmens 
VE. Deciding on adjuvant chemotherapy for 
elderly patients with stage III colon cancer: 
a qualitative insight into the perspectives of 
surgeons and medical oncologists, 2015. J 
Geriatr Oncol;6:219-224.
51.  Swaminathan D, Swaminathan V. Geriatric 
oncology: problems with under-treatment 
within this population, 2015. Cancer Biol 
Med;12:275-283.
52.  Given B, Given CW. Older adults and cancer 
treatment, 2008. Cancer;113:3505-3511.
53.  Lordick F, Mariette C, Haustermans K, 
Obermannova R, Arnold D, Committee EG. 
Oesophageal cancer: ESMO Clinical Practice 
Guidelines for diagnosis, treatment and 
follow-up, 2016. Ann Oncol;27:v50-v57.
54.  Bedenne L, Michel P, Bouche O, Milan C, 
Mariette C, Conroy T, Pezet D, Roullet B, Seitz 
JF, Herr JP, Paillot B, Arveux P, Bonnetain F, 
Binquet C. Chemoradiation followed by 
surgery compared with chemoradiation 
alone in squamous cancer of the esophagus: 
FFCD 9102, 2007. J Clin Oncol;25:1160-1168.
55.  Stahl M, Stuschke M, Lehmann N, Meyer 
HJ, Walz MK, Seeber S, Klump B, Budach W, 
Teichmann R, Schmitt M, Schmitt G, Franke 
C, Wilke H. Chemoradiation with and without 
surgery in patients with locally advanced 
squamous cell carcinoma of the esophagus, 
2005. J Clin Oncol;23:2310-2317.
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   221 20-3-2018   22:26:25
222 Chapter 12|
12
56.  Decoster L, Kenis C, Van Puyvelde K, 
Flamaing J, Conings G, De Greve J, Mets T, 
Milisen K, Lobelle JP, Wildiers H. The influence 
of clinical assessment (including age) and 
geriatric assessment on treatment decisions 
in older patients with cancer, 2013. J Geriatr 
Oncol;4:235-241.
57.  Kenis C, Bron D, Libert Y, Decoster L, Van 
Puyvelde K, Scalliet P, Cornette P, Pepersack 
T, Luce S, Langenaeken C, Rasschaert M, 
Allepaerts S, Van Rijswijk R, Milisen K, 
Flamaing J, Lobelle JP, Wildiers H. Relevance 
of a systematic geriatric screening and 
assessment in older patients with cancer: 
results of a prospective multicentric study, 
2013. Ann Oncol;24:1306-1312.
58.  Papamichael D, Audisio RA, Glimelius B, de 
Gramont A, Glynne-Jones R, Haller D, Kohne 
CH, Rostoft S, Lemmens V, Mitry E, Rutten 
H, Sargent D, Sastre J, Seymour M, Starling 
N, Van Cutsem E, Aapro M. Treatment 
of colorectal cancer in older patients: 
International Society of Geriatric Oncology 
(SIOG) consensus recommendations 2013, 
2015. Ann Oncol;26:463-476.
59.  King G, Nielsen R. Why Propensity Scores 
Should Not Be Used for Matching, Working 
Paper, ed.
60.  Lagergren J, Smyth E, Cunningham D, 
Lagergren P. Oesophageal cancer, 2017. 
Lancet.
61.  Shapiro J, van Lanschot JJ, Hulshof MC, 
van Hagen P, van Berge Henegouwen 
MI, Wijnhoven BP, van Laarhoven HW, 
Nieuwenhuijzen GA, Hospers GA, 
Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch 
OR, Ten Kate FJ, Creemers GJ, Punt CJ, Plukker 
JT, Verheul HM, Bilgen EJ, van Dekken H, 
van der Sangen MJ, Rozema T, Biermann K, 
Beukema JC, Piet AH, van Rij CM, Reinders JG, 
Tilanus HW, Steyerberg EW, van der Gaast A, 
group Cs. Neoadjuvant chemoradiotherapy 
plus surgery versus surgery alone for 
oesophageal or junctional cancer (CROSS): 
long-term results of a randomised controlled 
trial, 2015. Lancet Oncol;16:1090-1098.
62.  Backemar L, Wikman A, Djarv T, Johar A, 
Lagergren P. Co-morbidity after oesophageal 
cancer surgery and recovery of health-related 
quality of life, 2016. Br J Surg;103:1665-1675.
63.  Schandl A, Lagergren J, Johar A, Lagergren 
P. Health-related quality of life 10 years after 
oesophageal cancer surgery, 2016. Eur J 
Cancer;69:43-50.
64.  Baba Y, Yoshida N, Shigaki H, Iwatsuki M, 
Miyamoto Y, Sakamoto Y, Watanabe M, 
Baba H. Prognostic Impact of Postoperative 
Complications in 502 Patients With 
Surgically Resected Esophageal Squamous 
Cell Carcinoma: A Retrospective Single-
institution Study, 2016. Ann Surg;264:305-
311.
65.  Lauren P. The Two Histological Main Types 
of Gastric Carcinoma: Diffuse and So-Called 
Intestinal-Type Carcinoma. An Attempt at 
a Histo-Clinical Classification, 1965. Acta 
Pathol Microbiol Scand;64:31-49.
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   222 20-3-2018   22:26:25
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   223 20-3-2018   22:26:25
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   224 20-3-2018   22:26:25
Summary
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   225 20-3-2018   22:26:31
Binnenwerk proefschrift Margreet tijdelijk aangepast.indd   226 20-3-2018   22:26:31
227Summary |
Summary
This thesis aims to optimise care and outcomes for patients with oesophageal and gastric cancer 
in daily clinical practice. 
The thesis starts by assessing the magnitude of ‘missed’ cancers among patients with a Barrett’s 
oesophagus who progress to oesophageal adenocarcinoma or high-grade dysplasia (chapter 
2). For this study patients from the Northern Ireland Barrett’s Oesophagus Register diagnosed 
between 1993 and 2010 were linked to the Northern Ireland Cancer Registry to identify patients 
who developed oesophageal adenocarcinoma or high-grade dysplasia. A ‘missed’ case was 
defined as a diagnosis within 3-12 months following Barrett’s oesophagus diagnosis. Results 
demonstrate that oesophageal adenocarcinoma was ‘missed’ at index Barrett’s oesophagus 
endoscopy in up to 13% of all Barrett’s oesophagus patients and 9% of non-dysplastic Barrett’s 
oesophagus patients who progressed, which was significant but substantially lower than 
previously reported estimates.
Although oesophageal and gastric cancer surgery is centralised in the Netherlands, the 
disease is often diagnosed in hospitals which do not perform these procedures. Therefore, 
the objective of the next two studies is to investigate the influence of hospital of diagnosis on 
the probability of receiving curative treatment and its impact on survival among patients with 
oesophageal and gastric cancer (chapter 3 and 4). For these studies patients with potentially 
curable oesophageal or gastric cancer tumours diagnosed between 2005 and 2013 were 
selected from the Netherlands Cancer Registry. Curative treatment was defined as receiving 
surgery with or without neoadjuvant chemoradiotherapy, definitive chemoradiotherapy or an 
endoscopic tumour resection for oesophageal cancer. For gastric cancer patients, surgery was 
considered as curative treatment. The probability to receive curative treatment was defined as 
the proportion of patients diagnosed in a hospital that eventually underwent curative treatment, 
regardless of the hospital in which those treatments were undertaken. After adjustment, the 
proportion of oesophageal cancer patients receiving curative treatment ranged from 50% to 
82% and from 48% to 78% for patients with gastric cancer in 2010-2013, depending on hospital 
of diagnosis. Moreover, patients diagnosed in hospitals with a low probability of undergoing 
curative treatment had a worse overall survival in the period 2010-2013 (oesophageal cancer 
HR=1.15 95%CI 1.07-1.24; gastric cancer HR=1.21; 95%CI 1.04-1.41). These results indicates 
that treatment decision-making in oesophageal and gastric cancer patients may be improved.
The next study evaluates the impact of centralising gastric cancer surgery in the Netherlands 
for all gastric cancer patients (chapter 5). For this study all patients diagnosed in the Netherlands 
between 2009-2011 and 2013-2015 with gastric adenocarcinoma were included. Outcomes in 
the period before centralisation (2009-2011) were compared to the period after centralisation 
(2013-2015).Resection rates slightly increased from 38% pre-centralisation to 41% post-
centralisation (P=0.026). Postoperative 90-day mortality rates dropped from 11% to 7% during 
the time periods (P<0.01). Two-year overall survival rates increased from 55% to 58% for patients 
who had surgery (P=0.03) and from 27% to 30% for all patients (P=0.01), whereas the median 
overall survival of non-surgically treated patients remained stable (P=0.46). Improvements 
remained after adjustment for case-mix however, adjustment for hospital volume attenuated 
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this association for surgically treated patients. Results demonstrated a reduced postoperative 
mortality for surgically treated patients and an improved survival for all gastric cancer patients in 
the period after centralisation. Although other mechanisms may play a role, the fact that survival 
improved for both surgically treated patients and for all patients irrespective of treatment, but 
not among patients who did not undergo surgery, suggests that advances in (peri-)operative 
treatment and factors closely related to surgical treatment have made an important contribution 
to these improvements. Moreover, period of resection was correlated with hospital volume for 
patients who underwent surgery.
In several European countries perioperative chemotherapy for resectable gastric cancer is 
recommended based on the results of the UK MAGIC trial. However, little is known about its use 
in daily clinical practice. Therefore, the aim of chapter 6 is to examine the use of perioperative 
treatment and its impact on survival in the Netherlands. For this study patients diagnosed 
with potentially resectable gastric cancer between 2006 and 2014 were selected from the 
Netherlands Cancer Registry. Results revealed that still 74% of the patients was not treated 
with perioperative treatment in 2014. In addition, postoperative treatment was not administered 
to 43% of the patients who started with preoperative chemotherapy followed by surgery in 
2014. Cox regression analysis showed a better overall survival for patients who underwent 
perioperative treatment compared to patients who underwent preoperative treatment only 
(HR=0.80 95%CI 0.70-0.93; propensity matched sample: HR=0.84 95%CI 0.71-0.99). However, 
even after propensity score matching, patient groups may not be completely comparable and 
confounding due to nonrandomised assignment still exists.
If gastric cancer patients are able to undergo perioperative chemotherapy the optimal timing 
of chemotherapy after surgery seems equivocal. Therefore, the next study assesses the influence 
of timing of adjuvant chemotherapy on overall survival in patients receiving perioperative 
chemotherapy for gastric cancer (chapter 7). Data from patients undergoing perioperative 
chemotherapy for gastric adenocarcinoma in the period 2010-2014 were extracted from the 
Netherlands Cancer Registry. Half of the patients started within 6 weeks after surgery with 
chemotherapy (Interquartile range 4.9 – 7.7 weeks). A delayed start of adjuvant chemotherapy 
was associated with a longer hospital stay. After adjustment for case-mix factors, survival 
was comparable between patients who started within 6 weeks after surgery and patients 
who started between 6-8 and >8 weeks after surgery. These results suggest that the early 
postoperative period may be safely used for recovery and optimizing patients for the start of 
adjuvant chemotherapy.
As stated previously in this thesis many patients with oesophageal and gastric cancer may be 
unfit for surgery because of severe fragility, comorbidity and a poor nutritional status. Definitive 
chemoradiotherapy is considered to be a good alternative in patients with oesophageal cancer 
not eligible for oesophagectomy. However, little is known about the impact of comorbidity 
on the choice of curative treatment, i.e. definitive chemoradiotherapy or neoadjuvant 
chemoradiotherapy followed by surgery. Therefore, the aim of chapter 8 is to assess the 
effect of age and comorbidity on the type of curative treatment in patients with oesophageal 
cancer. All patients with potentially curable oesophageal cancer treated with definitive 
chemoradiotherapy or neoadjuvant chemoradiotherapy followed by surgery, diagnosed in 
the South East of the Netherlands between 2004 and 2014 were included. Having an older age 
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(≥ 75 years) and multiple comorbidities was associated with a higher probability to receive 
definitive chemoradiotherapy compared to neoadjuvant chemoradiotherapy and surgery. 
Survival was better for oesophageal adenocarcinoma patients who underwent neoadjuvant 
chemoradiotherapy followed by surgery instead of definitive chemoradiotherapy despite the 
number of comorbidities, whereas survival was comparable for patients with oesophageal 
squamous cell carcinoma having multiple comorbidities or being 75 years or older. 
Elderly patients represent a substantial proportion of the patients with oesophageal and 
gastric cancer. However, most treatment strategies and guidelines are based on clinical trials 
in which elderly patients are largely excluded. Therefore, the next study investigates treatment 
patterns and the impact of treatment strategies on overall survival among elderly patients 
(≥ 75 years) with potentially curable oesophageal cancer (chapter 9). Results revealed an 
increased use of definitive chemoradiotherapy in elderly patients from 1.9% to 20% as well 
as in younger patients from 5.2% to 17% in the period 2003-2013. Approximately 16% of the 
elderly patients underwent surgery and this proportion remained stable over time, whereas the 
use of surgery increased from 60% to 67% for young patients. Due to the increase in definitive 
chemoradiotherapy, treatment with curative intent doubled among the elderly patients from 
17% in 2003 to 37% in 2013. However, the proportion of younger patients receiving curative 
treatment was still significantly higher in 2013 (84%). After adjustment, survival was better for 
elderly patients with an adenocarcinoma who underwent neoadjuvant chemo(radio)therapy 
followed by surgery instead of definitive chemoradiotherapy, whereas survival was comparable 
for patients with a squamous cell carcinoma. 
Many patients with oesophageal and gastric cancer have metastatic disease at time of 
diagnosis (approximately 40%). The study in chapter 10 aims to assess trends in treatment 
and survival of young (< 70 years) and older (≥ 70 years) patients with metastasised gastric 
cancer diagnosed between 1989 and 2013. Palliative resection rates significantly decreased in 
young and older patients from 25% to 3% and from 26% to 5%, respectively, whereas the use of 
chemotherapy increased from 15% to 51% for young patients and from 2% to 21% of the older 
patients. Treatment among younger patients increased from 42% to 60% due to the increase in 
chemotherapy, while the proportion of older patients treated with chemotherapy, surgery or 
both remained stable (approximately 30%). Despite the changes in treatment, survival remained 
stable over time for all patients, even after adjustment for several clinicopathological factors.
Treatment for oesophageal cancer has evolved due to developments including the 
centralisation of surgery and introduction of neoadjuvant chemoradiotherapy. The last study 
(chapter 11) in this thesis evaluates trends in stage distribution, treatment and survival of 
oesophageal cancer patients between 1989 and 2014 in the Netherlands. Results demonstrated 
that 5-year overall survival rates more than doubled in the last 26 years from 8% to 22% for 
all patients particularly from 2005 onwards. Furthermore, the percentage of patients with an 
unknown tumour stage decreased from 34% to 10%, while the percentage of patients with 
a metastatic disease increased from 21% to 34%. Among the surgically treated patients 32% 
underwent a resection in a high-volume hospital (performing 20 or more procedures per year) 
in 2005 which increased to 92% in 2014. In addition, the use of neoadjuvant chemoradiotherapy 
increased for non-metastatic patients with an adenocarcinoma or squamous cell carcinoma from 
respectively 4.3% and 2.3% in 2000-2004 to 43% and 26% in 2010-2014.
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Inleiding
Kanker 
Door de naoorlogse geboortegolf, stijgende levensverwachting en veranderingen in leefstijl 
neemt het aantal nieuwe patiënten met kanker toe in Nederland. Kanker, ook wel een 
kwaadaardige tumor genoemd, is een ongecontroleerde deling van lichaamscellen. Per dag 
vinden miljoenen celdelingen plaats in ons lichaam. Hierbij kunnen kleine foutjes optreden. 
Deze foutjes worden normaal gesproken gerepareerd of beschadigde cellen worden opgeruimd 
door het afweersysteem. Indien dit niet gebeurd kan de cel ongecontroleerd gaan delen en 
ingroeien in omliggende weefsels. Soms zaaien ze uit naar andere delen van het lichaam. We 
noemen dat uitzaaiingen van kanker. 
In 2016 hebben ruim 108.000 mensen kanker gekregen in Nederland. Huidkanker is in 2016 
de meest voorkomende vorm van kanker bij mannen en vrouwen samen. Borstkanker is de meest 
voorkomende vorm van kanker bij vrouwen en prostaatkanker de meest voorkomende vorm 
van kanker bij mannen. Gelukkig is het aantal mensen dat kanker overleeft de afgelopen jaren 
aanzienlijk toegenomen. Door het eerder ontdekken van de kanker en betere behandelingen 
genezen er steeds meer mensen van kanker. 
Slokdarm- en maagkanker
Slokdarmkanker is momenteel de 8e meest voorkomende kankersoort onder mannen in 
Nederland. In 2016 kregen ruim 2.500 patiënten de diagnose slokdarmkanker, met name mannen 
in de leeftijdscategorie 60 tot 80 jaar. Het aantal mensen dat jaarlijks wordt gediagnosticeerd 
met slokdarmkanker neemt toe. De toename is vooral toe te schrijven aan een stijging van 
het adenocarcinoom, een vorm van slokdarmkanker die ontstaat als gevolg van overgewicht 
en reflux, oftewel het terugstromen van maagzuur in de slokdarm. In tegenstelling tot de 
stijging van het aantal patiënten met slokdarmkanker, is er een daling in het aantal patiënten 
dat jaarlijks gediagnosticeerd wordt met maagkanker. Deze daling heeft te maken met een 
lagere kans op besmetting met de Helicobacter pylori bacterie door verbeterde hygiëne en 
behandeling met antibiotica. De Helicobacter pylori bacterie kan in de maag overleven en 
leiden tot maagslijmvliesontsteking en maagkanker. Daarnaast wordt de afname in maagkanker 
gerelateerd aan de komst van de koelkast, waardoor minder gebruik wordt gemaakt van zout-
gerelateerde conserveringsmethoden. 
Een Barrett-slokdarm is het meest bekende voorstadium van slokdarmkanker. Bij mensen 
met een Barrett-slokdarm is het onderste deel van de slokdarm bekleed met ander weefsel dan 
normaal. Het weefsel is roze tot zalmkleurig vergelijkbaar met het weefsel van de maag. Ondanks 
dat de kans op slokdarmkanker hoger is voor patiënten met een Barrett-slokdarm, is de kans 
op het krijgen van deze ziekte klein. Minder dan vijf procent van de mensen met een Barrett-
slokdarm krijgt uiteindelijk slokdarmkanker. Het is onduidelijk waarom sommige mensen met 
een Barrett-slokdarm wel slokdarmkanker krijgen en anderen niet. Daarom worden patiënten 
met een Barrett-slokdarm regelmatig gecontroleerd middels endoscopie. Dat is een onderzoek, 
waarmee de arts de slokdarm en de maag aan de binnenkant kan bekijken. Tevens kunnen er 
stukjes weefsel worden weggenomen om te controleren op aanwezigheid van afwijkende, 
onrustige cellen.
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Bij diagnose zijn patiënten met slokdarm- of maagkanker gemiddeld 70 jaar oud. De 
behandeling gericht op genezing van slokdarm- en maagkanker bestaat doorgaans uit 
chemotherapie, radiotherapie (bestraling) of een operatie. Vaak wordt een combinatie van 
deze behandelingen gegeven. Bij patiënten met slokdarmkanker zonder uitzaaiingen wordt 
meestal gestart met een combinatie van chemotherapie en radiotherapie (chemoradiotherapie) 
gevolgd door een operatie. Patiënten met maagkanker krijgen doorgaans de aanbeveling om 
te starten met chemotherapie, gevolgd door een operatie en nogmaals chemotherapie. Helaas 
heeft ongeveer 40% van de patiënten al uitzaaiingen bij diagnose, waardoor genezing in veel 
gevallen niet meer mogelijk is. Deze patiënten kunnen vaak wel palliatief worden behandeld 
met chemotherapie, soms in combinatie met radiotherapie, om het leven te verlengen of om de 
kwaliteit van leven te optimaliseren. Zo’n palliatieve behandeling is afhankelijk van de conditie 
van de patiënt en de omvang van de ziekte. Indien patiënten niet meer in aanmerking komen 
voor palliatieve chemotherapie, kan er een stent worden geplaatst om de voedselpassage te 
waarborgen. 
Chirurgie maakt een belangrijk deel uit van de behandeling gericht op genezing van 
slokdarm- of maagkanker. Het gaat hierbij om complexe operaties met risico’s op complicaties 
en sterfte. Om met name de sterfte te verminderen en de overleving te verbeteren na deze 
complexe operaties, is men gestart met een proces van concentratie van deze chirurgische 
behandelingen. Dat wil zeggen dat alleen ziekenhuizen die minimaal twintig slokdarmkanker- 
of minimaal twintig maagkankeroperaties per jaar uitvoeren deze behandeling nog mogen 
uitvoeren. Dit betekent in de praktijk dat een deel van de patiënten met slokdarm- of maagkanker 
na het stellen van de diagnose doorverwezen moet worden naar een gespecialiseerd ziekenhuis 
voor een operatie.
Doel van dit proefschrift
Het onderzoek in dit proefschrift richt zich op verschillende veranderingen en uitdagingen 
in de diagnostisering en behandeling van patiënten met slokdarm- of maagkanker. De 
belangrijkste doelstellingen van dit proefschrift zijn als volgt: 
• Evalueren van zorg aan patiënten met een Barrett-slokdarm, waarbij de nadruk ligt op 
de kwaliteit van de endoscopische controle op verdere ontwikkeling van weefsel tot een 
kwaadaardige tumor.
• Bepalen wat de invloed is van het ziekenhuis van diagnose op de kans om een behandeling 
te krijgen, gericht op genezing voor patiënten met slokdarm- of maagkanker.
• Bekijken wat het effect is van concentratie van chirurgie in gespecialiseerde ziekenhuizen 
op de overleving van patiënten met maagkanker. 
• Bestuderen van trends in de behandeling en de invloed daarvan op de overleving voor 
specifieke groepen van patiënten met slokdarm- of maagkanker in de dagelijkse klinische 
praktijk.
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Onderzoeksgegevens
Om deze onderzoeksvragen te beantwoorden, heb ik gebruik gemaakt van de Nederlandse 
Kankerregistratie (NKR). Dat is een database met betrouwbare en objectieve gegevens van 
alle gevallen van kanker. Vanaf 1989 zijn de gegevens op landelijk niveau beschikbaar. De 
NKR wordt gebruikt voor wetenschappelijk onderzoek, maar ook voor het evalueren van 
bevolkingsonderzoeken en naleving van richtlijnen voor de behandeling en het ontwikkelen 
van beleid door zorginstellingen en de overheid. 
Belangrijkste bevindingen van dit proefschrift
Dit proefschrift start met een studie naar de kwaliteit van de endoscopische controle onder 
patiënten met een Barrett-slokdarm (hoofdstuk 2). Hiervoor is gebruik gemaakt van de 
Noord-Ierse kankerregistratie en een register met alle patiënten met een Barrett-slokdarm 
in Noord-Ierland. Deze twee datasets hebben we aan elkaar gekoppeld om te onderzoeken 
welke patiënten met een Barrett-slokdarm uiteindelijk slokdarmkanker hebben ontwikkeld. 
Vervolgens hebben we onderzocht hoeveel tijd er zat tussen de diagnose Barrett-slokdarm en de 
diagnose slokdarmkanker. Indien bij patiënten binnen drie tot twaalf maanden na de diagnose 
Barrett-slokdarm ook de diagnose slokdarmkanker werd gesteld, hebben we aangenomen dat 
de aanwezigheid van slokdarmkanker ten tijde van de diagnose Barrett-slokdarm is gemist. 
Uit de resultaten van deze studie blijkt dat bij 13% van de patiënten met een Barrett-
slokdarm die slokdarmkanker ontwikkelden de aanwezigheid van kwaadaardig tumorweefsel 
was gemist op het moment dat de diagnose Barrett-slokdarm werd gesteld. Dit percentage is 
relatief hoog, maar lager dan in eerdere studies is gevonden. Het is echter belangrijk om dit 
percentage te relativeren aangezien het hierbij gaat om 0,3% van alle patiënten die in Noord-
Ierland met een Barrett slokdarm zijn gediagnosticeerd in de periode 1993-2000. Het blijft een 
uitdaging om patiënten met een Barrett-slokdarm te identificeren die een hogere kans hebben 
op het ontwikkelen van slokdarmkanker. 
Door concentratie van slokdarm- en maagkankerchirurgie is het aantal ziekenhuizen waar 
een operatie wordt uitgevoerd gedaald, terwijl de diagnose in elk ziekenhuis kan worden 
gesteld. Dat betekent dat in de praktijk een toenemend aantal patiënten moet worden 
doorverwezen voor een operatie. In hoofdstuk 3 en 4 beschrijven we de resultaten van twee 
studies naar de invloed van het ziekenhuis van diagnose op de kans om een behandeling te 
krijgen gericht op genezing van slokdarm- en maagkanker. Voor deze studies selecteerden 
we patiënten uit de Nederlandse Kankerregistratie die gediagnosticeerd waren met niet-
uitgezaaide slokdarm- of maagkanker in de periode 2005 tot 2013. De resultaten van deze 
studies laten aanzienlijke verschillen zien tussen de ziekenhuizen van diagnose voor wat betreft 
de kans op een behandeling gericht op genezing voor slokdarm- of maagkanker, ongeacht 
in welk ziekenhuis de patiënt uiteindelijk werd behandeld na eventuele doorverwijzing. Zo 
varieerde de kans op een behandeling gericht op genezing van slokdarmkanker van 50% tot 
82%  tussen ziekenhuizen en van maagkanker van 48% tot 78%. Tevens werd een relatie gezien 
tussen de kans op het krijgen van een behandeling op basis van het ziekenhuis van diagnose 
en de overleving van patiënten met slokdarm- of maagkanker. Patiënten gediagnosticeerd in 
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een ziekenhuis met een hogere kans op een behandeling gericht op genezing hadden een 
betere overleving dan patiënten gediagnosticeerd in ziekenhuizen met een lagere kans op een 
dergelijke behandeling. 
De conclusie van deze studies luidt dat de gevonden variatie tussen ziekenhuizen en het 
effect hiervan op de overleving suggereert dat de besluitvorming rondom de behandeling van 
slokdarm- en maagkanker in Nederland nog verder kan worden geoptimaliseerd. Verschillen in 
werkwijze en samenstelling van het multidisciplinair overleg (MDO) tussen ziekenhuizen kunnen 
een verklaring zijn voor de variatie in de kans op het krijgen van een behandeling. In Nederland 
vindt in alle ziekenhuizen op één of meerdere momenten in de week een MDO plaats om nieuwe 
patiënten met kanker te bespreken. Het zou kunnen dat niet alle benodigde, tumorspecifieke 
expertise binnen dit overleg vertegenwoordigd was of dat externe tumorspecifieke expertise 
niet (tijdig) bij de besluitvorming werd betrokken. Vooral bij complexe behandelingen, zoals 
bij slokdarm- en maagkanker, is het uitermate belangrijk dat de juiste kennis en ervaring 
beschikbaar is binnen het MDO. Regionale, tumorspecifieke MDO’s in aanwezigheid van 
tumorspecifieke experts zouden de variatie tussen ziekenhuizen kunnen verminderen. Dit kan 
mogelijk bijdragen aan verbetering van de overlevingskansen van patiënten met slokdarm- en 
maagkanker. Vervolgonderzoek, gesubsidieerd door KWF Kankerbestrijding, zal uitwijzen welke 
factoren leiden tot variatie in behandeling en welke effecten dit heeft op de overleving van 
patiënten met slokdarm- of maagkanker. 
Hoofdstuk 5 van dit proefschrift evalueert de invloed van de concentratie van chirurgie 
voor patiënten met maagkanker in Nederland. Vanaf 2012 moeten ziekenhuizen minimaal 
tien maagkankeroperaties per jaar uitvoeren en in 2013 is dit aantal verhoogd naar twintig 
per jaar. Deze regels zijn met name opgesteld om de sterfte na een maagkankeroperatie te 
verminderen en de overleving te verbeteren. Voor deze studie hebben we patiënten uit de 
NKR geselecteerd die gediagnosticeerd zijn met maagkanker in de periode 2009-2011 (voor 
concentratie van deze chirurgie) en 2013-2015 (na concentratie). De uitkomsten van patiënten 
gediagnosticeerd in deze twee periodes zijn met elkaar vergeleken. We zagen dat de sterfte 
binnen 90 dagen na de operatie daalde van 11% naar 7%. Ook nam het percentage patiënten 
dat nog in leven was binnen twee jaar na de diagnose toe van 27% naar 30%. Ook na correctie 
voor verschillen in patiëntkarakteristieken (onder andere leeftijd en tumorstadium) tussen 
beide periodes, was de overleving van alle patiënten met maagkanker beter in de periode na 
introductie van concentratie van deze chirurgie. Deze bevindingen suggereren dat de zorg 
aan patiënten met maagkanker verbetert indien men deze patiënten vaker behandelt. Hoe 
vaker een arts een operatie uitvoert, hoe beter hij of zij dit doet. Ook is het aannemelijk dat 
artsen en verpleegkundigen een complicatie na een maagoperatie eerder herkennen en kunnen 
behandelen, indien zij meer patiënten behandelen. Daarnaast is het mogelijk dat artsen de 
mogelijkheden van chemotherapie voor een patiënt beter kunnen inschatten indien zij vaker 
patiënten met maagkanker behandelen.
In verschillende Europese landen worden patiënten met maagkanker behandeld met 
chemotherapie, gevolgd door een operatie en daarna nogmaals chemotherapie. Deze combinatie 
wordt ook wel perioperatieve chemotherapie genoemd. Deze behandelkeuze is het gevolg van 
een klinische studie uit 2006 waarin is aangetoond dat toevoeging van chemotherapie voor 
en na een operatie bijdraagt aan aanzienlijke verbetering van de overleving van patiënten met 
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maagkanker. In deze studie werden echter patiënten geïncludeerd die voldeden aan strikte 
selectiecriteria die geen rekening houden met eigenschappen van patiënten die we zien in 
de dagelijkse klinische praktijk. Hierbij kan je denken aan de selectie van vitale patiënten met 
weinig andere ziektebeelden. Oudere patiënten worden hierdoor vaak geëxcludeerd. Door deze 
strikte selectiecriteria gelden de resultaten van dergelijke klinische studies niet zonder meer 
voor alle patiënten met maagkanker. Daarom beschrijven we in hoofdstuk 6 de toepassing 
van perioperatieve chemotherapie en de invloed daarvan op de overleving voor patiënten 
met maagkanker in de dagelijkse klinische praktijk. In deze studie includeerden we patiënten 
met maagkanker die in aanmerking komen voor perioperatieve chemotherapie op basis van 
tumorstadium en zijn gediagnosticeerd in de periode 2006-2014. De uitkomsten van deze 
studie laten zien dat in 2014 bijna driekwart (74%) van de patiënten niet werd behandeld met 
perioperatieve chemotherapie, terwijl zij daar qua tumor stadium wel voor in aanmerking 
komen. Daarnaast krijgt bijna de helft van de patiënten die chemotherapie kregen vóór een 
operatie géén chemotherapie ná de operatie. 
Er zijn verschillende redenen te noemen waarom patiënten geen perioperatieve 
chemotherapie kregen. Patiënten met maagkanker zijn gemiddeld 72 jaar oud, hebben vaak 
te maken met bijkomende ziekten, ondervoeding en gewichtsverlies. Indien deze patiënten 
starten met chemotherapie zijn er ook diverse oorzaken waarom zij daarna geen operatie 
krijgen, zoals bijwerkingen tijdens of na de chemotherapie of omdat de ziekte toch blijkt te 
zijn uitgezaaid naar andere plaatsen in het lichaam. Daarnaast kunnen patiënten te maken 
hebben met complicaties na de operatie, waardoor zij niet meer in staat zijn om chemotherapie 
te krijgen. Aangezien slechts een klein deel van de patiënten met maagkanker de huidige 
behandeling met perioperatieve chemotherapie wil volgen en daadwerkelijk kan afronden, is 
het de vraag of dit de beste behandeling is voor deze specifieke groep patiënten. Voor zover 
we nu weten lijkt dit de beste behandeling, maar de resultaten van deze studie suggereren dat 
we in de toekomst opzoek moeten naar een andere behandeling die beter wordt verdragen 
en minder bijwerkingen heeft.
Indien patiënten met maagkanker wel in staat zijn om chemotherapie te krijgen na de 
operatie, dan lijkt het momenteel onduidelijk wanneer zij daarmee moeten starten. In de 
Nederlandse richtlijn voor de behandeling van maagkanker wordt namelijk geen tijdsinterval 
vermeld. Daarom onderzoeken we in hoofdstuk 7 het effect van de timing van chemotherapie 
na een behandeling met chemotherapie gevolgd door een operatie op de overleving van 
patiënten met maagkanker. Voor dit onderzoek selecteerden we patiënten met maagkanker 
die chemotherapie, een operatie en daarna nogmaals chemotherapie kregen in de periode 
2010-2014. We zagen dat de helft van de patiënten binnen zes weken na de operatie startte 
met chemotherapie. Een langer herstel na de operatie, bijvoorbeeld door complicaties van 
de operatie, ging vaak gepaard met een latere start met chemotherapie. Nadat we hadden 
gecorrigeerd voor verschillen tussen patiënten die eerder dan wel later met chemotherapie 
waren gestart, zagen we dat patiënten die binnen zes weken waren gestart niet per se een 
betere overleving hadden dan patiënten die binnen zes tot twaalf weken na de operatie met 
chemotherapie waren gestart. Deze resultaten ondersteunen het beeld dat er ruimte is om de 
patiënten eerst te laten herstellen van de operatie.
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Zoals al eerder is beschreven in deze samenvatting, kunnen patiënten met slokdarm- en 
maagkanker minder fit zijn voor een operatie vanwege andere aanwezige ziektebeelden, 
ondervoeding en gewichtsverlies. Definitieve chemoradiotherapie wordt in toenemende mate 
beschouwd als een goed alternatief voor patiënten met slokdarmkanker die minder geschikt 
zijn voor een operatie. Definitieve chemotherapie is het gelijktijdig volgen van chemotherapie 
en radiotherapie zonder een operatie. Deze behandeling is bedoeld om de patiënt te genezen. 
In hoofdstuk 8 hebben we gekeken wat de invloed is van leeftijd en andere aanwezige 
ziektebeelden op de keuze van een behandeling gericht op genezing en op de overleving. 
Voor deze studie hebben we behandeling gedefinieerd als definitieve chemoradiotherapie of 
chemoradiotherapie gevolgd door een operatie. We hebben patiënten met slokdarmkanker 
geselecteerd uit de Nederlandse Kankerregistratie die deze behandelingen kregen in de 
periode 2004 tot 2014. Zoals verwacht hadden patiënten van 75 jaar en ouder of met twee of 
meer andere ziektebeelden een hogere kans om definitieve chemoradiotherapie te krijgen. 
Echter, de overleving van patiënten met een adenocarcinoom (een type slokdarmkanker) 
was beter wanneer zij chemoradiotherapie gevolgd door een operatie kregen, dit ongeacht 
leeftijd en het aantal andere ziektebeelden. Terwijl de overleving voor patiënten met een 
plaveiselcelcarcinoom, een ander type slokdarmkanker, gelijk was tussen beide behandelingen 
voor oudere patiënten en patiënten met twee of meer andere ziektebeelden. Dit suggereert dat 
definitieve chemoradiotherapie overwogen kan worden bij patiënten met slokdarmkanker (type 
plaveiselcelcarcinoom) die 75 jaar of ouder zijn of twee of meer andere ziektebeelden hebben. 
Een aanzienlijk deel van de patiënten die gediagnosticeerd worden met slokdarm- of 
maagkanker is 70 jaar of ouder. De effectiviteit van medische behandelingen wordt vaak bepaald 
op basis van klinische studies, waarbij oudere patiënten grotendeels worden uitgesloten. 
In hoofdstuk 9 evalueren we de behandeling en overleving van oudere patiënten met 
slokdarmkanker die op basis van de omvang van hun ziekte in aanmerking zouden kunnen 
komen voor een behandeling gericht op genezing. In de periode 2003 tot 2013 zagen we een 
flinke toename van het percentage patiënten dat definitieve chemoradiotherapie onderging bij 
zowel jongere als oudere patiënten met slokdarmkanker. Zo kreeg 2% van de oudere patiënten 
in 2003 definitieve chemoradiotherapie, terwijl in 2013 20% van de oudere patiënten deze 
behandeling kreeg. Het percentage oudere patiënten dat geopereerd werd bleef stabiel, 
ongeveer 16%. Door de toename van definitieve chemoradiotherapie onder oudere patiënten 
verdubbelde het aandeel op genezing gerichte behandelingen van 17% in 2003 tot 37% in 
2013. Echter, 37% is laag vergeleken met jongere patiënten. In deze laatste leeftijdscategorie 
krijgt 84% een behandeling gericht op genezing. Vergelijkbaar met de resultaten uit hoofdstuk 
8, was de overleving van oudere patiënten met een adenocarcinoom (een type slokdarmkanker) 
beter bij patiënten die chemoradiotherapie gevolgd door een operatie kregen vergeleken met 
patiënten die definitieve chemoradiotherapie kregen. De overleving na deze behandelingen 
was vergelijkbaar voor oudere patiënten met een plaveiselcelcarcinoom, een ander type 
slokdarmkanker.
Ongeveer 40% van de patiënten met slokdarm- en maagkanker heeft een uitgezaaide 
ziekte op het moment van diagnose. In hoofdstuk 10 onderzoeken we de veranderingen in de 
behandeling en overleving van jongere en oudere patiënten met uitgezaaide of vergevorderde 
maagkanker die gediagnosticeerd zijn in de periode 1989 en 2013. Deze patiënten kunnen 
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in aanmerking komen voor een operatie ter verlenging van hun leven, hierna aangeduid als 
“palliatieve operatie”. Uit de analyses die voor dit proefschrift zijn uitgevoerd, blijkt dat het 
aandeel palliatieve operaties tussen 1989 en 2013 aanzienlijk daalde, zowel bij jongere patiënten 
(van 25% naar 3%) als bij oudere patiënten (van 26% naar 5%). Tegelijkertijd is het percentage 
patiënten dat chemotherapie kreeg aanzienlijk gestegen van 15% naar 51% bij jongere patiënten 
en van 2% naar 21% bij oudere patiënten. Ondanks deze veranderingen in behandeling zien we 
geen verbetering in de overleving bij zowel jongere als oudere patiënten met uitgezaaide of 
vergevorderde maagkanker. De veranderingen in palliatieve, levensverlengende, behandelingen 
hangen mogelijk samen met een verbetering in diagnostiek en de beschikbaarheid van nieuwe 
systemische behandelingen (waaronder chemotherapie). Bovendien kan de daling in het aantal 
palliatieve operaties verklaard worden door een wijziging in de Nederlandse richtlijnen die vanaf 
2009 is geïmplementeerd. Daarin wordt geadviseerd om palliatieve operaties uitsluitend te 
geven aan patiënten tot 70 jaar met een minimaal uitgezaaide of vergevorderde ziekte.
Verschillende ontwikkelingen hebben plaatsgevonden in de behandeling van 
slokdarmkanker. Vanaf 2008 worden patiënten steeds vaker behandeld met chemoradiotherapie 
voorafgaand aan de operatie om de tumor te verkleinen, zodat de operatie beter kan worden 
uitgevoerd. Een andere ontwikkeling betreft de concentratie van chirurgie voor patiënten met 
slokdarmkanker. Vanaf 2006 moeten ziekenhuizen minimaal tien slokdarmkankeroperaties per 
jaar uitvoeren en in 2011 is dit aantal verhoogd naar twintig per jaar. Deze regels zijn met name 
opgesteld om de sterfte na een slokdarmkankeroperatie te verminderen en de overleving te 
verbeteren. In hoofdstuk 11 beschrijven we veranderingen in behandeling en overleving van 
patiënten met slokdarmkanker in de periode 1989 tot 2014. De uitkomsten laten zien dat de 
overleving van alle patiënten met slokdarmkanker de afgelopen 26 jaar meer dan verdubbeld 
is. De overleving van patiënten zonder uitzaaiingen is zelfs verdriedubbeld. In 2005 kreeg een 
derde van de geopereerde patiënten een operatie in een ziekenhuis dat meer dan twintig 
operaties per jaar uitvoerde, terwijl bijna alle geopereerde patiënten in 2014 een operatie kregen 
in een dergelijk ziekenhuis. De toename in de overleving van patiënten met slokdarmkanker 
kan worden toegeschreven aan de inzet van chemoradiotherapie voorafgaand aan de operatie 
en aan concentratie van slokdarmkankeroperaties. In de toekomst zou de overleving van deze 
patiënten mogelijk nog verder kunnen verbeteren door vroegere detectie van kwaadaardige 
tumoren, maar waarschijnlijk nog meer door de inzet van effectieve en gepersonaliseerde 
systemische behandelingen (waaronder chemotherapie).
Concluderende opmerkingen
De overleving van patiënten met slokdarmkanker is de afgelopen 26 jaar aanzienlijk toegenomen, 
waarschijnlijk door de inzet van chemoradiotherapie voorafgaand aan de operatie, maar ook 
door concentratie van slokdarmkankeroperaties in gespecialiseerde ziekenhuizen. De overleving 
voor patiënten met maagkanker lijkt eveneens te zijn toegenomen sinds de concentratie van 
maagkankeroperaties, die later is gestart dan de concentratie van slokdarmoperaties. Door 
deze complexe operaties te concentreren, is het waarschijnlijk dat de overleving van patiënten 
met maagkanker in de nabije toekomst nog verder verbetert. De gevonden variatie tussen 
ziekenhuizen wat betreft behandeling en het effect hiervan op de overleving van deze patiënten 
suggereert dat de besluitvorming rondom de zorg voor patiënten met slokdarm- en maagkanker 
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in Nederland nog verder kan worden geoptimaliseerd. Daarnaast is het belangrijk om de effecten 
van een behandeling te evalueren onder specifieke groepen patiënten. De onderzoeken in dit 
proefschrift dragen bij aan deze ontwikkeling, waarin steeds meer wordt gestreefd naar een 
behandeling op maat voor de individuele patiënt met slokdarm- of maagkanker.
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Dankwoord
Het is gelukt! Mijn proefschrift is af! Een boek dat het resultaat is van mijn promotieonderzoek. 
Een periode die voorbij is gevlogen en vele mooie momenten kende. En wat heb ik veel mogen 
leren. Graag wil ik iedereen bedanken die een bijdrage heeft geleverd aan deze bijzondere 
periode en het daaruit voortvloeiende proefschrift. Een aantal personen wil ik hieronder graag 
in het bijzonder bedanken. 
Promotiecommissie
Prof.dr. Lemmens, beste Valery, jij gaf mij de kans om dit promotieonderzoek uit te voeren. 
Bedankt voor jouw vertrouwen in mij als onderzoeker en voor alle keren dat je mij weer 
nieuwe energie gaf na afloop van een overleg. In jouw aanwezigheid startte ieder overleg met 
de broodnodige gesprekken over koetjes en kalfjes. Daarnaast heb ik veel bewondering voor 
jouw kennis van kankerepidemiologie en je altijd positieve instelling. Bedankt voor de fijne 
samenwerking!
Dr. Nieuwenhuijzen, beste Grard, jouw klinische input is van onschatbare waarde geweest voor 
mijn promotieonderzoek. Jij bruiste van de ideeën en wat ik heb daar (zeker in het begin) 
veel aan gehad. Ik kan me nog goed herinneren dat we elkaar hebben ontmoet na afloop van 
een congres in Liverpool. In mijn ogen ben jij een gedreven chirurg. Een chirurg waarnaar ik 
patiënten zonder enige twijfel zou verwijzen. Bedankt voor de prettige samenwerking!
Dr. Verhoeven, beste Rob, zonder jou was dit proefschrift nog niet klaar. Bedankt voor je 
snelle reactie op manuscripten. En misschien nog wel belangrijker; bedankt voor je kritische 
opmerkingen die ieder manuscript weer naar een hoger niveau tilde. We hebben samen vele 
congressen en symposia bezocht. Ik weet nog goed dat we met andere collega’s terecht kwamen 
in een prachtige cocktailbar na afloop van een congres in Krakau. Dat was een mooie avond. 
Rob, bedankt voor alle leerzame, maar ook gezellige momenten!
De leden van de beoordelingscommissie, prof.dr. J.J.B. van Lanschot, prof.dr. G.A.P. Hospers, 
prof.dr. M.J. Bruno, prof.dr. M. Verheij en dr. H.G. Coleman, allen hartelijk bedankt voor de tijd 
en moeite die jullie hebben besteed aan het lezen van mijn proefschrift. Ik kijk ernaar uit om 
met jullie van gedachten te wisselen op 25 mei 2018.  
Collega’s
Beste IKNL collega’s, wat was het fijn om met jullie samen te werken. Velen van jullie hebben 
dagelijks een glimlach op mijn gezicht weten te toveren. Ik heb genoten van alle koffiepauzes, 
lunchwandelingen, etentjes, borrels en (promotie)feestjes. Als ik nu een poging doe om alle 
namen te noemen ga ik ongetwijfeld iemand vergeten. Daarom wil ik een enkeling in het 
bijzonder bedanken. Simone, ik had me geen betere overbuurvrouw kunnen wensen dan jou. 
Lindy, met jou op kantoor was het nooit saai. Belle, ik heb genoten van onze gesprekken over je 
teckel Jos. Maarten en Britt, ik vind het geweldig dat jullie onder het ‘genot’ van hardstyle muziek 
aan het werk zijn wanneer iedereen al naar huis is. Nicole E, bedankt dat jij mijn stagebegeleider 
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wilde zijn gedurende mijn master. Lonneke, ook jij wist mij vaak te inspireren door jouw passie 
voor kankeronderzoek. Erna, jij bent een hele zorgzame collega, iemand die zeker niet mocht 
ontbreken. Mieke, ik voelde me nooit bezwaard om vragen aan jou te stellen. Pauline, het was 
fijn om met jou over SAS te discussiëren. Felice, bedankt voor alle praktische tips in de eindfase 
van mijn promotieonderzoek. Gijs, waarom ben je niet eerder bij IKNL komen werken? Ik heb 
genoten van jouw aanwezigheid! En tot slot natuurlijk Amanda. We zijn tegelijk begonnen en 
tegelijk klaar met ons promotieonderzoek. Jij hebt echter enorme bergen moeten trotseren. Ik 
heb veel respect voor jou als collega, maar ook als mens. Bedankt dat je mijn paranimf wilt zijn!
Ook wil ik alle datamanagers van IKNL bedanken voor het registreren van een uiteenlopende 
hoeveelheid gegevens over patiënten met kanker. Jullie werk is cruciaal geweest voor het 
onderzoek dat beschreven wordt in dit proefschrift. 
Dear dr. Helen Coleman, it was a pleasure for me to work with you in Northern Ireland. You 
are such a good researcher and also a care taking person. Thank you for introducing me to 
the world of Barrett and Biomarkers. I am honoured that you are a member of my dissertation 
committee. Dear Anna, tumour verification officers and other staff from the Northern Ireland 
Cancer Registry, I loved the atmosphere that you have at your cancer registry. Thank you for all 
the wonderful coffee and lunch breaks. 
Mijn dank gaat ook uit naar alle co-auteurs voor hun waardevolle toevoegingen aan het 
onderzoek dat beschreven wordt in dit proefschrift. 
Nu gaan we wat meer richting huis
Vrienden en vriendinnen, jullie hebben middels de nodige afleiding bijgedragen aan dit 
promotieonderzoek. Bedankt voor alle leuke ski- en zonvakanties, gezellige avonden, feestjes 
en tennismomenten. Jeanne, laat je het confetti kanon thuis die je wilde afvuren na de 
promotieplechtigheid van je zus? ;-) 
Schoonfamilie, fijn dat we zo goed met elkaar kunnen opschieten. Pieter, geen zorgen, met een 
doctorstitel op zak kun je nog steeds boerin worden. Mieke, ik had me geen betere schoonmoeder 
kunnen wensen dan jou! Bedankt voor de fijne gesprekken en ontspannende wandelingen. 
Peter, jouw stiptheid zal er ongetwijfeld voor zorgen dat iedereen op tijd aanwezig is bij de 
verdediging van mijn proefschrift. Ben, ik vond het leuk dat je regelmatig op de koffie kwam 
als ik thuis werkte aan mijn onderzoek. Lenna, wat fijn dat je je ook bij de Vlemminxen voegde. 
Jan, jij hebt een groot deel van mijn promotietijd met mij en je broertje in één huis gewoond. 
Daardoor hebben wij elkaar heel goed leren kennen. Ik heb genoten van je gezelligheid!
Opa, oma en Han bedankt voor de mooie gesprekken, fijne verjaardagen en etentjes.
Lieve papa, mama en zusjes Yvonne, Sylvia en Leonie, wat een geluk dat ik samen met jullie 
ben opgegroeid. Pap en mam, wat fijn dat ik altijd - verwacht en onverwacht - bij jullie mag 
langskomen en mag blijven zolang ik wil. Bedankt voor de onvoorwaardelijke liefde, goede 
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adviezen en oprechte interesse. Leonie, ik vind het knap dat je zo goed op jezelf kan wonen en 
voor je dieren kan zorgen. Ik ben benieuwd of de taarten bij de receptie kunnen tippen aan jouw 
bakkunsten. Yvonne, wat mooi dat je je maatje Arjan hebt gevonden. Jullie zijn leuk samen! En 
natuurlijk bedankt voor alle kopjes thee, je luisterend oor en goede tips. Sylvia, vroeger, maar 
ook de afgelopen jaren hebben we mooie avonturen beleefd. Jij kent mij als geen ander en wist 
mij op de juiste momenten een spiegel voor te houden gedurende mijn promotietijd. Ik ben 
trots dat jij mijn paranimf wilt zijn! 
Lieve Jos, wie had ooit gedacht dat een vakantieliefde op 18-jarige leeftijd zou leiden tot alles 
wat we nu hebben. Afstand doet verlangen was op ons van toepassing. Zes jaar lang reisden we 
elk weekend op en neer tussen Overijssel en Noord-Brabant. En ik zou het zo weer over doen. 
De afgelopen jaren wist jij altijd te benadrukken wat ik had bereikt en op de momenten dat het 
minder goed ging zorgde je ervoor dat ik bleef staan zodat ik weer verder kon gaan. Ik hoop dat 
we later als 80-jarigen op een bankje mogen zitten, aan de rand van een vijver omringd door 
bloemen en dat we tegen elkaar mogen zeggen: wat hebben we toch een goed leven gehad. 
Margreet
Maart 2018
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Curriculum Vitae
Margreet van Putten was born on the 14th of November 1989 in 
Deventer, the Netherlands. In 2008 she finished pre-university 
education at the Carmel College Salland in Raalte. Subsequently, 
she started to became a nurse at Windesheim University of 
Applied Sciences in Zwolle. During this study she worked in 
the Isala hospital, in care providing institutions and home care. 
Furthermore, she went to Surinam for a 3-month internship. 
After graduating from nursing school she started in 2012 with the 
premaster Health Sciences and in 2014 she completed the Master Health Sciences cum laude 
at the VU University Amsterdam. During her master she conducted scientific research at the 
Netherlands Comprehensive Cancer Organisation (IKNL). Subsequently, she started her PhD 
research at IKNL, location Eindhoven. Her research focused on the quality of care among patients 
with oesophageal or gastric cancer. As part of her PhD she performed a study at the Queen’s 
University and Northern Ireland Cancer Registry in Belfast for a period of 3 months. 
Margreet is living together with her boyfriend Jos in the rural area of Oirschot, the Netherlands.
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PhD portfolio
Name PhD student: Margreet van Putten
Erasmus MC Department: Public Health / Netherlands Comprehensive Cancer Organisation 
(IKNL)
PhD period: August 2014 – May 2018
Promotor: Prof. dr. V.E.P.P. Lemmens
Copromotors: Dr. G.A.P. Nieuwenhuijzen & Dr. R.H.A. Verhoeven
Year Workload 
Hours (ECTS)
Courses
Basic course in Oncology, NVvO 2015 40 (1.4)
Multilevel analysis – EpidM, Vumc 2015 24 (0.9)
APC- analysis - from epidemiology to health promotion – NIHES 2015 8 (0.3)
Advanced course in epidemiologic methods – LUMC 2016 32 (1.1)
Internal course on survival analysis – by Paul Dickman from Karolinska Institute 
Sweden at IKNL
2016 24 (0.9)
Global Cancer Short Course – Queens University, Belfast, Northern Ireland 2016 32 (1.1)
Scientific integrity – Erasmus MC 2016 8 (0.3)
Oral presentations
IKNL Symposium ‘NKR in beweging’ 2015 32 (1.1)
NVGE autumn meeting 2015 32 (1.1)
DUCG study evening 2015 32 (1.1)
10th National Barrett’s symposium 2016 32 (1.1)
ESSO (2 presentations) 2016 64 (2.3)
IKNL symposium ‘NKR naar buiten’ 2017 32 (1.1)
Poster presentations
2 posters ESMO GI 2017 32 (1.1)
1 poster IACR 2017 32 (1.1)
1 poster ESDE 2017 32 (1.1)
International conferences
ESSO, Liverpool, United Kingdom 2014 32 (1.1)
10th National Barrett’s symposium, London, United Kingdom 2016 8 (0.3)
ESSO, Krakow, Poland 2016 32 (1.1)
ECCO, Amsterdam, the Netherlands 2017 32 (1.1)
ESMO GI, Barcelona, Spain 2017 32 (1.1)
IACR, Utrecht, the Netherlands 2017 24 (0.9)
ESDE, Utrecht, the Netherlands 2017 24 (0.9)
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Year Workload 
Hours (ECTS)
Dutch seminars and conferences
NVGE autumn meeting 2015 16 (0.6)
IKNL symposium ‘NKR in beweging’ 2015 8 (0.3)
1th DUCG symposium 2015 8 (0.3)
2th 5D’s congress 2016 8 (0.3)
Federaday ‘Cancer and numbers’ 2016 8 (0.3)
10th gastrointestinal symposium IKNL 2016 8 (0.3)
Satellite symposium translational research on oesophageal malignancies  - EPGS 2016 8 (0.3)
Symposium, ‘It is time to individualize multimodality treatment for oesophageal 
cancer’
2016 16 (0.6)
DICA congress 2017 16 (0.6)
2th DUCG symposium 2017 8 (0.3)
IKNL symposium ‘NKR naar buiten’ 2017 8 (0.3)
DUCG study evenings 2015-2018 32 (1.1)
Supervising Master’s thesis
Ibtissam Mokadem ‘Recurrence after preoperative chemotherapy and surgery 
for gastric adenocarcinoma’
2016-2017 80 (3)
Vera Haagsman ‘The impact of regional multidisciplinary team meetings on 
treatment decision making in patients with oesophageal and gastric cancer’
2017-2018 80 (3)
Teaching
Lectures about cancer epidemiology for second-year medicine students, 
Erasmus MC
2016-2017 80 (3)
Other tasks
3-month internship at Queens University Belfast, Northern Ireland 2016 240 (8.6)
Extending the registry and assessing the quality of the extended registry for 
oesophageal and gastric cancer
2015-2017 280 (10)
Provide training to registry clerks 2015-2017 40 (1.4)
Answering questions of registry clerks about the registry 2015-2018 40 (1.4)
Making regional reports about oesophageal and gastric cancer for hospitals 2015-2016 240 (8.6)
Total 1896 (68)
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